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Abstract
In this dissertation, I undertake three empirical analyses using data from the Africa
Centre for Health and Population Studies, which is located in the Hlabisa subdistrict of
northern KwaZulu-Natal, South Africa. In the ﬁrst analysis I assess if antiretroviral therapy
(ART) usage in the household is associated with a reduction in individual HIV acquisition
risk. To my knowledge, this analysis is the ﬁrst attempt to quantify the preventive impact
of a public sector treatment program based in a rural community with poor knowledge and
disclosure of HIV status, frequent migration, late marriage, and multiple partnerships. I
argue in the second analysis that eﬀorts to optimize the preventive eﬃcacy of ART in South
Africa and elsewhere will be critically dependent on the ability of the public health sector
to initiate and then keep HIV-infected patients on treatment. Here, I examine the socio-
demographic and structural factors that are associated with poor or imperfect adherence
to antiretroviral medications, which can be obtained for free at multiple health-care centers
within the study area. The third analysis continues this work by examining the diagnostic
performance and cost-eﬀectiveness of two monitoring strategiesCD4 and HIV-1 viral load
count testingto detect poor patient response to ART. My approach is based on the idea
that the cost-eﬀectiveness of a treatment monitoring strategy is a function of its predictive
performance.
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Chapter 1
Introduction
In this dissertation I examine the survival and preventive beneﬁts of antiretroviral ther-
apy (ART) use in a rural South African community. ART can dramatically reduce the risk
of mortality and improve the health outcomes of HIV-infected patients (Nakagawa et al.,
2012). In recent years, research has shown that ART can also prevent the transmission of
HIV from an infected individual to an uninfected, sexual partner (Baggaley et al., 2013;
Anglemyer et al., 2013; Loutfy et al., 2013). Together, the survival and preventive beneﬁts
of ART have been described as a `double-hat-trick' in the global ﬁght against HIV/AIDS
(Montaner, 2011).
South Africa has the world's highest estimated number of people (more than six mil-
lion) living with HIV/AIDS (UNAIDS, 2013). In the KwaZulu-Natal province, where this
study takes place, the prevalence of HIV is reported to be around 30% for 1949 year-olds
(Department of Health, 2014). Since 2004, the scale-up of ART by the South African gov-
ernment constitutes one of the most successful public health interventions ever undertaken
in sub-Saharan Africa (UNAIDS, 2012b). Attention is now being devoted to a range of
issuesnotably, HIV testing and disclosure; treatment uptake, retention, adherence and
resistance; risk compensation in sexual behavior; high rates of migration; and health-care
capacitythat are likely to attenuate the potential of ART to substantially reduce the rate
of new infections in hyperendemic communities.
In this dissertation, I undertake three analyses using data from the Africa Centre for
Health and Population Studies, which is located in the Hlabisa subdistrict of northern
KwaZulu-Natal. In the ﬁrst analysis I assess if ART usage in the household is associated
with a reduction in individual HIV acquisition risk. To my knowledge, this analysis is the
ﬁrst attempt to quantify the preventive impact of a public sector treatment program based in
a rural community with poor knowledge and disclosure of HIV status, frequent migration,
1
2late marriage, and multiple partnerships. I argue in the second analysis that eﬀorts to
optimize the preventive eﬃcacy of ART in South Africa and elsewhere will be critically
dependent on the ability of the public health sector to initiate and then keep HIV-infected
patients on treatment. Here, I examine the socio-demographic and structural factors that
are associated with poor or imperfect adherence to antiretroviral (ARV) medications, which
can be obtained for free at multiple health-care centers within the study area. The third
analysis continues this work by examining the diagnostic performance and cost-eﬀectiveness
of monitoring strategies to detect poor patient response to ART.
The three empirical analyses that I present in this dissertation speak to an impor-
tant sociological theme. This theme concerns how the broader social context varies an
individual's HIV acquisition risk, as examined in the ﬁrst analysis, or adherence to ART
treatment, as examined in the second and third analyses. More generally, the three anal-
yses are confronted with the broader sociological question of how institutional processes,
structural inequalities, resource allocation mechanisms, and socioeconomic status come to
be embodied as individual pathology (Farmer in Diderichsen et al., 2001). In addressing
this question, I suggest that it would be useful to ﬁrst consider the range of causal fac-
tors hypothesized to aﬀect a particular health outcome, and then to consider how these
factors interact with one another at various levels within a hierarchical, conceptual frame-
work. I make the argument throughout Chapter 2 that higher level factors of interest to
the sociologist must operate on factors at successively lower levels within the conceptual
framework before the health outcome in question can be observed. In Chapter 2, I identify
and delineate three broad but distinct levels, which are the proximate determinants (Level
1), socioeconomic position (Level 2), and the societal context (Level 3). My aim in this
chapter is to motivate a sociological approach to the study of health outcomes that draws
heavily from this proposed model.
In Section 2.1, I turn to discussion of the social constructs and factors situated at the
highest level of the proposed model. Here, I place emphasis on the broader, macro-social
structures and processes that shape the everyday lives of individuals and their health. Fol-
lowing the work of Coleman (1994), I pay speciﬁc attention to the sociological understanding
of system behavior as the product of actors or agents. This theoretical point of departure
explains how high-level social actors come to deﬁne political and economic policies, shape
3institutional processes, and determine the resource allocation mechanisms that result in the
diﬀerential exposure and vulnerability of population groups to illness and disease. Impor-
tantly, the constructs that are situated at this macro-social level are seen to either promote
or restrict an individual's health related behaviors.
In Section 2.2 I turn to a discussion of the factors associated with an individual's
socioeconomic position, which represents the micro-social level of the proposed conceptual
model. This level relates the quality of an individual's health to his or her position in
the social system. Generally, the higher the position the better the health. Socioeconomic
position is an important level in the proposed multilevel model because it marks the point
at which macro-social resources enter into and aﬀect the lives of individuals. I then turn to
a review of the factors associated with socioeconomic position, and explain how these can
be analyzed in relation to other levels of the proposed conceptual framework.
I introduce the proximate determinants framework in Section 2.3. I argue that this
framework has been developed to identify the biological or behavioral variables through
which macro- and micro-social factors must operate to inﬂuence an individual's health
outcomes. The incorporation of biological variables into sociological explanations of health
is admittedly not a common practice. But the reality that disease, illness, and death are
also biological phenomena is inescapable; and thus whatever factors lie upstream in the
sequence of causes, at some point in the chain there must be biological processes at work
(Evans, 1994: 12). Rather than sidelining the important role of macro- and micro-social
factors in the proposed conceptual model, the proximate determinants actually provide a
convincing explanatory framework for how these higher level factors make their way into
the human body.
I develop the proposed conceptual model in Chapter 3 by discussing the macro-social,
micro-social and individual level factors that are associated with HIV-related outcomes
in sub-Saharan Africa. I brieﬂy provide a cursory outline of the viral etiology of HIV,
its progression to a global pandemic, and the social determinants that make the epidemic
particular to the African continent. Sub-Saharan Africa is one of the few contexts (alongside
Haiti) to experience the emergence of a generalized, self-sustaining, heterosexual HIV/AIDS
epidemic (De Cock et al., 2012; Caldwell and Caldwell, 1993). I argue here that the complex
4epidemiology of HIV/AIDS in this context warrants the use of a conceptual framework that
addressed the multilevel determinants of HIV spread and treatment adherence.
In Section 3.1.1 I review the proximate determinants of HIV: these are the behavioral
and biological mechanisms through which macro- and micro-social factors must operate
to aﬀect HIV transmission and infection. I discuss the work of Boerma and Weir (2005),
Lewis et al. (2007), and Bärnighausen and Tanser (2009) who have been instrumental
in the development of the HIV proximate determinants framework. Much of the work
in Chapter 3 is devoted to the household context, which is the micro-social level of the
proposed model. The household is the site (analogous to the role of socioeconomic position
in Chapter 2) where community level eﬀects are mediated, and where social relationships
deﬁne, constrain, and reproduce a range of HIV-related behaviors. The household is often
considered to be the focus of sociological work, since it is a context in which decisions about
sexual activity and fertility are made. I provide an extensive discussion in Section 3.1.2
of a number of household-related constructs, and devote some attention to the diﬀerences
between the conjugal nuclear family system of the West and the kinship family system
in Africa. In Section 3.1.3 I brieﬂy identify and discuss four macro-social factors that
are related to HIV outcomes. These are: 1) social attitudes and beliefs, 2) institutions
and structures, 3) epidemiological conditions, and 4) demographic characteristics of an
individual's community.
I describe the study background and data collection methods used by the Africa Cen-
tre for Health and Population Studies (Africa Centre) in Chapter 4. The Africa Centre is
situated within the study area and is located in the northern KwaZulu-Natal province of
South Africa. The study area is predominantly rural and consists of an urban township
and informal peri-urban settlements. The Africa Centre's demographic surveillance system
(ACDIS) was purposefully designed to mirror the complex demographic reality of the sur-
rounding community. In Section 4.2 I discuss the Africa Centre's operationalization of key
demographic concepts (for example, the diﬀerences between the homestead and household)
which have made the surveillance data particularly ﬂexible in terms of recording the mo-
bility and migration of individuals in and out of the study area, among its other strengths
and advantages. An important feature of the data is that it can be linked to patient records
5from a public-sector HIV treatment program implemented in the 17 clinics and the local
hospital within the study area.
I turn to the ﬁrst empirical analysis in Chapter 5 where I examine the preventive beneﬁts
of ART at the household level. The strongest evidence for the preventive eﬀect of ART has
come from studies of HIV-serodiscordant coupleswhere one partner is infected and the
other is notin stable sexual relationships. In this analysis, I argue that the preventive
eﬃcacy of ART has yet to be fully quantiﬁed in communities with poor knowledge and
disclosure of HIV status, frequent migration, late marriage, and multiple partnerships.
These communities are common to the sub-Saharan African context. To do this, I link
patients' records from a public-sector HIV treatment programme in the study area, with
Africa Centre's HIV surveillance and demographic data collected between 2004 and 2012. I
outline in Section 5.2 the methods used to construct the HIV prevalence and ART coverage
measures for each household. I then regress the time to HIV seroconversion for 14,505
individuals, who were HIV-uninfected at baseline and individually followed up over time
regarding their HIV status, on household ART coverage among coresidents of the opposite-
sex, controlling for household HIV prevalence and a range of other potential confounders.
I present and discuss the results in greater detail in Sections 5.3 and 5.4.
The preventive beneﬁts of ART will be critically dependent on the ability of HIV-
infected partners to take their medications up to three times per day (on a daily basis)
for the remainder of their lives. In Chapter 6 I discuss how high adherence to ART is
the single most important predictor of positive health outcomes and reduced mortality in
HIV-infected patients. In Section 6.1 I explain and justify the use of patient viral load
countthe number of HIV copies in a milliliter of bloodas a biomarker or proxy for
ART adherence. I then undertake a survival and logistic regression analysis to assess the
association between adherence and the socio-demographic and structural predictors. In this
analysis, the socio-demographic variables capture the patient's age, sex, employment status,
education level, and migration; and the structural variables speciﬁcally reﬂect a patient's
level of interaction with the health-care setting. I then compare the magnitude of these
odds ratios with a biological variableCD4 T-cell countto gain a better assessment of the
predictors of imperfect ART adherence. Finally, in Section 6.3 I use a receiver operating
6characteristics (ROC) analysis to further assess the predictive performance of the socio-
demographic and structural variables.
I continue with the topic of ART adherence in the third empirical analysis of this disser-
tation. Brieﬂy, the results from Chapter 6 indicate that regular interaction with the clinic
setting could enable health-care providers to better monitor patient response to ART, lead-
ing in turn to the earlier detection of adherence issues and the appropriate modiﬁcation of
existing treatment options. However, the implementation of eﬀective treatment monitor-
ing strategies are often constrained by the economic realities of resource-limited settings.
Although considered the gold standard, the strong diagnostic performance of viral load
monitoring is oﬀset by the logistical costs associated with centralized laboratory facilities
and the HIV assay (Reynolds et al., 2009). CD4 monitoring is generally promoted as an
aﬀordable alternative to VL monitoring, but concerns have been raised about the diagnostic
performance of this monitoring strategy. In this analysis, I derive a single measure that
includes the cost to undertake baseline testing and the cost of incorrectly switching patients
to more expensive treatment options. Again, Chapter 7 speaks to the broader sociological
theme in this dissertation by considering how macro-social forces related to public health-
care policy, economic conditions, resource-constraints, and institutional capacity come to
aﬀect patient response to ART.
I consider the three empirical chapters to be the substantive contribution of this dis-
sertation. To summarize, the ﬁrst analysis quantiﬁes the preventive eﬃcacy of ART at the
household level, the second examines the socio-demographic and structural variables associ-
ated with poor adherence to ART, and the third evaluates the diagnostic performance and
cost eﬀectiveness of two monitoring strategies to detect poor adherence to ART. In each
chapter I address an applied problem in the HIV treatment and care setting. As a result,
I do not use the empirical analyses to evaluate, test, or conﬁrm the multilevel framework
developed in Chapter 2. In addition, the presented conceptual framework is not meant to
invoke the application of multilevel statistical models in this dissertation. Rather, I consider
this framework to be a backdrop to the empirical analyses presented in Chapters 5, 6, and
7. In short, I use a multilevel model of health to more generally explain how the complex set
of societal, household, and individual level factors come to inﬂuence HIV-related outcomes,
a task to which I now turn.
Chapter 2
A Multilevel Approach
A multilevel approach to the study of health outcomes has gained popularity in recent
years (March and Susser, 2006; Raudenbush and Bryk, 2002; Diez-Roux, 2000; Susser, 1998;
Coleman, 1994; Krieger, 1994; Smith, 1989). I argue in this chapter that this approach is
useful for explaining how social contexts come to inﬂuence individuals and their health-
related behaviors. A multilevel approach aligns strongly with a sociological understanding
of health and society, which considers the individual to be inﬂuenced by multiple social
systems that are arranged into successively distinct and broader levels. These levels of
social inﬂuence typically include the interpersonal, household, community, and societal
contexts (Scribner et al., 2010). Importantly, while individuals are considered to act and
make decisions for themselves, a multilevel approach assumes that they cannot fully escape
from the social reality in which they are embedded. The health-seeking behaviors of a
wife, for example, are likely to be directed by the interpersonal relations with her husband,
whose own behaviors are reinforced by the social expectations of a patriarchal household,
which in turn are shaped by the broader social, cultural, and traditional norms of the local
community. I propose to use this conceptual schema to guide and inform the empirical
analyses presented in Chapters 5 and 6 of this dissertation.
In this section I present a hierarchical model of health that consists of three ordered
levels, shown in Figure 2.1. At the highest level are the factors associated with the societal
context (level 3). This level encompasses a set of particularly diﬀuse constructs, and gen-
erally refers to aspects of a social system that exert a powerful formative inﬂuence on the
health outcomes of an individual or group. These macro-social factors are often described
as the `basic', `underlying', or `upstream' determinants of health. Below this level are the
factors associated with an individual's position within the social hierarchy (level 2). In
this proposed model, socioeconomic position marks the point at which the macro-social
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8factors (from level 3) enter into and aﬀect the lives of individuals. It is generally believed
that the higher the position in the social hierarchy, the better one's health (Cockerham,
2007; Galobardes et al., 2006; Hertzman et al., 1994). At the lowest level (Level 1) are the
behavioral and biological (i.e., the proximate) determinants through which the macro- and
micro-social factors must operate to aﬀect the health of an individual.
Figure 2.1: A Multilevel model of health determinants
A major challenge for sociological models of health is to explain how factors operating at
the societal context come to be embodied as individual pathology. As I will discuss through-
out this chapter, a multilevel approach does not consider complex societal constructslike
health-care policy, resource allocation mechanisms, or institutional racismto directly af-
fect an individual's health outcomes. Instead, these higher-level factors must pass through
successively lower levels along the causal chain until the particular health outcome is ob-
served. Consider the impact of economics and patriarchy, two societal level factors, on
HIV transmission risk, an individual level outcome. In poor, rural communities that tra-
ditionally privilege men, a male with material resources often occupies a higher position
within the social order (see Section 2.2). This socioeconomic standing will mean that he
can increase the rate at which he has sexual contact with one or more partners (see Sec-
tion 3.1.2). Through patriarchal beliefs and attitudes about contraception, this male may
further refuse to consistently utilize condoms. Here, coital frequency, concurrency, condom
use, and the concentration of HIV in the sexual partner's blood are the proximate determi-
nants that vary the male's infection risk (see Section 3.1.1). The proposed model provides
9a clear causal chain linking the broader socioeconomic context and patriarchal norms to
the decisions an individual makes about his sexual behavior, which then operate through
the proximate determinants to aﬀect HIV transmission risk.
The incorporation of behavioral or biological variables into explanations of health and
society is admittedly not a common practice in sociology. My use of the proximate deter-
minants in this dissertation should not be seen as a sidelining of the important inﬂuence of
sociological constructs (such as power, class, diﬀerential resource allocation, inequality, etc.)
on health outcomes. Indeed, I have brieﬂy shown in the example above how societal level
factors can shape and inform an individual exposure to illness and disease. As explained,
these social constructs must make their way through the lower levels of the hierarchical
schema before they are embodied as individual pathology.
I do not propose here that the health outcomes of individuals can only be explained
through their actions directed toward other people and guided by their expected behaviour
a position often referred to as methodological individualism (Hayek cited in Lukes, 1968; see
also Watkins, 1952a,b, Coleman, 1994). The viability of methodological individualism as
an explanatory framework has been heavily debated by sociologists since the work of Émile
Durkheim, i.e., that social facts exist sui generis. This debate concerns whether social
events or social facts exempliﬁed by propositions concerning institutional or organizational
units of analysis, can really be reduced to individual level outcomes, or to psychological or
biological principles (Jepperson and Meyer, 2011; Udehn, 2002; Walsh, 1997; Elster, 1982).
I am inclined toward sociological explanation of health outcomes that are consistent
with what is known about the characteristics or behaviors of more elementary units in
the hierarchical framework. Here, consistency refers to the principle that the various
disciplines within the behavioral and social sciences should make themselves consistent,
and consistent with what is known in the natural sciences as well (Barkow et al. in Walsh,
1997: 123). The principle of consistency respects the demarcation of distinct levels of
analyses by academic discipline: for example, the sociologist would seek to investigate the
impact of systemic behavior on population health diﬀerentials, whereas a psychologist would
be prompted to examine the psychological motives that increase or decrease exposure to
health risks; a biologist would be inclined to examine the set neural, hormonal, evolutionary
and genetic factors that determine individual susceptibility to health pathology. Thus,
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vertical integration occurs in a multilevel explanatory system when the levels of analysis
are consistent with one another.
In health research, biological explanations may satisfactorily identify the genetic or
immunological mechanisms that result in the succumbing of an individual to a sexually
transmitted infection (to use an example of a health outcome). But this explanation may
not be suﬃcient to explain a diﬀerence in prevalence between two population groups, unless
the biologist is able to demonstrate some genetic or immunological feature that diﬀerenti-
ates population A from population B in terms of infection susceptibility. The sociologist
may better account for this diﬀerence in prevalence by identifying some macro-social factor,
say, a particular institutional arrangement that is highly successful in informing and edu-
cating the populace about safe sex practices, and supplying and distributing the necessary
health care services and resources to achieve this end. This hypothetical scenario could be
construed as an example of vertical integration because the explanation for the institutional
diﬀerence between the two populations is consistent with the biological explanation for how
sexual infections are transmitted, i.e., increased condom use in population A or B (but not
both, and holding all else equal) would reduce the risk of exposure to infected blood or
semen during the course of a single sexual episode. Explanations which restrict cultural
or experiential meaning to the social domain only, and which cannot link these insights to
lower level phenomenon may not be as eﬀective in accounting for the observed diﬀerence in
disease prevalence in our hypothetical scenario.
2.1 Societal context
Those who work from a sociology of health perspective are concerned with explaining how
broader, macro-social structures, processes and institutions shape the everyday lives of
individuals and their health. From this perspective, attention is drawn to the political,
economic, and cultural contexts of population health; the social system which conﬁgures,
stratiﬁes and reproduces health dynamics; and the resource allocation mechanisms that
result in the diﬀerential exposure and vulnerability of population groups to disease and
illness. The inclusion of societal context as a higher-order level can be motivated by the
observation that systemic or institutional factors often constrain or regulate the decisions
individuals make about their health. Referring to fertility outcomes in the developing
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context, Herb Smith (1989: 172) alludes to the importance of macro-social factors with the
following example.
Patriarchy is a social institution subsuming large numbers of women within
families, families within kin groups, and kin groups within communes or vil-
lages. The subordination of youth to their elders and of women to men is not
a feature of particular households, families, or kin groups, but of the larger
social structure. Individual variation (deviance) is of little account when ar-
rayed against the larger forces militating for conformity to essential behaviors,
including fertility. When change comes, it comes not through the collective ex-
ercise of individual choice, but through the collapse of a larger system that had
heretofore constrained all choices of behavior open to individuals.
The fertility example above illustrates how the decisions individuals make with regard to
their reproductivity come to be determined by multiple social inﬂuences. From a sociological
perspective, these inﬂuences emerge from the behaviors of social actors operating at the
societal level. Here, the meaning of the social actor diﬀers from our understanding of
the individual as a person. The social actor is an authorized agent who chooses interests
and actively manages the rules of the social environment (Meyer, 2010: 3). Rather than
being embedded objects within the institutional structure, the social actor is a competent,
rational decision maker and strategist.
A good example of this kind of social actor is in the sphere of governance, which refers
to the means by which a society organizes itself and implements decisions. The most well
known social actor in this context is a political party, a coalition, or a social movement
that acts to realize a set of interests that may substantially shape or reconﬁgure the social
system. In some historical examples, the rise of a cultural or political group to power has
resulted in the total transformation of the social order, including the resource allocation
mechanisms that aﬀect health (Gilson and McIntyre, 2001).
Social actors can develop and implement macroeconomic policies, which determine the
formal allocation of resources at the national and local level. This sphere of social inﬂuence
typically involves labor market policies designed by social actors to regulate or provide
incentives for individuals, organizations or corporations. Macroeconomic policies may help
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to assist disadvantaged groups, or they may privilege the needs of one social group over
another.
Social and public policies are implemented by political actors, often positioned in the
sphere of governance, and provide the legal basis for the distribution of social goods and
services. The intentions of such policies can aﬀect a range of social factors from labor
practices to social welfare, housing and land distribution, education, and basic municipality
services. Closely related to this sphere of inﬂuence are cultural and social values, which
may involve the degree to which a set of actors frame health as a priority, the extent to
which collective resources are directed toward public health programs and services, and
willingness of a society to assume responsibility for the distribution of social resources.
In the discussion above, I considered how an individual's health risks and opportunities
are shaped, informed, and reproduced by a set of social actors, which could be global
or international actors (e.g., the World Health Organization), national actors (a ruling
political party) or local actors (a husband). Social actors achieve these ends by exerting
patterned eﬀects on the actions of individuals without requiring repeated and authoritative
interventions to achieve these regularities (Clemens and Cook, 1999). In this way, social
actors provide scripts and schemas for a range of social behaviors, and these behaviors are
in turn reinforced through numerous socialization processes. Some of these processes may
involve constraints on social action (lack of political will to provide basic health care services
at the national level), the shaping of institutional interactions (government policies which
restrict the ability of medical institutions to dispense medications), or control over the access
to resources (delays in the comprehensive roll out of life saving treatments).1 In many
respects, social actors are the central engine powering the types of macro-level factors that
aﬀect health (Diderichsen et al., 2001: 16). The macro-social factors listed above implicitly
point to the key sociological concepts of power, prestige, status, and hierarchy, which emerge
more explicitly in the micro-social level (socioeconomic position) of the proposed conceptual
model discussed below.
1 The examples in parenthesis are based on the South African government's decision to delay the roll
out of life saving medications to HIV-infected individuals between the years 20002004 (see Forsyth et al.,
2008; Butler, 2005).
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2.2 Socioeconomic position
Factors associated with socioeconomic position comprise the second level of the proposed
conceptual model. Socioeconomic position refers to the social and economic factors that
inﬂuence which positions individuals or groups will hold within the structure of society
(Galobardes et al., 2006). Socioeconomic position is an important level in this proposed
model because it is generally believed that a person's health is linked to the position he or
she occupies within the social system (Cockerham, 2007; Galobardes et al., 2006; Hertzman
et al., 1994).
According to Graham (2004: 107), it is socioeconomic position that marks the point
in the model where societal level resources enter and aﬀect the lives of individuals. An
individual's position in the social hierarchy can determine the degree of access to and
control over resources, which in turn can be used to minimize or avoid risks of disease
or illness. Such resources may include power, wealth, prestige, social capital and social
support. Because resources are unevenly distributed throughout society, certain groups
or individuals ultimately acquire a greater or lesser share of the stock of private or public
resources. The capacity to access resources is strongly associated with the amount of wealth,
status and power one has in society. Typically, this is indicated by the construct social class,
which is loosely deﬁned here as a category or group of people arranged in a hierarchical
pattern from top to bottom (Cockerham, 2007). Those at the top will have better access to
safer neighborhoods, sources of wholesome foods, health knowledge, behavioral intervention
strategies, and medical careresources which improve an individual's health opportunities.
The distribution of such resources in the social hierarchy is uneven, and it is precisely this
reality which produces and maintains population health heterogeneity.
The relationship between socioeconomic position and health can be more formally out-
lined as follows:
• Society is hierarchically stratiﬁed. This stratiﬁcation leads to the formation of groups,
the members of which share a common position and shared `life chances' (Galobardes
et al., 2006).
• Because of the hierarchical conﬁguration of society, social groups are arranged relative
to other groups at the top or bottom of the hierarchy.
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• Socioeconomic positions are therefore inherently unequal, and a person's socioeco-
nomic position may leave him or her either advantaged or disadvantaged in relation
to members of other social groups.
• Because of the hierarchical stratiﬁcation of society, the resources that enter into the
social system are unequally distributed. As a result, structural and institutional
factors begin to reinforce and reproduce the inequalities associated with one's socioe-
conomic position. This determines access to resources at every point in the casual
chain: societal, environmental, behavioral, and disease related (Graham, 2004: 112).
The focus on the key sociological terms of hierarchy, inequality, resources allocation,
and status requires us to think of the determinants of health in two notionally distinct,
but interconnected ways. A ﬁrst formulation of the term refers to the social causes of
ill-health. The social causes of ill-health, which Graham (2004) calls health determinants,
describe the vector of social factors that promote and undermine the health of populations
and individuals. The social factors that relate to the social position of an individual (for
example, educational qualiﬁcations, occupational mobility) and the socioeconomic context
in which an individual is embedded (for example, high living standards and life expectancy)
are considered to be important health determinants. The second formulation refers to the
social causes of disparities in health, which Graham calls health inequality determinants. In
the context of this paper, the distinction between health determinants and health inequal-
ity determinants is important because the latter formulation refers to the social processes
underlying the unequal distribution of these factors between groups occupying unequal po-
sitions in society (Graham, 2004: 102). Thus, while many industrialized nations have
recently witnessed improvements in the factors associated with better health, these im-
provements have done little to signiﬁcantly reduce the poor health outcomes of groups
characterized by some social disadvantage (i.e., groups that are poor, non-white, female,
unemployed or working class). From a public health and policy perspective, initiatives
devoted to addressing health inequality determinants may require diﬀerent programmatic
features relative to the management of health determinants.
While the importance of socioeconomic position as a determinant of health has been
stated, the more diﬃcult question arises as to how to deﬁne its measurement and how
it can be analyzed in relation to other determinants in a multilevel setting. This task is
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complicated by some obvious diﬃculties. First, the construct of socioeconomic position is
broad and deﬁes a concise deﬁnition. Second, socioeconomic position is a latent variable
that cannot be directly measured (Oakes, 2011). Third, socioeconomic position diﬀers
according to the place one holds in the social hierarchy. A measure of social position will
have to be sensitive to the social, economic, cultural and demographic factors of a person's
life situation, a complexity which is empirically diﬃcult to capture. Oakes and Rossi (2003)
and Oakes (2011) devote greater attention to the available composite or proxy measures
that have been developed to measure socioeconomic position, six of which I review below.
Social Class: Max Weber deﬁnes class as the typical probability of 1) procuring goods,
2) gaining a position in life, and 3) ﬁnding inner satisfactions, a probability which derives
from the relative control over goods and skills and from income-producing uses within a
given economic order (Weber, 1978: 302). It is through class structures that health in-
equalities are generated and maintained. Social class contours stratiﬁcation which allocates
power and wealth to groups and individuals. One of the more important aspects of class
in this context is the intergenerational transfer of economic position from parents to their
children. In this way parental incomes have a strong impact on child health that is not
due to genetic inheritance or the health status of parents (Bowles and Gintis, 2002; War-
ren and Hauser, 1997: 17). Parental income and wealth are therefore strong predictors of
likely economic status of the next generation. Such intergenerational transmission is further
consolidated as the advantages or disadvantages of a particular class membership position
accumulate over time.
Income: One way to capture a person's position within the social hierarchy is through
income. Income is an indicator of an individual's material possessions, which is converted
to expenditure on improved health enhancing environments, behaviors, and services. For
example, income can be used to purchase more nutritious foods, better housing and safer
neighborhoods, easier access to health care and prevention, and so on (Galobardes et al.,
2006). Since money is related to status and prestige, an improved social standing may
result intrinsically in improved self esteem and self worth, which in turn positively aﬀects
health outcomes. In this way, psycho-social factors may provide a buﬀer to environmental
risks and exposures which damage health. It should be recognized, however, that income
and income inequality are not the same constructs. Lynch et al. (2004) argue that despite
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discussion of fundamental causes, there is little that has been said about the fundamental
mechanisms that link social disadvantage to diﬀerent sorts of health outcomes. They stress
the importance of recognizing that the determinants of health diﬀer at the population
and individual levels. A distinction must be made between income inequality which is a
characteristic of the social system, and income, which is a characteristic of the individual.
The former may be determined by broad macro-social contexts related to history, politics
and economics. The latter, on the other hand, is determined by a person's cognitive abilities,
education, skills and aptitude for certain tasks. A multilevel approach suggests that the
investigator be attentive to the diﬀerences between macro-level determinants and individual
level outcomes. Such a distinction will help to speciﬁcally address the role of income
inequality as a social determinant of health.
Race and Gender: The term race is a socio-political-cultural construct that is deeply
unstable and internally contradictory (Omi and Winant, 2011: 367). Nevertheless, race
is often considered to be an important construct because it has shaped, and continues to
shape, the social system in which we live. Gender, like race, is a social construct which is
also a fundamental basis for discrimination, limiting access to power, prestige and resources
for the majority of women. Race and gender have been the principal components of social
formation and stratiﬁcation, with groups being ranked (often on the basis of sex, skin color
or other phenotype characteristics) in such a way so as to privilege some and disadvantage
others. Societal determinants shape deﬁnitions of race and gender which put into play in-
stitutional policies and practices which in turn aﬀect socioeconomic position. There is both
an institutional and individual dimension to racism and sexism, and it is the former that
is of importance as a social determinant of health. The implementation of discriminating
policies, systematic inequality and diﬀerential access to health care are broad cases of in-
stitutional racism and sexism that may aﬀect how health care resources are accessed and
utilized (Kunitz and Pesis-Katz, 2005). From a multilevel context, understanding racism
and sexism as an institutional rather than a speciﬁcally individual construct may help us
to understand diﬀerences in health status between groups of color and sex (Williams, 1997;
Karlesen and Nazroo, 2006).
Education: This is an indicator that measures early life socioeconomic position; it also
operates in a number of ways to inﬂuence health outcomes at the group and individual
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level. Education is one of the primary ways in which an early adult transitions from their
parent's received socioeconomic position to their own socioeconomic position. Parental
educational attainment has a direct relationship with a child's educational opportunities,
and a father's education and social class have been shown to aﬀect a child's health status
at birth (Case et al., 2005). The attainment of cognitive, intellectual skills and abilities
in early childhood may predispose individuals at a later stage in the life course to be
more receptive to health education messages and engage in health promoting behaviors.
Advanced educational status may also result in better living standards and employment,
which translate into better health outcomes. While children from higher income families
typically have higher educational attainment, the experience of poorer childhood health
and lower investments in human capital are associated with lower educational attainment
(Case et al., 2005; Warren and Hauser, 1997). Disadvantages associated with ill health may
limit access to subsequent educational resources, and further predispose groups with limited
educational opportunities to the onset of adult diseases and complications over time.
Occupation: This is an indicator of socioeconomic position, and is related to health
outcomes in a number of ways. Marmot et al.'s (1991) classic study of British civil servants
showed a strong association between occupation and mortality. The authors report that
those lower in the income grade hierarchy were more likely to report ﬁnancial and housing
diﬃculties. One of the key mechanism linking occupation to health is income. As discussed
earlier, income can determine the access to and accumulation of material resources. These
resources can be used by an individual to reduce his or her exposure to disease, toxicity, and
illness. Occupational hierarchy can also expose workers to a speciﬁc pattern of health risks
(Diderichsen et al., 2001). Lower class groups or individuals typically work in conditions
which expose them to higher levels of toxicity and disability (Case et al., 2005). For ex-
ample, manual workers (compared to non-manual workers) undertake strenuous tasks that
involve repetitive strain, physical labor, alongside continuous exposure due to often harsh
weather conditionsfactors which increase the risk of mortality. Workers with lower con-
trol over their job and higher work load are also at greater risk of disease, are less likely to
exercise and maintain a balanced diet, and are likely to have lower educational achievement
(Marmot et al., 1991). Chronic health conditions in childhood can also signiﬁcantly aﬀect
opportunities for employment in adulthood (Case et al., 2005).
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These proxy measures help to illustrate the importance of socioeconomic position as a
health inequality determinant. Due to the conditioning eﬀects of socioeconomic position,
subgroups and individuals are likely to demonstrate behaviors that increase their exposure
to particular health risks; and individuals higher up the social hierarchy will tend to be less
aicted by illness. As I have mentioned, the spotlight on health disparities and inequalities
introduces us to the idea that groups or individuals who have better access to social goods,
capital and resources are able to enact a range of protective measures that secure their health
prospects. It is in this respect that Link and Phelan (1995: 81) stress the relevance of social
conditions as the fundamental causes of disease. They argue the need to shift our attention
away from the belief systems of Western culture which stress the capacity of individuals to
control their personal fate, a belief system which has orientated the explanatory models of
health outcomes to focus on only on proximate risk factors or individualized care (of the ill
or the sick). Such a viewpoint counters the prevailing cultural and programmatic treatment
of social conditions and health, and pose the question of what social factors put people at
risk of risks? (Link and Phelan, 1995: 85).
2.3 Proximate determinants
In the preceding sections I presented the macro- and micro-social levels of a hierarchical
model of health. I argued that socioeconomic position assumes a critical position in the
multilevel model because it is the point at which societal level factors enter into the lives
of individuals. These macro- or micro-social factors, however, do not directly cause poor
health, illness or disease. From the perspective of this conceptual framework , the societal
and socioeconomic variables must operate through a set of intermediary variables in order to
inﬂuence individual health outcomes. These intermediary variables are called the proximate
determinants of health.
The proximate determinants framework has been developed and used most extensively
in the ﬁeld of demography. In this context, demographers have been mainly concerned with
explaining how the macro-level processes of fertility, morbidity and mortality diﬀer across
social groups. Davis and Blake (1956) ﬁrst outlined an analytic framework for studying dif-
ferences in population fertility due to the eﬀects of social structure. Comparative analyses
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typically show profound variation in fertility levels despite the biological, and hence univer-
sal, process of human conception and birth. As conceived by Davis and Blake, an analytic
framework must classify the intermediary variables through which social factors operate to
aﬀect fertility levels. Three temporally ordered steps in the reproductive process, which
are generalizable to human culture, can be identiﬁed as: 1) intercourse, 2) conception and,
3) gestation and parturition. The eleven intermediate variables are subsets of these three
stages in the reproductive process.
There are six factors that aﬀect exposure to intercourse (deﬁned as the formation and
dissolution of unions in the reproductive period, or exposure to intercourse within unions):
1) The age of entry into sexual union; 2) permanent celibacy which is the proportion of
women never entering sexual union; 3) the amount of reproductive period spent after or
between unions (when unions are broken by divorce, separation, or desertion, or by broken
by the death of husband); 4) voluntary abstinence; 5) involuntary abstinence; and 6) coital
frequency. The factors aﬀecting exposure to conception involve 7) fecundity or infecundity
as aﬀected by involuntary causes; 8) the use or non-use of contraception (by mechanical,
chemical means, or other means; and 9) fecundity or infecundity as aﬀected by voluntary
causes such as sterilization. The factors aﬀecting gestation and parturition include 10) fetal
mortality from involuntary causes; and 11) fetal mortality from voluntary causes.
Without speciﬁcally stating how cultural factors operate through these eleven interme-
diary variables, attempts to explain the relevance of cultural factors on fertility are typically
inconclusive or confused (Davis and Blake, 1956: 213). By deﬁnition, these interme-
diary variables are not culturally speciﬁc, must exist in every society (through biological
necessity), and all eleven intermediary variables must be included in a fertility analysis.
The eﬀects of the intermediary variables on fertility are either positive or negative. For ex-
ample, the practice of celibacy or contraception would naturally suppress fertility (holding
the remaining intermediary variables constant), whereas increased coital frequency would
have an enhancing eﬀect. If, for reasons relating to certain characteristics of social organi-
zation, a subset of the intermediary variables are ruled out, then the remaining subset must
account for or explain the pattern of fertility within that social context. Due to the partic-
ularities of social contexts, diﬀerent population groups may have varying combinations of
the intermediary determinants, as in the case where industrialized societies, for example,
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tend to have higher values on contraception, or delayed age at marriage, when compared
to societies from the developing context.
To demonstrate their framework, Davis and Blake (1956) refer to the historical case of
Ireland, and decompose the role of cultural-economic factors on the intermediary variables
of fertility. The authors claim that the cultural determinants of inheritance along with par-
trilocal factors contributed to later marriage among the Irish, which resulted in decreased
levels of fertility. They argue that the causal relationship between the cultural-economic
characteristics of Ireland and fertility patterns can only be properly understood by identi-
fying and classifying the intermediary variables through which the underlying determinants
operate. The work of Davis and Blake is cited here because of the conceptual attempt to
explain the pathways through which macro-social processes inﬂuence biological outcomes.
Bongaarts (1978) and Bongaarts and Potter (1983) replaced the term intermediary
variables with the proximate determinants, and further developed the fertility framework
of Davis and Blake (1956). The proximate determinants directly inﬂuence fertility: a change
in the value of one proximate determinant (holding the remaining determinants constant),
is associated with an increase or decrease in a fertility outcome. Fertility variations or
changes at the population level should thus theoretically be traced to a change in one or
more of the proximate determinants. While socioeconomic factors may be weakly correlated
with fertility levels, they may strongly inﬂuence the proximate fertility determinants. Each
proximate determinant has a separate inﬂuence, indicating the possible pathways through
which socioeconomic factors can inﬂuence fertility outcomes. Bongaarts (1978) list eight
determinants of fertility relating to the factors that aﬀect exposure 1) proportion married;
marital fertility control factors 2) contraception and 3) induced abortion; and natural fertil-
ity factors, which are 4) lactational infecundability, 5) frequency of intercourse, 6) sterility,
7) spontaneous intrauterine mortality, and 8) duration of the fertile period.
Bongaarts (1993) paper is a working example of a proximate determinants framework in
action, which is a methodical attempt to parse out the eﬀects of socioeconomic development
versus family planning interventions on fertility levels in developing contexts. Bongaarts is
in eﬀect grappling with the question of how to account for the role of competing macro-social
processes (or institutional eﬀects) on fertility rates and outcomes. To address this ques-
tion, Bongaarts speciﬁes the outcome variable as a measure of reproductive performance,
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or fertility. The physiological process of birth is deﬁned as a function of three proximate
determinants: 1) supply of births measured as natural fertility, 2) demand for births mea-
sured as wanted fertility and, 3) degree of preference implementation, scaled from 0 to 1,
which measures the decision making process in which couples weight the cost of fertility
regulation against unwanted childbearing. The macro-social processes of socioeconomic de-
velopment and family planning are mediated by the behavioral and biological variables of
supply, demand and preference implementation. Bongaarts tests his model by regressing
the three proximate determinants on socioeconomic development and program eﬀort. The
results show that the development index has a highly signiﬁcant impact on wanted fertility
and the programme eﬀort score is a highly signiﬁcant determinant of the index of preference
implementation (Bongaarts, 1993: 452). Using this framework, Bongaarts (1993: 453) ar-
gues that past studies of the determinants of fertility have been hampered by the absence
of a convenient analytical framework for quantifying the relationships between successive
layers of factors that link fertility to its basic determinants.
Bongaarts and Potter's identiﬁcation and selection of the proximate determinants of
fertility has not gone without critique. (A review of this critique is beyond the scope of
this paper, see Stover (1998) for a more detailed discussion.) My aim has been to ﬂesh out
the potential mechanisms by which social things make their way into the human body. As
discussed above, the proximate determinants framework provides a useful methodological
means for getting at this question. This framework can be applied to health outcomes other
than fertility, as will be discussed in more detail in Section 3.1.1. A proximate determinants
framework may further help the analyst to identify and order the various competing risks
that interact to aﬀect the health and well-being of individuals. This conceptual proposition
need not necessarily be construed as challenging the contribution of important sociological
precepts (power, class, diﬀerential resource allocation, inequality, etc.) with respect to the
study of health outcomes. The biological and behavioral factors, which are situated at the
individual level, are the components through which the inﬂuences of these deeper social
forces are realized.
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A note on the application of multilevel models in statistics
In this chapter I have discussed how a multilevel approach, along with the proximate deter-
minants framework, can be used to outline the causal mechanisms by which societal-level
factors inﬂuence individual health outcomes. I ﬁnd it necessary at this stage to make a
distinction between the multilevel framework proposed in this dissertation and the use of
multilevel models in the statistical analysis of health data. Essentially, my aim is to present
a conceptual framework that explains how societal level factors are manifested as individual
pathology. Here, I make a loose appeal to notions of causality by delineating the series of
levels through which societal level factors must operate in order to inﬂuence the health of
an individual. It is in this context that I make use of the term `multilevel'. Multilevel
statistical models, on the other hand, seem to be primarily concerned with the technical
problems related to the grouping of individual properties within hierarchically ordered lev-
els. In this context, the assumptions of traditional linear models are violated because of
the untenable assumption of independent or uncorrelated residuals. Multilevel statistical
models oﬀer a way to account for the hierarchical nature of the data so that so that the
appropriate estimates and standard errors can be produced.
In this dissertation I consider the question of how social things make their way into the
human body to be quite diﬀerent from the technical issues raised by the hierarchical struc-
ture of (health) data. The former relates to an epistemological approach that draws more
broadly on the ideas of causality and the principle of vertical integration. Arguably, the
latter appears to be a statistical response to the empirical challenges inherent in the spatial
and temporal ordering of our social reality. I am concerned more with the ﬁrst than the
second theme, and as a result I do not attempt to test the proposed conceptual framework
through the statistical application of multilevel models in this dissertation. Indeed, I do
not consider the proposed multilevel model presented in this chapter to be the deﬁnitive
contribution of the dissertation. Once developed over the course of Chapter 3, I consider
the proposed conceptual framework to remain `on-call' or in the `background' as I turn to
the essence of this work, which is contained in the three empirical chapters. Thus, instead
of validating a theoretical or statistical approach, each empirical chapter in this dissertation
addresses an applied problem in the real-world context of HIV treatment and careit is in
this area that I endeavor to make the substantive contribution.
Chapter 3
The Epidemiology of HIV/AIDS
HIV/AIDS can be described as one of history's worst pandemics, resulting in more than
60 million infections and 30 million deaths (De Cock et al., 2011). Globally, HIV continues
to spread unabated and with no end in sight. By the end of 2010, the total estimated
number of adults and children living with HIV was 34 million (31.635.2 million), another
2.7 million (2.42.9 million) were estimated to be newly infected with HIV, and 1.8 million
(1.61.9 million) were estimated to have died of AIDS (UNAIDS, 2011).1 The goal to
have more than 5 million people on treatment constitutes one of the biggest public health
interventions thus far witnessed (UNAIDS, 2010). By 2010, however, only 20% of sub-
Saharan Africa was estimated to have ART coverage (UNAIDS, 2011).
AIDS (Auto-Immune Deﬁciency Syndrome) is caused by the retrovirus HIV (Human
Immunodeﬁciency Virus). Retroviruses diﬀer from other viruses because they can transcribe
DNA (deoxyribonucleic acid) from a viral RNA (ribonucleic acid) template, a process that
is reverse to the usual ﬂow of genetic information (Montano and Williamson, 2002).2 At
the initial stage, HIV attaches, encodes, fuses, and then penetrates the cellular membrane
of a host cell. Once inside the nucleus of a host cell, the HIV pathogen utilizes a reverse
transcriptase enzyme to create a DNA copy of the viral genome, which it then synthesizes
with the host DNA strand. The now combined DNA strand is passed over into the new
cell and ﬁnally released as an independent cella process that ensures the replication of
1 Uncertainty ranges of point estimates reported in parenthesis.
2 Viruses are non-living particles that have two parts: an outer capsid composed of protein subunits,
and an inner core of nucleic acid, either RNA or DNA, but not both. The capsid is surrounded by an
outer membranous envelope, which contains viral glycoprotein spikes used to interact with the membrane
of the host cell. Having penetrated the membrane, a retrovirus relies on the host's enzymes to function;
ribosome's (portions of the cell responsible for metabolism) transfer RNA and adriosine triphoshate for its
own production. RetrovirusesHIV belongs to a sub-group called lentivirusesreplicate by taking over
the metabolic machinery of the cell it has inﬁltrated.
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the viral genome for a lifetime. (HIV replication can also take place in non-dividing cells.)
Because reverse transcriptase does not have a proofreading function, errors are allowed
to go uncorrected during the viral life cycle. These mutations, which respond rapidly to
evolutionary pressures, result in advanced resistance to antiretorviral (ARV) development
and further forestall the discovery of an AIDS vaccine or `cure' (Kuritzkes, 2011).
Once integrated into the DNA replication process, HIV targets speciﬁc CD4 T-lymphocyte
cells, also known as helper T-cells. T-cells help to stimulate the production antibodies that
recognize and destroy foreign pathogens. A host's immune system is compromised by the
twin burden of increasing viral load (due to replication) and a decrease in CD4 cells; at
a critical stage, the infected person is neither able to contain nor eliminate a broadside of
opportunistic (viral, bacterial, fungal and parasitic) infections. There are three phases fol-
lowing HIV infection: the period of primary infection; an asymptomatic period; and ﬁnally,
overt AIDS. HIV can take 1 year to more than 20 years to progress to full blown AIDS;
the median time to onset is 10 years, and in sub-Saharan Africa the average duration is
only 8.5 years. Variability in the progression to AIDS depends upon the susceptibility of
the individual, HIV virulence, immune response, and other endogenous and exogenous co-
factors. Progression and measurement of immunodeﬁciency in an individual is determined
by the number and percentage of CD4 and CD8 T-lymphocytes in the blood. Individuals
with counts less than 50/mm3 have a 50% annual mortality rate, while individuals with
counts of less than 200/mm3 have mortality rates of 10% to 15% per year (Zijenah and
Katzenstein, 2002).
HIV-1 and HIV-2 are the two types of retroviruses known to cause AIDS. HIV-1 contains
a further 14 sub-types (AK, M, N and O) (see Hemelaar et al., 2006 for a more detailed
description of the geographical origins of each of these sub-types). HIV-1 is the predominant
cause of the AIDS epidemic in sub-Saharan Africa, and is thought to have originated from
three cross species transmission events to produce three distinct sub-groups (M, N and O)
(Diop et al., 2002). The oldest case of HIV-1 was traced back to a man living in Leopoldville,
Belgium Congo (now the Democratic Republic of Congo) in 1959 (a retrospective diagnoses
of his blood specimen was undertaken). This sample was shown to be close in sequence
to HIV-1, and thought to enter into the human population in the 1940s (Montano and
Williamson, 2002). In 1985, a second AIDS-causing virus, HIV-2, was discovered; at the
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time cases were reported in most west African countries. While sharing many virologic
and biological features of HIV-1, studies have shown HIV-2 to be limited in its spread, to
have lower rates of sexual and perinatal transmission, slower progression to AIDS, and a
protective eﬀect against subsequent HIV-1 infection (Kanki et al., 2002). The spread of
HIV-1 and HIV-2 went unnoticed throughout Africa in the 1970s.
In the early 1980s homosexual men in the United States began to clinically present
with a set of symptoms that have since became known as AIDS. By 1983 it was understood
that sexually transmitted infections and blood transfusions were the major pathways of
this yet unidentiﬁed AIDS agent (De Cock et al., 2012). In the United States, early risk
groups were identiﬁed as men who have sex with men (MSM), intravenous drug users,
blood transfusion recipients and hemophiliacs. In 1983 French scientists isolated HIV-1,
and the following year American scientists presented evidence that HIV was the cause of
AIDS.3 During this period, little was known of HIV/AIDS outside of the United States.
Subsequently, cases were reported in Haiti, then in Europe and over the next decade the
epicenter of the epidemic moved from California to a full-scale global pandemic. In the
United States, western Europe, Australia and New Zealand, and parts of Latin America,
HIV infection was predominant in men who have sex with men, whereas intravenous drug
use characterized transmission routes in southern Europe, parts of south and south-east
Asia, and countries in the former Soviet Union (De Cock et al., 2012).
By the mid-1990s more than 20 million people were estimated to be living with HIV/AIDS.
In 2001 an estimated 20.3 million (20.924.2 million) adults and children were living with
HIV, 2.2 million (1.92.4 million) became infected, and 1.4 million (1.21.6 million) people
were estimated to have died of AIDS in sub-Saharan Africa alone (UNAIDS, 2010). That
year, sub-Saharan Africa accounted for three-quarters of the world's AIDS deaths. In this
context, AIDS was responsible for one in ﬁve deaths, twice as many as the second leading
cause of death (Piot and Bartos, 2002). UNAIDS (2011) ﬁgures put the total number of new
HIV infections in sub-Saharan Africa for 2010 at 1.9 million (1.7 million2.1 million), with
the total number infected estimated at 22.9 million (21.624.1 million). Despite declines in
the total number of people being infected with (and dying from) AIDS, the sub-Saharan
3 The group of scientists under the leadership of Robert Gallo initially called HIV human T-lymphotropic
virus type III (HTLV-III).
26
region remains the most heavily aﬀected by HIV.4 With only 12% of the world's popula-
tion, 68% of all people living with HIV reside in sub-Saharan Africa, a region which also
accounted for 70% of new HIV infections in 2010 (UNAIDS, 2011). Substantial geographic
variation in HIV prevalence exists in this region, with Swaziland and South Africa estimated
at 25.9% (with a 95% CI of 24.9% to 27.0%) and 17.8% (17.2% to 18.3%) respectively, and
Senegal at 0.9% (0.7% to 1.0%) for adults aged 1549 years in 2009 (Lewis, 2011).
In sub-Saharan Africa, HIV is predominantly spread through heterosexual intercourse
(horizontal transmission) (Caldwell and Caldwell, 1996, 1993).5 There are three biological
factors that have been identiﬁed to determine the heterosexual transmission of HIV. These
are 1) the exposure of susceptible to infected persons, 2) the eﬃciency of transmission per
contact, and 3) the duration of infectivity (Boerma and Weir, 2005).
The probability of HIV transmission for one sexual act between a heterosexual couple is
thought to be around 0.001 (Cohen, 2012). Transmission eﬃciency is known to be enhanced
in the presence of sexually transmitted diseases (STDs), high numbers of lifetime sexual
partners, and intercourse with sex workers (Cohen, 2012; Tanser et al., 2011; Shahmanesh
et al., 2008; Hargreaves et al., 2008; Lewis et al., 2007; De Walque, 2006). Transmission
events in 1030% of couples typically involve a third partner (Wawer et al., 2005), and only
a minority of new infections occur between couples in a stable relationship (Gray et al.,
2011). Viral loaddeﬁned as the number of copies in a milliliter (copies/ml) of bloodis
becoming more widely recognized as a major determinant of the infectivity level of an HIV
positive person (Smith et al., 2011). In one of the earliest and most widely cited studies,
Fideli et al. (2001) showed that the viral load of the index case was the strongest predictor of
heterosexual HIV transmission. In this respect, the sexual transmission of HIV-1 is strongly
correlated with the concentration of HIV in the partner's blood (Cohen et al., 2011).
In higher income countries, male-to-female transmission is more eﬃcient than female-
to-male transmission, although these ﬁndings have not been replicated in African studies
(Gray and Wawer, 2012). The vertical transmission of HIV from mother to infant, either
4 Since 1998, AIDS-related deaths have however steadily decreased, as free antiretroviral therapy has
become more widely available in the region; decline in mortality may also be an artifact UNAIDS estimate
revisions.
5 Although Lewis (2011) does mention that MSM transmission routes are beginning to attract increasing
interest from epidemiologists. See also Price et al. (2012).
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in utero, intrapartum or postpartum via breastfeeding, is the second most important trans-
mission route in sub-Saharan Africa. The risk of vertical transmission is approximately
35% and 20% in breastfeeding women and non-breastfeeding women respectively; of the
430 000 children that were infected in 2008, 90% of the cases were the result of vertical
transmission (Coutsoudis et al., 2010 citing WHO, 2009). Global diﬀerences in HIV preva-
lence and incidence are further compounded by higher rates of breastfeeding among African
women (Bulterys et al., 2002). Although intravenous drug use is quite low in Africa, one in
eight users are reported to have contracted HIV through this route (Lewis, 2011). Biolog-
ically, blood transfusion is the most eﬃcient pathway for HIV transmission: of those that
receive seropositive blood, 90% become infected (Piot and Bartos, 2002). In Africa, HIV
acquisition through blood transfusion is the consequence of poverty and the deterioration of
health services across the continent. African women and children are particularly at risk of
receiving contaminated blood because of transfusion requirements associated with malaria
induced anemia, sickle cell disease and obstetric complications. Overall, however, infection
via blood transfusion does not constitute a major route of HIV transmission in sub-Saharan
Africa.
3.1 A multilevel model of HIV/AIDS
Sub-Saharan Africa is one of the few contexts (alongside Haiti) to experience the emergence
of a generalized, self-sustaining, heterosexual HIV/AIDS epidemic (De Cock et al., 2012;
Caldwell and Caldwell, 1993). Investigators have presented a number of explanations for
the particularly heterosexual dimensions of the epidemic in the sub-Saharan context (Cald-
well, 2000; Caldwell and Caldwell, 1996). And sociologists have addressed the broader
demographic transitions in Africa, changes to the cultural and social institutions of African
communities, and the reorganization of social life and behavioral relations since the mid-20th
century (Swidler, 2009; Bongaarts, 2007; Crenshaw et al., 2000; Bongaarts and Watkins,
1996; Morris and Kretzschmar, 1997; Caldwell et al., 1993, 1989).
The incorporation of African societies into the global, economic orderﬁrst initiated
under the logic of colonialism, and then subsequently in the transition to modernityis a
key theme in this story (Wallerstein and Smith, 1992). During these two historical phases,
African communities experienced large-scale disruptions to the established political order,
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kinship structure, and indigenous belief systems. These disruptions were systematically
exacerbated by the importation of institutionalized education, the introduction of wage
employment, and the adoption of Western belief systems. European settlers brought with
them the Western nuclear family system, which fundamentally reconﬁgured the rules of
kinship, and changed with it the relations between husbands and wives, between parents
and children, and between members of the extended kin and conjugal family (Martin and
Beittel, 1987). It is within this terrain of broad social upheaval that the African HIV
epidemic is thought to have emerged (Caldwell et al., 1989).
The HIV/AIDS epidemic in sub-Saharan Africa has a complex social history. Eﬀorts to
manage the spread of HIV in this context are further complicated by existing traditional
and cultural beliefs about disease which are at odds with western medicine; a predominantly
patriarchal social structure which constrains the ability of woman to exercise health-seeking
behaviors; enduring structural and institutional inequalities which are mainly the historical
byproducts of colonialism and racism; and a lack of health-care infrastructure to provide
adequate services and medications.
The predominantly heterosexual spread of HIV/AIDS in this context involves the often
intimate sexual relations between two people, bringing the issues of interpersonal power,
inequality, and dependency into play. An adequate explanatory framework of HIV will need
to acknowledge the social, behavioral, and biological inputs that have shaped the character
of the current epidemic in sub-Saharan Africa. As Gillespie et al. (2007: 12) aﬃrm:
A major analytical challenge is to deﬁne the causal pathways operating from
distal socioeconomic factors to proximal individual behaviors and ultimately
physiological factors. Diﬀerent socioeconomic factors may aﬀect health at dif-
ferent times in the life course, operating at diﬀerent levels (e.g. individual,
household and neighborhoods) and through diﬀerent causal pathways.
In an attempt to get at a better understanding of these multiple causal pathways, I
propose a conceptual framework consisting of three levels. These levels are: the community
context or the macro-social level; the household relations that are situated at the micro-
social level; the individual level, which includes the behavioral and biological determinants
of HIV-related outcomes (see Figure 3.1). I make reference to this conceptual model in the
empirical chapters, where I present an analysis of the preventive and survival beneﬁts of
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ART in a rural South African community. Brieﬂy, my starting assumption is that macro-
social forces deﬁne and shape social relations at the household level, before being mediated
by the proximate determinants.
Figure 3.1: Multilevel Model for HIV-related outcomes
A unique contribution of this chapter is my conceptual treatment of the household
factors associated speciﬁcally with HIV acquisition risk. Households are conceptually im-
portant components in the proposed multilevel model because of the range of integral func-
tions that take place within this domain. A household can be deﬁned as a group of persons
that share a home or living space, and who aggregate and share their resources (Scott
and Marshall, 2009). These functions may include among others, socialization processes,
union formation, marriage, birth, childbearing, resource allocation, death and dissolution. I
choose to focus on social relations of the household because, unlike other health-related be-
haviors (such as smoking, obesity, alcoholism) or infections diseases (the spread of measles
or inﬂuenza through casual contact), HIV infection or transmission involves two or more
people and the (often intimate) links between these two people. The predominantly het-
erosexual spread of HIV in this context therefore compels us to consider the sorts of social
things that help HIV get into the body. Heimer (2007: 566) explains this objective quite
well when she writes that [w]hat happens inside the body may be a biological matter, but
the [HIV] virus's journey between bodies in blood, semen, and breast milk is both biological
and social. The exchange of bodily ﬂuids within the household settings are shaped and
deﬁned by the broader social institutions of marriage and fertility.
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For this reason I concentrate on the social relations of the household, since this is the
level where i) decisions about fertility and sexual interaction are enacted, and ii) where
the broader inﬂuences of societal factors are mediated. This point is partly informed by
Easterlin (cited in Smith, 1989: 176), who argues, in the case of fertility, that a framework
be developed at the level of the couple or household since it is assumed that they are the
ultimate decision makers about fertility, and if the community or society desire higher or
lower fertility, they must somehow inﬂuence couples or households.
Social relationships matter because in a multilevel model of health, the household level
variables must mediate the community level inﬂuences on individual level behaviors. This
assumption is based on the hierarchical relationship between the community and household
contexts. Households that are located in a local community (community A, for example) will
tend to be more similar with one another than households from diﬀerent local communities
(communities B, C, D, . . . ). Here the community level is seen to shape and conﬁgure
household characteristics related to resource allocation mechanisms, domestic productivity,
and the social relations between household members. In addition, the social relations
between household members are further deﬁned by the systemic allocation of resources and
opportunities within the household, which ultimately shape existing relationship structures
and processes within the household. I argue that it is at this level that the broader,
community factors related to power, control, inequality and economic dependency enter
into the lives of individuals, which either enhance or suppress the risk of HIV acquisition.
An important question that must be accounted for in a multilevel model of HIV acqui-
sition relates to whether household level factors play the role of main or buﬀering eﬀects.
Positioning the household level between the cultural context and the individual outcomes
level therefore provides us with a useful starting point for investigating the role of household
factors (for example, social relationships, socioeconomic position, migration) on exposure to
HIV-related risks. Thus, while socio-demographic trends and patterns can be seen to shape
contemporary families or households, it is simply not clear how such trends and patterns
may inﬂuence HIV-related outcomes, without ﬁrst considering the household functions that
mediate them. These household factors must in turn be linked to lower-level individual be-
haviors, which are deﬁned as the proximate determinants of HIV (discussed in more detail
in Section 3.1.1).
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3.1.1 A proximate determinants framework of HIV
A proximate determinants framework motivates the attempt to understand the behavioral
and biological mechanisms through which social factors must operate to inﬂuence HIV-
related outcomes. Consider the following simpliﬁed example: a geo-political area enters
into a period of economic decline, signiﬁcantly increasing the unemployment rate within a
local community. In response to this economic crisis, malesa large proportion of which are
household-headsmigrate in search of employment opportunities outside their immediate
social network. The migrant subsequently gains access to new social networks, characterized
by high HIV prevalence in urban areas (Abimanyi-Ochom, 2011). At this point, no valid
causal mechanism has been oﬀered for the evidence that links migration with an increased
probability of HIV infection or transmission. To complete the causal chain, this male actor
(in our thought experiment) must engage in some or other behavior, typically, risky sexual
behavior, that is conditional upon his entry into a new social network, before he is infected
with HIV. Because of the distance between the male household-head and his partner, we can
then begin to unpack the set of household level variables that result in the increased risk of
HIV acquisition for the female partner who has thus far remained in her local community.6
The macro-social (economic decline, the onset of poverty, unemployment) and the mi-
cro level (the type of partnership and migration) factors must, by deﬁnition, be identiﬁable
and antecedent to the proximate determinants of HIV transmission and acquisition. For
example, out-migration may introduce an individual to new social networks and sexual
partnersin the absence of household constraintswhich increase the number of sex part-
ners acquired, concurrency, and sexual mixing. These behavioral changes consequently
aﬀect the biological determinants of HIV infection or transmission. The probability of HIV
acquisition at the household level is increased upon the male partner's return, due to the
local household network structure and the degree of closeness between the couple.
Boerma and Weir (2005) present a proximate determinants framework of HIV trans-
mission. As with the approach to fertility, we can think of there being a set of proximate
determinants through which the social determinants must operate in order to inﬂuence the
6 In network analysis, closeness is deﬁned as the distance between two social actors, which refers to the
number of ties between actors (and not necessarily geographical space), which in the case of a conjugal
partnership is a value of one (Wassermann and Faust, 1994).
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probability of HIV transmission. The authors identify and list the HIV proximate determi-
nants in Figure 3.2. The proximate determinants link the set of social factors (underlying
determinants) with the biological determinants, which are identiﬁed as 1) the exposure of
susceptible to infected persons, 2) eﬃciency of transmission per contact, and 3) duration of
infectivity. Reducing any of the biological determinants to zero implies, by deﬁnition, that
there is a zero probability of HIV transmission.
Figure 3.2: The Determinants of HIV Transmission (Boerma and Weir, 2005)
The social or underlying determinants, which refer to the socioeconomic, demographic
and epidemiological characteristics of a community, must operate through the proximate
determinants in order to inﬂuence HIV transmission. The proximate determinants, deﬁned
as either biological or behavioral variables, have direct links to the biological determinants.
Increasing or decreasing values on one or more of the proximate determinants (while holding
the remaining determinants constant) varies the probability of HIV transmission. For ex-
ample, Bloom et al. (2002); Auvert et al. (2001) and Fortson (2008) show that circumcision
has a strong protective eﬀect in men by reducing the transmission eﬃciency of HIV. The
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presence of an STD (Gillespie et al., 2007), and the longer an infected man remains with
and STD (before seeking help) the more likely he is to have had unprotected sex (Langeni,
2007), thereby increasing HIV transmission eﬃciency. Men who pay for sex are more likely
to increase the values on the behavioral proximate determinants of sex partner acquisition,
coital frequency, concurrency and sexual mixing, thus increasing the biological determinant
of exposure of susceptible to HIV-positive persons (Lewis et al., 2007). Poor socioeconomic
status may constrain a mother's health-promoting choices for her infant, leading to con-
tinued breastfeeding and an increase in the probability of the vertical transmission of HIV
from mother to infant (Rollins et al., 2008).
Lewis et al. (2007) argue that without developing a conceptual framework, confusion
about the relevance and inﬂuence of social and behavioral variables on HIV outcomes is
likely. Identifying who is at risk, and why, is generally complicated because of the range
of behavioral decisions that place individuals at risk of infection, the heterogeneity of risks
within a susceptible population, and the complex social norms which govern sexual behavior.
In their study, Lewis et al. (2007) deﬁne the proximate determinants as describing individual
behavior as well as characteristics of the partner or partnership. In their results, the authors
conclude that the most important proximate determinant was lifetime number of partners
for both men and women.
Bärnighausen and Tanser (2009) inform us that further work still needs to be done on
the factors that determine epidemic spread, and to explain why sub-populations experience
diﬀerent epidemics. In sub-Saharan Africa, the HIV epidemic is characterized by a series
of interlinked subepidemics that operate within diﬀerent social and geographical spaces
(Bärnighausen and Tanser, 2009: 436). For this reason, it is important to distinguish the
factors that shape an individual's sexual behavior from the factors that determine the level
of infection in a community from which an individual is likely to choose a sexual partner.
Generally, risk-related or health-promoting behaviors cluster within certain communities,
which are likely to predispose individuals to corresponding health outcomes. Bärnighausen
and Tanser (2009: 437-438) address some limitations of the framework by Boerma and Weir
(2005) by suggesting the following:
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In our framework, the community is loosely 
defined as the group of people from which an 
individual is likely to choose a sexual partner. 
For practical reasons, in epidemiological anal-
yses, communities are usually defined on the 
basis of administrative geographical boundaries 
(e.g., census areas and clinic catchments) 
because individuals are more likely to choose 
sexual partners from their immediate neighbor-
hood in comparison to neighborhoods further 
away. For example, empirical analyses have 
shown that the STIs tend to spatially cluster in 
geographically defined communities [27,65–69], 
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Figure 1. Proximate-determinants framework of HIV acquisition. 
ART: Antiretroviral treatment; STI: Sexually transmitted infection; VCT: Voluntary counseling and testing.
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Figure 3.3: The Determinants of HIV Acquisition (Bärnighausen and Tanser, 2009)
1) They prefer the use of HIV acquisition rather than HIV transmission as the outcome,
on the basis that the former is an easier measure to obtain given the availability of com-
prehensive molecular databases. They deﬁne this new set of biological determinants as a)
duration of time in the community, b) rate of sexual contact with infected individuals over
time, and c) the probability of acquiring HIV during one sexual contact with an infected
individual. These three biological variables are functions of the proximate determinants.
2) By further elaborating upon the underlying or community level determinants: many
of the individual level determinants have community level counterparts, which can be con-
structed by aggregating the characteristics of the individuals who comprise the community.
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The proximate determinants at the community level capture the various aspects of HIV
transmission. Although the person transmitting is usually not known in the dataset, the
proximate determinants of transmission can be determined at the community level.
3) A proximate determinants model must include feedback loops from HIV acquisition
to the proximate determinants of HIV acquisition. As HIV prevalence increases (a health
outcome), individuals may begin to adjust behavior, such as reducing sex partner acquisition
and concurrency (which are the proximate determinants) thereby reducing the rate of sexual
contact with infected individuals.
3.1.2 The household context
I have thus far outlined the role of the proximate determinants in a multilevel model of
HIV acquisition. In this section I will argue that household level variables be considered as
an important set of mediating variables that are situated between the community context
and the proximate determinants. I will proceed to outline how household factors can be
incorporated in a multilevel analysis of HIV acquisition.
The term household is a broad concept which deﬁes a deﬁnitive conceptual deﬁnition. In
the social sciences, diﬀerent disciplines have focused on particular aspects of the household
structure and its functions. For example, social anthropologists have stressed the kinship
dimensions of social life, and have preferred to focus on the relations between the family and
the household (Caldwell et al., 1993, 1989). Perspectives orientated around economics have
deﬁned the household as a unit of production and consumption, with particular attention
devoted to the division of labor and the allocation of resources within this domain (Becker,
1974). Feminists have brought attention to gendered aspects of the household, focusing
particularly on the socially deﬁned and prescribed roles in the interaction between men and
women (See for example, Ferree, 1990).
Adding further complexity to this conceptual formulation is the diﬀerence in types of
ties, links or relations between family members between the West and other geo-political
contexts. Attempts to arrive at a precise deﬁnition of the household and family system
is not a matter of mere academic curiosity; rather, identifying the prevailing urban family
system, and the boundaries of the household, constitute the very practical business of
modern states and the market (Becker and Murphy, 1988). It is through the household
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that essential information about the population is collected. In the West, the household
is an attractive starting point for this objective, since it is operationalized to be a self-
contained unit that is relatively easy to identify, sample and access. Ideas of the household
as a site of production and consumption further provide state bureaucrats, demographers,
economists and entrepreneurs with vital data about the behaviors of citizens.
Survey strategies have managed to successfully and systematically collect a wealth of
information on Western households. This is because of the speciﬁc characteristics of the
household that make it amenable to data collection methods. The Western household is
typically operationalized as a (a) discrete and (b) bounded, (c) residential unit with (d) an
unambiguous membership (e) centred about a conjugal couple and (f) for a while, their
minor dependent oﬀspring. It is (g) invariably a unit of consumption in which (h) all
income may be shared but some pooling of income must occur (Russell, 2003a: 8).
This methodological framework of survey sampling is heavily centered on the conception
of a Western conjugal nuclear family system. This conceptualization relates to more than
simply the size or composition of the household, it also refers to the structural and relational
components that describe the cohesion and mobility of household members. These observa-
tions have prompted researchers to question whether Western formulations of the household
can eﬀectively capture the social reality of kinship systems and households in other parts of
the world (Wilk and Miller, 1997). Failure to consider and appreciate these structural and
functional characteristics may threaten the validity of inferences made about households
that do not particularly meet the deﬁnition of the Western conjugal nuclear system.
Russell (2003b) has discussed this issue in some detail, and has drawn attention to
the set of problems that derive from the collection of information from southern African
households. These problems stem from a set of characteristics that diﬀerentiate the family
and household systems of the West from sub-Saharan Africa. As an ideal-type, the deﬁning
feature of the Western household is its bilateral mode of descent. In this system neither
the wife's nor the husband's family takes precedence over the other; the couple each have
their own constellation of close relatives, and there is usually no overlap of kin between
the two families. A partner thus passes through life with access to two conjugal family
households: the one into which he or she was born, and the one to which he or she married.
Typically, marriages are between two people of the same age. Once married, the couple
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establish their own independent household to raise their children to maturity. In the West,
then, the household is centered around the tightly-connected couple, and the greater (if not
all) share of decision making regarding the rearing of their children is made by the parents.
For this reason, the conjugal-nuclear system and the household are sometimes considered
as one and the same thing.7
In sub-Saharan Africa, the family system is predominantly unilineal, with descent
through the father (Caldwell et al., 1993; Goody, 1973). This system establishes the for-
mation of identities, determines who resides where and with whom, and favors the repro-
ductive preferences of the husband. African culture bestows upon men considerable power
in household aﬀairs and, more speciﬁcally, in the reproductive decision-making process
(Dodoo, 1998). For this reason, demographers have begun to pay greater attention to the
role that male household-heads play in the inability of women to translate their reproduc-
tive and sexual health goals into reality. Marriages are typically between an older man and
a younger women. Fertility is of great importance, and marriage is the right to a woman's
fertility; women bear children for their husband's lineage. For example, Dodoo (1998) ob-
serves that the purpose of the traditional payment of bridewealth from the groom's family
to bride's family is to compensate the bride's family for future births which will become
part of the groom's lineage. In this respect, children will belong to the patrilineage of the
man who impregnated their mother, or they may belong to mother's husband regardless
of the impregnator. In contradistinction to the conjugal nuclear system, child bearing is
rarely the exclusive responsibility of the parents. African children are more likely to spend
a substantial part of their time in the household of either their paternal or maternal grand-
parents (Russell, 2003b). In many respects, the kinship structure may be considered to
be less cohesive but generally more interconnected to a larger kinship system; and high
household member mobility may further contribute to the speciﬁc character of the African
household.
In black households of southern Africa, marriage is not a couple-centered institution,
and this is a key distinction in comparison with the Western family system (Russell, 2003b).
In this kinship system the lineage bond is emphasized over the conjugal tie, which ostensibly
produces a less restrictive relation between a man and a womenand therefore between
7 See, for example, the Oxford dictionary's deﬁnition of the family as a group consisting of two parents
and their children living together as a unit.
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a husband and wifethan is typically observed in Western partnerships. Caldwell et al.
(1993) observe that emotional links within the African household are weak, and that women
are not supposed to inquire of a husband's sexual relations outside of marriage. Husbands
are generally much older than wives, and divorce is fairly common among most ethnic
groups. Partners are unlikely to discuss whether they are infected, and the sexual routines
and norms do not permit for the identiﬁcation of STDs in the partner (if sex in undertaken
in the dark, for example). Many non-symptomatic persons do not know of their STD or
HIV status, and for women there are costs associated for disclosure (i.e., accusations of
inﬁdelity). High levels of polygamy are also features of the household structure in certain
areas south of the Sahara. According to Caldwell et al. (1993), polygamy can only exist
if men marry for the ﬁrst time at an age ten years later than woman, therefore delaying
the onset of marriage for men to their late twenties. An implication of delayed marriage is
the high proportions of unmarried post-pubertal men whose surplus sexuality is absorbed
into the extended family, or into relations with widows, deserted wives and polygamously
married women not receiving support from older husbands.
Caldwell et al. (1989) argues that the basic social system, and consequently the basic
family unit, in sub-Saharan Africa is a mother and her children. Considerable marital
instability, high divorce rates, husband mobility, and the emphasis of lineage over spousal
links result in high levels of female headed households.8 Female-headed houses are also
largely the product of male out-migration to urban areas in search of employment and
income. Male out-migration increases exposure to new sexual opportunities, on the one
hand, and a diminished capacity to control the movement and decisions of women back
at home, on the other. These factors have contributed extensively to the nature of the
HIV/AIDS epidemic in the sub-Saharan context. The epidemic has been driven by factors
relating to a higher level of sex outside marriage, and higher levels of transactional sex and
prostitution due to the concentration of men in urban areas. STDs which are important
cofactors in the transmission of HIV, are prevalent and are accompanied by a low rate of
safe sex practices undertaken in households dominated by male decision-making.
8 The consequences of single-headed female households are nevertheless less consequential than in West-
ern societies. Here, household arrangements are secondary to the essentials associated with the female's
patriclan name, which guarantees to her entitlements and claims to a share of the paternal homestead.
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The particular structure of the household, and the relations between the extended
kin network, are important considerations that must be accounted for in the study of
HIV/AIDS. Furthermore, identifying the household level factors may help us to more care-
fully assess the relationship between socioeconomic status and HIV risk. Socioeconomic
status may be uniquely reﬂected among the various components of the particular house-
hold structure, and the relations between members of the household. Including household
level factors in a multilevel model of HIV infection means that we can continue to incor-
porate the constructs of hierarchy, power, control and inequality in an analysis, as was the
case in the reviewed discussion of socioeconomic position. These constructs are infused
into, and permeate, the household network, and therefore characterize the relations be-
tween household members. Because the exercise of power is ubiquitous, it may be useful to
speak more speciﬁcally about the various aspects of social relations at the household level,
and how these aspects may expose individuals to the risky behaviors that result in HIV
transmission or acquisition. As a point of departure, it would be useful to partition this
relatively broad concept into the dimensions of type of relation, contact frequency, dura-
tion of contact, multiple membership, empowerment, partnership cohesion, socioeconomic
status, household network, composition, and formation/dissolution.
Type of relation: This is a property that describes the linkages between two or more
household members. Of particular interest are the types of partnershipsmarital, conjugal,
non-conjugal and casualbetween actors that include sexual relations. As is discussed in
the section below, partnership or union type is closely related to relational aspects of power
and control. Past research has suggested that attention continue to be devoted to evaluating
diﬀerences in HIV risk by partnership or relationship type. For example, Abimanyi-Ochom
(2011) and Auvert et al. (2001) report that women who were ever married, widowed, and
divorced were more vulnerable to HIV acquisition than the never married. Langeni (2007)
report that being married and having had sex with more than one partner in the last 12
months multiplied the odds of having had unprotected sex by three times. Bloom et al.
(2002) report that marital status was the strongest risk factor for HIV seroconversion,
with those formerly married four times more likely to be HIV-infected than those who
never married. Auvert et al. (2001) report that a higher frequency of unprotected sex
may also take place in a marital unions than in casual relationships. In his paper, Reniers
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(2008) discusses how individuals use marriage as a resource with which to manage exposure
to HIV, either through mechanisms of negative or positive selection. Negative selection
mechanisms may include marriage to a partner who has HIV, or who is likely to commit
adultery. Reniers ﬁnds that those who use positive selection mechanisms for remarriage are
less likely to be infected than those who remain single.
Frequency of contact: This describes the strength of social ties, and includes a measure
of the degree and quality of contact and interaction between household members. Mobil-
ity, travel or migration are considered to be useful proxies for the measure of frequency of
contact. In sub-Saharan Africa, the traditions that regulate sexuality and marriage are
disrupted by employment practices that take men away from home for extended periods
(Heimer, 2007: 570). Travelers are more likely to have a higher levels of partner acquisi-
tion, because of the mobility aﬀorded by a higher socioeconomic position and occupational
opportunity (Morris et al., 2004). Here travel is seen to weaken social constraints and in-
crease exposure to new sexual partnerships which increase the proximate determinants of
multiple sexual partners and coital frequency. Migration results in bridges to other net-
works, characterized by higher HIV prevalence among sex workers or in urban areas, for
example. Thus, frequency away from the household, duration of time away from the house-
hold, the frequency and duration of return visits may be important indicators of HIV risk.
The type of relationship between household partners will also have something to say about
the frequency of contact, including sexual contact. For example, research has shown that
consistent condom use is less likely with a regular than a casual partner (Chimbindi et al.,
2010).
Empowerment: Feminist scholars have drawn attention to the traditional and patri-
archal structure of the household in South Africa (Shisana et al., 2010; Albertyn, 2003)
and elsewhere (Borovoy and Ghodsee, 2012; Brines, 1994; Sorensen and McLanahan, 1987),
which results in the inherent inequality of its female members. A patriarchal hierarchy typ-
ically confers power to the male household-head, enabling him to regulate and control the
behaviors of other household members, as well as to determine the allocation of resources
within the family (Ulin, 1992: 63; see also Iyayi et al., 2011; Orubuloye et al., 1993). Women
who do not have access to independent capital and resources are often forced to depend on
alternative strategies to procure goods, which may push some women to form unions with
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economically independent men or to engage in transactional sex. This power diﬀerential is
further compounded by the social norms which favor men in terms of control over sexual
decision-making (Jewkes et al., 2010; Kalichman et al., 2005). As a result, women who are
economically dependent on their partners may not be able to insist on condom use and
safe sex practices (Gillespie et al., 2007). The social norms governing sexual behavior in
sub-Saharan Africa often imbue men with greater freedom to engage with multiple sexual
partners (often younger women) and to dominate or control sexual decision making.
Aspects of household relations that reﬂect power and control may be important social
determinants of HIV outcomes. Research has shown that disempowerment, economic de-
pendency, structural violence, low socioeconomic status, and the failure to negotiate safe
sex practices are associated with a higher probability of HIV acquisition, particularly among
women in the developing context (Luke et al., 2011; Bandali, 2011; Hawkins et al., 2009;
Luke, 2003).
Because many women are economically dependent on men, the degree to which
they are able to express their own will is often limited. This lack of choice
or lack of powerleads some women to engage in high-risk behaviours, which
increases their chance of contracting the HIV virus (Opportunity International,
quoted in Wojcicki, 2005: 4).
Measures of empowerment and control are methodologically diﬃcult to obtain with
surveillance data. Wojcicki (2005) suggests that socioeconomic status and education can
be used as two proxy measurements for empowerment. In a review of the literature, Luke
et al. (2011: 1050) report that women's wage labor and income is positively associated
with decision making about household expenditure and the use of contraception; and that
women who worked for cash had more power to negotiate the timing and frequency of sex
with their husbands than nonworking women. Disempowerment refers to women who do
not have access to independent capital and resources, and who therefore depend on alter-
native strategies to procure goods, which may push some women to engage in transactional
sex or to form unions with economically independent men.9 Dependency on men for
9 Leclerc-Madlala (2008) discusses that women may express agency in their choice of older men as this
is an act of self-assertion, cleverness and an important contributor to self-perception of modern, sexually-
liberated women.
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economic transfer reduces the bargaining position of women, and ultimately their capac-
ity to engage in protective sexual behaviors. In their studies, Davidoﬀ-Gore et al. (2011)
and Abimanyi-Ochom (2011) show that young people and women with greater economic
resources, and hence increased decision-making power, were able to successfully negotiate
condom use in their relationships.
In developing countries, women generally have limited access to educational resources.
Education may be further linked to employment status, access to resources, greater mobility
and hence increased autonomy and independence. A number of studies have investigated
the relationship between education and HIV risk. For example, Davidoﬀ-Gore et al. (2011)
report that inconsistent condom use is associated with a lower level of education, lower
amounts of income and larger amounts of money and gifts received from sexual partners.
Glynn et al. (2004) found that more educated persons reported less frequent sexual be-
havior. More highly educated women were less likely to report a lack of control in sexual
relationships and less likely to use condoms inconsistently (Weiser et al., 2007); better oﬀ
women reported fewer partners and were less likely to engage in transactional sex (Lop-
man et al., 2007). Wojcicki (2005) notes that a some studies show a positive association
between higher socioeconomic status and increased HIV risk. More funds for some women
may actually increase exposure through greater access to partners or opportunities for
travel. Higher educational status may also make some women more mobile, access better
jobs and therefore gain access to partners with higher mobility.
Partnership Cohesion: Closely related to the household component of empowerment
is partnership cohesion. Partnership cohesion measures the quality of social relationships
which, depending on the kinds of behaviors, may be either health promoting or health
damaging. Whereas empowerment indicates the capacity of individual household members
to negotiate protective health behaviors, partner cohesion refers to the various aspects of
an intimate sexual relationship that vary the risk of HIV acquisition. Union, partnership
and marital relations are often considered to mediate health outcomes, an important ob-
servation particularly in the context of HIV/AIDS. The degree of integration, stability,
and symmetry typically describe the characteristics of a sexual partnership between two
household members (usually between the male household-head and his partner).
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Within the general population, there is a tendency toward homophily, or assortative
mating where prospective partners are chosen on the basis of similarity (symmetry), and
where partners are selected from within their social networks (Kalmijn and Vermunt, 2007).
In network theory, symmetry (or homophily) is thought to result in strong ties reducing
the potential for transitivitythe ability of weak ties to reach across to clusters that may
be characterized by high HIV prevalence (Aral et al., 2004). A strong network structure,
characterized by small size, strong ties, high density, high homogeneity, and low dispersion
appear to be helpful in maintaining social identity and hence health and well-being (House
et al., 1988: 304). In this sense, larger networks with weaker ties, greater heterogeneity and
higher dispersion are likely to produce greater changes in health and well-being, which in
the context of a high prevalence HIV epidemic, may ultimately increase the exposure and
eﬃciency of HIV transmission and infection.
It is worth noting that the issue of gender is central to this discussion of the relational
aspect of economic and partner symmetry. Research has shown that partnerships charac-
terized by a high level of stability, integration, and symmetry buﬀer the household from
HIV-related risks. The aspect of partnership cohesion to receive the most attention is age
symmetry because of higher HIV prevalence among older men, and the gender-based power
diﬀerences in age disparate relationships that reduce the ability of younger female partners
to negotiate safe sex practices (Leclerc-Madlala, 2008; Luke, 2003). Age disparate relation-
ships are generally deﬁned as an age gap of greater than 5 years between a female (usually
the younger) and male partner. Langeni (2007), for example, showed that for every year's
increase in the age diﬀerence between partners there was a 28% increase in the odds of
having had unprotected sex. In their work, Chimbindi et al. (2010) discuss how having
a partner older by at least a year signiﬁcantly reduced the likelihood of using a condom
compared to partners of the same age. Age asymmetry may be further correlated with
relationship type. In their study, Ott et al. (2011) report substantially larger age diﬀerences
in spousal relationships than in casual relationships.
Partner stability within the household may also be an important factor in HIV risk. As
discussed in the previous section, relation type is associated with HIV risk, while partner
stability characterizes the quality of the partnership. A number of studies have looked at the
behavioral and sexual practices associated with partner stability. Shai et al. (2010: 1383)
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report that South African women (in the Eastern Cape province) with only one partner had
a much more equitable power distribution in their relationships, which facilitated condom
use; results also showed that condom use was enhanced by the relative stability of having
only one partner. Pulerwitz et al. (2002) discuss how greater equity in a relationship in-
creases a woman's ability to use condoms; whereas women in poorly perceived relationships
reduced opportunity for discussion and negotiation of condom use (Jewkes et al., 2003).
However, Chimbindi et al. (2010) report that condom use declined with the formation and
duration of stable relationshipsa ﬁnding that corresponds with decreased condom use in
marital relations compared with the never married (Bloom et al., 2002; Auvert et al., 2001).
Among asymmetric or discordant partnerships, communication may be challenged and
likely involve precepts of power, inequality or control. Kohler et al. (2007: 27) ﬁnd that
social networks inﬂuence not only the perception of AIDS risks but also important house-
hold decision processes in the adoption of preventative behavior. They also report that
increased interaction between partners tended to increase discussion and communication
about HIV/AIDS, thereby informing safer sexual practices. Households characterized by
partner absence, relationship discord, and large diﬀerences in income are associated with
increased probability of HIV infection (Ott et al., 2011; Reniers, 2008; Kohler et al., 2007;
Luke, 2003). Factors relating to fear of divorce or abandonment may aﬀect motivation to
disclose one's status, which has strong implications for the adoption of protective behav-
iors against HIV risk and transmission. Gender based violence and fear of physical abuse
may prevent disclosure for fear of reprisal (Anglewicz and Chintsanya, 2011). Furthermore,
union instability and discord may lead to heavy sexual mixing with two or more part-
ners outside the household network, thereby increasing in the proximate determinants of
concurrency, coital frequency, and multiple sexual partners.
Socioeconomic status: It is generally acknowledged that studies of HIV acquisition and
spread in sub-Saharan Africa are undertaken in areas characterized by relative poverty
in the context of generalized chronic poverty (Gillespie et al., 2007: 6). In this context,
the relationship between socioeconomic status and health is quite dynamic and complex.
Gillespie et al. (2007) report a weak positive relationship between national wealth and HIV
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prevalence across the continent. Countries with a good transport infrastructure, strong
urban-rural linkages, and high professional mobility have a higher HIV incidence rate.10
A number of studies have reported a positive association between socioeconomic status
when measured as either wealth or educationand HIV acquisition. A substantial body
of research has argued that higher levels of education and wealth generally lead to greater
personal autonomy and mobility, thereby increasing the demand for sexual partners and
heightening the risk of HIV infection (Ho-Foster et al., 2010; Glick and Sahn, 2008; Gille-
spie et al., 2007; Hargreaves et al., 2008; De Walque, 2006; Shelton et al., 2005; Wojcicki,
2005; Hargreaves and Glynn, 2002). In her study of ﬁve African countries, Fortson (2008)
found that better educated respondents were more likely to have engaged in premarital sex
and have a positive HIV serostatus. In their work, Msisha et al. (2008) link higher dispos-
able income and increased mobility in wealthier neighborhoods to high-risk behavior and
involvement in multiple sexual networks. Generally, increases in economic resources, oc-
cupational opportunity, education and mobility, along with pre-existing behavior patterns,
tend to make the wealthier social groups more vulnerable to HIV infection, despite better
access to health resources (Gillespie et al., 2007).11
The socioeconomic status of a household is theorized to be closely associated with indi-
vidual exposure to HIV acquisition. The socioeconomic status of a household can determine
the degree of access to, and control over, resources which in turn can be used to minimize
or avoid HIV risk. Such resources may include forms of social, emotional or informational
support, economic aid and security, and care-giving. These characteristics can be mea-
sured by the wealth index of a household, the socioeconomic status of the household-head,
and reported social support mechanisms (Loewenson et al., 2009). Empirical studies have
shown an association between household socioeconomic status and risk of HIV. Gillespie
et al. (2007: 9) report on studies which show that for girls, sexual debut is earlier in poor
households (particularly those that experience an economic shock); one study in Kenya
shows that asset poverty is signiﬁcantly related to risky sexual outcomes including early
sexual debut, multiple sexual relationships. Women in wealthier households reported higher
10 Structural diﬀerences between countries, and political commitment to intervention programs, may
signiﬁcantly account for between country HIV incidence and prevalence variation (Robinson, 2011).
11 This relationship may have begun to change over time, along with the changing dynamic of the AIDS
epidemic. Further research is needed to ascertain whether more wealthier social groups have begun to adopt
safer sexual practices in light of increased public awareness and educational interventions.
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condom use, although professional women (in Kenya and Uganda) were at higher risk of
HIV infection than non-professional women (Abimanyi-Ochom, 2011). In a study of women
in Botswana, women who earned more or the same as their partner were reported as having
at least one sexual partner in the last month (Ho-Foster et al., 2010).
In their study, Bärnighausen et al. (2007) examine the relationship between socioeco-
nomic status and HIV seroconversion risk, speciﬁcally with respect to the hypothesis that a
decrease in socioeconomic status may increase the risk of HIV infection. The authors argue
that household wealth and expenditure capture diﬀerent ﬁnancial aspects of socioeconomic
status. Wealth is considered to be a more sensitive measure of long-term socioeconomic
position, and is measured through a household asset index which include items such as
house ownership, water source, toilet type, electricity, household goods, and livestock for
example. Households were categorized as belonging to poorest 40%, middle 40% or wealth-
iest 20%. Household expenditures capture the short-term ﬁnancial liquidity of members in
the household, which may determine how behaviors are regulated or constrained in terms
of access to treatment (of STDs, for example), travel, spending (on rent, shopping, elec-
tricity, transport, telephones and bills, etc.). The authors report that members belonging
to the middle category of the relative wealth index, rather than the poorest category, were
at greater risk of HIV acquisition (Bärnighausen et al., 2007). Chimbindi et al. (2010)
report that increased condom use is associated with belonging to a household with a high
socioeconomic status. Importantly, belonging to a family with a middle or high socioeco-
nomic status is associated with increased condom use among young adults. In their study,
Davidoﬀ-Gore et al. (2011) found that households in the third and fourth wealth quintiles
had a greater odds of inconsistent condom use. These results support earlier research that
young men and women in households with lower wealth are more likely to use condoms
inconsistently, compared to those in wealthiest households.
Hallman (2005) explore how the relative household wealth index inﬂuences the sexual
behaviors and experiences of young men and women aged 14-24 years. She ﬁnds that females
residing in a low-wealth household were more likely to have an earlier sexual debut, a greater
chance of having a non-consensual sexual debut, and have a higher rate of physically forced
or exchanged sex. Low wealth for females was also associated with having multiple sexual
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partners and a lower chance of condom use at last sex. Low wealth also reduced the
discussion about safe-sex practices for both men and women.
Household network: This refers to the linkages between individuals with whom one has
close relations or aﬀection, which naturally includes family members within the household
(Due et al., 1999, see also Hawe et al., 2004). A type of dyadic relation may exist between a
key/central actor (a household-head) and another similar actor (a partner), or may involve
a two-mode relations with a diﬀerent set of actors (i.e., non-household members such as
sex-workers or a non-conjugal partner).
Household composition: An important aspect to consider is household composition,
which may describe a conjugal-headed household, a single-parent household, a grandparent-
headed household, an orphaned household, or a household containing both close and ex-
tended kin. The unique composition and formation of the household may directly aﬀect
the allocation of, or access to, resources and economic opportunities.
Formation and dissolution: The formation and dissolution of the household over time
refers to the addition (e.g., births) as well as the loss (e.g., deaths, permanent out-migration)
of household members. The loss of a member may present a signiﬁcant shock to the house-
hold, reducing a potential source of income, and compromising the stability and protective
eﬀects of an integrated household against hazardous behaviors. A newborn may place a
burden on household resources, although increased family size may oﬀer the potential of
additional income sources.
Household level factors are important because they are theorized as antecedent to the
patterns of sexual mixing that typically result in behavioral exposure or protection from
HIV infection. Households are one way of seeing forms of social organization in action, and
they reﬂect the broader, macro-social norms and values, which are subsequently reinforced
and infused into the linkages between household members. It is at the household level
that social power and control is exercised, particularly over sexual relationships and risk
taking. As stressed throughout this paper, social networks are in turn connected to broader
social and community contexts. Such societal factors, whether they be demographic or
epidemiological (our macro-social level in the proposed model), determine the conditions
and opportunities for the formation of social and sexual relationships, and thus the risk of
HIV acquisition.
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3.1.3 The community context
The community context is conceptualized as a macro-social level, and is the highest-order
level. I propose that four variables can be used to capture community level eﬀects. These
are: 1) social attitudes and beliefs, 2) institutions and structures, 3) epidemiological
conditions, and 4) demographic characteristics.
Social Attitudes and beliefs: Collective attitudes and behaviors are generally the product
of larger, normative social forces operating within the prevailing community. Misinforma-
tion about HIV/AIDS, for example, can often emanate from cultural sources of explanation
(Kalichman and Simbayi, 2004; Gottlieb et al., 2009). Community stigmatizing attitudes
toward HIV-positive persons, acceptance of behaviors involving multiple partner acquisition
or concurrency, and resistance to condom use, are likely to be informed by traditional beliefs
about health, illness, and death that are at odds with a western medical perspective (Visser
et al., 2009; Kopelman, 2002; Forsyth et al., 2008). These community level attitudes and
beliefs are acknowledge here because they can strongly inﬂuence the HIV-related behaviors
of individuals.
Proximity to physical or bounded structures: The spatial proximity of individuals to
institutions or structures identiﬁes the second community level determinant. Examples can
include distance to health resources (clinic or hospital), transport routes (local road or
national highway), socioeconomic resources (school, urban area with occupational oppor-
tunities), or entertainment (drinking establishment, sports venue). Additional research has
shown strong links between geographic and institutional characteristics and HIV incidence
and prevalence (Tanser et al., 2009). Bloom et al. (2002) and Feldacker et al. (2011) re-
port that there is a strong relationship between type of community and HIV incidence, not
explained by individual risk factors.
Epidemiological condition: The epidemiological condition of a community can be an
important determinant of an HIV-related outcome at the individual level. For example,
the level of HIV prevalence in a given community will indicate the probability at which an
individual will select an infected partner; or diﬀerences in community HIV incidence will
place individuals at a diﬀerential risk of HIV acquisition (Bärnighausen et al., 2010; Auvert
et al., 2001). The level of ART coverage in the community has been shown to provide a
protective eﬀect against individual HIV acquisition (Tanser et al., 2013).
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Demographic Characteristics: These include, for example, the wealth, income, and edu-
cation characteristics of a community, and migratory patterns in and out of such a commu-
nity. Bärnighausen and Tanser (2009: 438) argue that many demographic characteristics
are typically the counterparts of the proximate determinants situated at a lower level in
the proposed hierarchical model. These demographic characteristics can be obtained by
summing the characteristics of individuals that make up the local community. On the
other hand, the demographic characteristics may be some property of the community that
is unique to it, and is not shared by other communities within a relatively close social
proximity.
In this chapter I proposed a conceptual framework consisting of a community, household,
and individual levels. My starting assumption is that the characteristics of the community
constrain or reproduce social processes within the household, which then operate through
the proximate determinants to aﬀect a given HIV-related outcome. I have argued for
the need to systematically diﬀerentiate the macro-social processes from individual level
behaviors because of the complex epidemiology of HIV/AIDS in sub-Saharan Africa. In
the two empirical chapters to follow, I use this conceptual framework to inform my analyses
of the preventive and survival beneﬁts of ART. I now turn to a description of the study
area and the data before moving on to these two chapters.
Chapter 4
Study Background
South Africa has a quasi-federal system, with each sphere of governmentnational,
provincial, and localhaving elected political representatives and areas of authority. Fol-
lowing the transition to democracy in 1994, the four Apartheid provinces of the Transvaal
and Orange Free State (Boer Republics) and Natal and the Cape (formerly English Colonies)
were broken into the nine provinces of the Eastern Cape, the Free State, Gauteng, KwaZulu-
Natal, Limpopo, Mpumalanga, the Northern Cape, North West and the Western Cape.
South Africa has eleven oﬃcial languages: English, Afrikaans, Ndebele, Sepedi, Xhosa,
Venda, Tswana, Southern Sotho, Zulu, Swazi and Tsonga.
Under Apartheid, the population was classiﬁed into four racial groups: Black, White,
Indian and Colored. The South African Census and Statistics South Africa have maintained
this classiﬁcation. Blacks comprise 79.5% of the population, while the remaining three
groups are distributed as White, 9%; Coloured, 9%; and Indian/Asian, 2.5%.) (Statistics
South Africa, 2011). The total population size of South Africa is estimated to be 50.6
million people, of which 52% are female. Gauteng is home to the largest share of the
South African population, with approximately 11.3 million people (22,4%) living in this
province. KwaZulu-Natal is the second most populated province with 10.8 million people
(21,4%). Of the population younger than 15 years, approximately 23% (3.66 million) live
in KwaZulu-Natal and 19.4% (3.07 million) live in Gauteng. Life expectancy at birth for
2011 is estimated at 55 years for males and 59 years for females (Statistics South Africa,
2011).
As of 2011, an estimated 14.5% of the male and 23.2% of the female population (aged
1549 years) were reported as HIV-positive, and the national HIV prevalence estimate
for this age group was 18.8% (Department of Health, 2014). In 2010, not one of the of
the 52 health districts in South Africa recorded an antenatal HIV prevalence below 8%.
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The KwaZulu-Natal province recorded the highest antenatal prevalence at 39.5%, with ﬁve
districts in that province recording above 40% (Department of Health, 2011).
Figure 4.1: HIV prevalence by district, South Africa (Department of Health, 2014).
4.1 Africa Centre for Health and Population Studies (ACDIS)
The Africa Centre for Health and Population Studies was established by the University
of KwaZulu-Natal and the South African Medical Research Council in 1997, funded by a
large core grant from the Wellcome Trust, UK. In 2000 the Africa Centre Demographic
Information System (ACDIS) was started, and in 2003 population-based HIV testing was
incorporated into ACDIS. The ACDIS was set up to describe the demographic, social and
health impact of the HIV epidemic [...] and to monitor the impact of intervention strategies
on the epidemic (Tanser et al., 2008).
4.2 Demographic Surveillance Area (DSA)
The ACDIS project is situated in the southern part of the Mpukunyoni Tribal Area of the
Hlabisa Local Municipality and the KwaMsane Township and Indlovu Village of Mtubatuba
Local Municipality. This area is demarcated by clear geographical boundaries on three
sides, making it possible to deﬁne exactly the population in what is called the Demographic
Surveillance Area (DSA). These boundaries are: 1) the Umfolozi River in the south, 2) the
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Figure 4.2: Location of study area in South Africa (Tanser et al., 2008; Houlihan et al.,
2011)
Umfolozi Game Reserve in the west, and the 3) the N2 national highway in the east. (In the
north the boundary for the DSA cuts across the middle of the Mpukunyoni area.) In the
eastern section of the DSA, bordering the N2 highway, the DSA is quite ﬂat and densely
populated. To the western and northern parts, the DSA becomes increasingly mountainous
and thinly populated.
There are three identiﬁable and diﬀerent living environments in the DSA: 1) The
KwaMsane township, which is an urban area, 2) KwaMsane reserve which is a peri-urban
area, and the 3) Mpukunyoni tribal area, which is a typical rural area. The area is 438 km2
and has considerable variation in population density (around 20 to 3000 /km2). The resi-
dent population of the DSA is numbered at 75,000 although given migration this ﬁgure may
be closer to 87,000 registered individuals (Africa Center, 2008). The area is predominantly
Zulu-speaking and despite its predominantly rural status, the principle income is waged
employment and state pensions rather than agriculture production.
4.3 Data collection.
All data for this study are collected by the Africa Centre. The Africa Centre administers
household questionnaires every six months to a key informant in the household. Information
53
individual’s risk of HIVacquisition (community-
level HIV prevalence, marital status, household-
levelwealth, and the number of sexual partners in
the past 12 months). After ruling out confound-
ing by these factors, there was a steep and highly
significant decline in an individual’s adjusted HIV
acquisition hazard with increasing ART cover-
age (Fig. 3B). Holding other factors equal, an
HIV-uninfected person who lived in a communi-
ty with ART coverage of 30 to 40% was on av-
erage 38% (P < 0.0001) less likely to acquire HIV
infection than anHIV-uninfected person living in
a community with ART coverage of <10% (Fig.
3B). When we include ARTcoverage (%) in the
model as a continuous variable we find that, over-
all, a 1% increase in ART coverage is associated
with a 1.4%decline [adjusted hazard ratio (aHR) =
0.986] in the risk of acquisition of new HIV in-
fection (Table 1).
As expected, a key independent predictor of
the risk of acquiring new HIV infection was the
level of existing HIV infection in the local com-
munity surrounding an HIV-uninfected individual
(Fig. 3C). Controlling for other factors, an HIV-
uninfected individual was 2.2 times as likely to
acquire HIV in a community where HIV prev-
alence was >25% relative to the base category
of <10% (P < 0.0001). In line with previous re-
search conducted in this population, age, sex,
number of sexual partners in the past 12 months,
and marital status were other independent pre-
dictors of HIV acquisition (Table 1). The ART
coverage hazard ratios were robust to the addition
of different control variables and changed little
across four nested models (table S2). Living in a
peri-urban community was also associated with a
greater risk of acquiring infection, but this effect
was rendered insignificant by the addition of
community-level HIV prevalence (table S2).
In the multivariable base-case model, we con-
trol for the known important determinants of HIV
acquisition in this population (16, 17). More-
over, the lack of spatial clustering observed in the
model residuals (see supplementary materials) in
this analysis suggests that unmeasured community-
level factors are not influencing our results.
Nevertheless, we also wanted to further exclude
the potential influence of other HIV prevention
services whose scale-up over space and time
could have correlated with that of ART. To this
end, we analyzed the time trends in six variables
Fig. 2. Female (A) and male (B) age variations in HIV incidence (95% CI) by 5-year age-group for entire sample of repeat testers (N = 16,667; 53,605 person-
years of observation). Superimposed on the graphs are log-normal functions (obtained by maximum likelihood) fitted to the incidence point estimates.
Fig. 3. Results of the multivariable analysis showing an HIV-uninfected
individual’s HIV aHR (95% CI) and associated P values for different
categories of ART coverage, that is, the proportion of the total HIV-
infected population receiving ART (A and B), and HIV prevalence (C) in
the surrounding local community (derived using a standard Gaussian
kernel of radius 3 km, as shown in Fig. 1, A and B). (A) displays the aHRs
adjusted for systematic differences in age and sex, and (B) and (C)
display the aHRs adjusted for all other variables in the final model (see
Table 1 and table S2 multivariable analysis).
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individual’s risk of HIVacquisition (com unity-
lev l HIV prevalence, marital status, household-
lev lwealth, and the number of sexual partners in
the past 12 months). After ruling out confound-
ing by these factors, there was steep and highly
significant decline in a i dividual’s adjusted HIV
acquisition haz rd with increasing ART cover-
age (Fig. 3B). Holding other factors equal, an
HIV-uninfected person who lived in a com uni-
ty with ART coverage of 30 to 40% was on av-
erage 38% (P < 0.00 1) less likely to acquire HIV
infection than HIV-uni fected person living in
a com unity with ART coverage of <10% (Fig.
3B). When we include ARTcoverage (%) in the
model as conti uo s vari ble we find that, over-
all, a 1% increase in ART coverage is associated
with a 1.4%decline [adjusted haz rd atio (aHR) =
0.986] in the risk of acquisition of new HIV in-
fection (Table 1).
As expected, a key indep ndent predictor of
the risk of acquiring new HIV infection was the
lev l of exist ng HIV infection i the local com-
munity surrounding an HIV-uninfect d individual
(Fig. 3C). Controlling for ther factors, an HIV-
uninfected individual was 2.2 times as likely to
acquire HIV in a com unity where HIV prev-
alence was >25% relative to the base category
of <10% (P < 0.00 1). In line with previous re-
search conducted in this po ulation, age, sex,
number of sexual partners in the past 12 months,
and marital status were other indep ndent pre-
dictors of HIV acquisition (Table 1). The ART
coverage haz rd atios were obust to he addition
of different control vari bles and changed litt e
across four nest d models (table S2). Living in a
peri-urban com unity was lso associated with a
greater risk of acquiring infection, but this eff ct
was rendered insignificant by the addition of
com unity-lev l HIV prevalence (table S2).
In the multivari ble base-case model, we con-
trol for the known important determina ts of HIV
acquisition in this po ulation (16, 17). More-
over, the lack of spati l c ustering observed in the
model residuals ( ee supplementary materials) in
this an lysis suggests that unmeasured com unity-
lev l factors are not influencing our results.
Nev rtheless, we also wanted to further xclude
the potential influence of ther HIV prev ntion
services whose scale-up over space and time
could have correlated with t at of ART. o this
end, we an lyzed the time trends in six vari bles
Fig. 2. Female (A) and male (B) age vari t ons in HIV incidence (95% CI) by 5-year ge-group for entire sample of rep at test rs (N = 16,667; 53,605 person-
years of bservation). Superimposed on the graphs are log-normal functions (obtained by maximum likelihood) fitted to he incidence point estimates.
Fig. 3. Results of the multivari ble an lysis showing an HIV-uninfected
individual’s HIV aHR (95% CI) and associated P values for different
categories of ART coverage, that is, the prop rtion of the total HIV-
infected po ulation rec iving ART (A and B), and HIV prevalence (C) in
the surrounding local com unity (derived using a standard Gaussian
kernel of radius 3 km, as shown i Fig. 1, A and B). (A) displays the aHRs
adjusted for systematic differences in age and sex, and (B) and (C)
display the aHRs adjusted for all other vari bles in the final model (see
Table 1 and table S2 multivari ble an lysis).
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Figure 4.3: Female (left) and male (right) age variations in HIV incidence (95% CI) by
5-year age-group . Superimposed on the graphs are log-normal functions (obtained by
maximum likelihood) ﬁtted to the incidence point estimates (Tanser et al., 2013).
is collected on the attributes and events of physical structures, households and individuals
and their relationship to one another. The Africa Centre also maintains a geographical
information system (GIS) capacity that allows for the spatial analysis of the variables
collected. Table 4.2 shows the information collected at the household visit. Nested within
the household survey is the population based HIV surveillance survey. This HIV survey
is conducted annually and collects information on HIV status, sexual behavior, and other
relevant biomeasures by interviewing each eligible ho sehold member in person. T ble 4.3
shows the individual level data at the start of each y ar for h period 20042012.
Sample/Participants. An individuals must be a member f a household with he
study area to be eligible for inclusion in the study cohor , even if he or sh is not physically
living in the homestead. This cohort includes all women aged 1549 years and men aged
1554 years who were resident in the surveillance area and thus eligible for HIV testing. In
2007, eligibility was extended to cover all residents aged >15 years of age. In addition to the
resident sample, a 12.5% stratiﬁed sample of non-residents (`migrants') was also included
in each round of data collection (Tanser et al., 2008).
4.4 Transition of the HIV epidemic
Population based HIV surveys in the study area have shown some of the highest population
based infection rates ever documented worldwide (Tanser et al., 2008: 960). In 20032004,
prevalence peaked at 51% (95% CI 47-55%) among women aged 2529 and 44% (95% CI
3849%) in men aged 3034.3. The study area has seen a steady increase in HIV prevalence
54
from 21.8% (95% CI 20.922.7) in 2004 to 29.0% (95% CI 27.930.1) in 2011, which has
been attributed to the government scale up of ART during this period (Zaidi et al., 2013).
Non-resident men were nearly twice as likely (adjusted OR=1.8) to be infected than their
resident counterparts; the corresponding ratio for women was 1.5. Geographically, the
prevalence of HIV varies from >35 % in informal settlements near the N2 highway to <10 %
in the more inaccessible routes in rural areas (Tanser et al., 2009). Figure 4.3 shows the
overall population-level HIV incidence for men and women for the 20042011 period. And
Figure 4.4 shows HIV prevalence, incidence and transmission probability by community area
in the study area. Previous research has show that between 2000 and 2005 orphanhood
doubled. However, in terms of the household impact of HIV/AIDS, no evidence was found
for the increase in child-headed or skipped-generation households (Tanser et al., 2008).
 
Figure 4.4: Community ranking according to HIV prevalence, incidence, and transmission
probability. Each homogeneously colored area is a traditional Zulu community, called an
Isigodi. The numbers in the areas represent the community rank according to HIV preva-
lence (A), incidence (B), and transmission probabilities (C) (Bärnighausen et al., 2010).
4.5 Homesteads, households and residencies
The Africa Centre makes a conceptual distinction between homesteads, households and
residencies. Homesteads are are a type of bounded structure. A bounded structure is
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deﬁned by the Africa Centre as a building, or a group of buildings, on land belonging to
a single person or organisation, and used for one main purpose (Africa Center, 2008: 20).
These bounded structures are often identiﬁed by easily recognizable fences or open land
between neighboring homesteads. A homestead is more speciﬁcally deﬁned as a grouping
of houses or huts on one piece of land, which belongs to a single owner and which is mainly
used as a place for people to live (Africa Center, 2008).
Mean
(Low)
Mean
(High)
Households per homestead 1.04 1.11
Individuals per homestead 6.65 7.02
Households per individual 1.06 1.07
Individuals per household 6.53 7.22
Household co-members per individual 8.49 9.45
Table 4.1: DSA Household membership and living arrangements. Data are high and low
means for the 13 semiannual cross-sections, January 2004-June 2010 (Bor et al., 2011).
The Africa Centre deﬁnes households as a a social group of one or more members
[that] share in the joint household resources and know each other well enough to provide
information about each other. In each household, one of the members is considered to be
the head of household (Africa Center, 2008: 30). A household member is further deﬁned
as a person who considers him or herself as a member of that household, and is considered
by household members to be a member. This distinction means that multiple households,
which refer mainly to individual memberships, can be contained within a single homestead
(a physical dwelling place). In such a scenario, a homestead can begin as a single household
with more households established on the same plot of land over time. This could occur
when family members separate from the main household to establish their own household
on the same plot of land. In another scenario, tenants may move into an existing plot of
land and establish their own household.
An individual is a resident of a homestead if he or she physically lives in the homestead.
An individual can continue to be a member of a household while they are outside of the
study area, but they cannot be recoded as being a resident in the homestead during this
time. Table 4.1 shows the data for the homesteads, households, and individuals. There are
on average 1.041.11 households per homestead. Overall, 8.59.5 individuals typically live
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within a homestead, and there are on average 6.57.2 individuals living within a household.
There are additional co-members in a household (8.59.5) because individuals can continue
to be a household member even through they are not physically present in the household.
On average, individuals are members of 1.061.07 households. Migration is deﬁned as the
event that occurs when an individual or household moves from one homestead to another
(Africa Center, 2008). I illustrate residential mobility and external migration concepts in
greater detail in Section 5.2.
4.6 Data collection
Subject Types of information
Homestead Latitude, longitude, Owner, Number of households.
Household Formation and dissolution, Household head.
Individuals Individual details: inc. date of birth, sex, parents. Household member-
ship(s).
Household members Update household list: members who join, leave or die. Residency sta-
tus: including pattern of return visits, marital and partnership status,
relationship to household head.
Births Pregnancy outcomes: abortions, still and live births. Delivery environ-
ment: including assistance, place, birth-weight.
Deaths Location and care provision at time of death. Open description of circum-
stances.
Migrations Details of place of origin or destination. Type of migration, e.g. household
or individual migration.
Child health On ﬁrst birthday: vaccination history.
Table 4.2: Data collected at each routine household visit, 2000 and ongoing (Tanser et al.,
2008: 958)
4.7 The Hlabisa HIV Treatment and Care Programme
The Hlabisa HIV Treatment and Care Programme was established in late 2004 by the South
African Department of Health and the Africa Centre as a response to a national plan which
aimed to triple the number of individuals accessing ART between 2007 and 2012. The
Hlabisa treatment program has seen a dramatic scale-up of ART since its inception, with
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1800 patients on treatment in late 2006 to more than 20,000 by the close of 2012. ART is
distributed through 16 primary health care clinics and the local district hospital (Hlabisa)
by nurses and treatment counselors using the standard South African drug regimens, which
conform to World Health Organization (WHO) ART guidelines. In 2010 patients with
CD4 counts< 350 cells/µl were elegible for testing, an increase from the initial treatment
eligibility threshold of < 250 cells/µl. Details relating to age, sex, contact information, clinic
visits, laboratory data and records of ART activity (WHO clinical stage, previous ART,
regimen at initiation, changes to regimen during treatment) are updated and maintained
on the ARTemis database (Houlihan et al., 2011). The data from ACDIS can be matched
with patient data using each individual's unique South African identiﬁcation number (Bor
et al., 2011).
4.8 Ethical approval
All research initiatives at the Africa Centre are ﬁrst undertaken in consultation with a
Community Advisory Board (CAB) for comment and feedback. The CAB consists of ap-
proximately 25 members that are chosen by the community, the Board also provides a
forum to discuss the results of speciﬁc studies and how best to disseminate these to the
community. All data are stored in a secure SQL database on-site; Africa Centre database
personnel are responsible for the entering of all data values, coding of all missing values,
labelling of all data values, and construction of variables from the raw data. The de-linking
of individual names from all records, including all procedures to ensure conﬁdentiality, are
undertaken by Africa Centre personnel. All persons in the dataset are anonymous to the in-
vestigators. Ethical approval for research conducted by the Africa Centre has been granted
by the University of KwaZulu-Natal, South Africa
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2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Under surveillance at start 88335 90442 90403 90424 90600 90752 91239 93283 92891 93049 93179 93100 93042
Born 2118 2031 2019 1936 2007 2081 2000 2034 2008 1902 1842 1722 1097
Started Membership 1311 563 431 307 291 370 471 410 552 641 918 742 292
Imigrated during year 3033 3087 4346 3227 2585 2455 2370 2318 2038 2283 1927 1358 546
Died during year 1267 1476 1520 1591 1484 1404 1273 1332 1208 1131 1015 934 690
Membership end 1650 1976 2206 1510 1233 1275 1344 1398 1374 1445 1059 399 465
Outmigrated during year 1084 1550 2041 1293 1053 751 582 922 661 739 788 606 318
Lost to follow-up 354 718 1008 900 961 989 1003 1502 1197 1381 1904 1941 1962
Table 4.3: All Individuals (incl. non-residents) at the start of year
Chapter 5
Use of ART in households and risk of HIV acquisition
Background: Studies of HIV-serodiscordant couples in stable sexual relationships have
provided convincing evidence that ART can prevent the transmission of HIV. I aimed to
quantify the preventive eﬀect of a public sector HIV treatment and care programme based
in a community with poor knowledge and disclosure of HIV status, frequent migration, late
marriage, and multiple partnerships. Speciﬁcally, I assessed whether an individual's hazard
of HIV acquisition was associated with ART coverage among household members of the
opposite sex.
Methods: In this prospective cohort study, I linked patients' records from a public-
sector HIV treatment programme in rural KwaZulu-Natal, South Africa, with population-
based HIV surveillance data collected between 2004 and 2012. I used information about
coresidence to construct estimates of HIV prevalence and ART coverage for each household.
I then regressed the time to HIV seroconversion for 14,505 individuals, who were HIV-
uninfected at baseline and individually followed up over time regarding their HIV status,
on opposite-sex household ART coverage, controlling for household HIV prevalence and a
range of other potential confounders.
Findings: 2037 individual HIV seroconversions were recorded during 54 845 person-
years of follow-up. For each increase of ten percentage points in opposite-sex household ART
coverage, the HIV acquisition hazard was reduced by 6% (95% CI 29), after controlling for
other factors. This eﬀect size translates into large reductions in HIV acquisition hazards
when household ART coverage is substantially increased. For example, an increase of 50
percentage points in household ART coverage (eg, from 20% to 70%) reduced the hazard
of HIV acquisition by 26% (95% CI 939).
Interpretation: These ﬁndings provide further evidence that ART signiﬁcantly re-
duces the risk of onward transmission of HIV in a real-world setting in sub-Saharan Africa.
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Awareness that ART can prevent transmission to coresident sexual partners could be a
powerful motivator for HIV testing and antiretroviral treatment uptake, retention, and
adherence.
5.1 Introduction
Over the past decade, several studies have shown that ART can reduce the transmission
of HIV from an infected to an uninfected sexual partner (Baggaley et al., 2013; Anglemyer
et al., 2013; Loutfy et al., 2013). The strongest evidence for the preventive eﬀect of ART
has come from studies of HIV-serodiscordant couples in stable sexual relationships. In
2011, investigators of the HPTN 052 trial, now regarded as the landmark HIV treatment-
as-prevention study, reported that early ART reduced HIV transmission by 96% in HIV-
serodiscordant couples who had disclosed their HIV status to each other (Cohen, 2012). This
result conﬁrmed the ﬁndings of two earlier observational studies, which showed that ART
was associated with a 98% (Bunnell et al., 2006) and a 92% (Donnell et al., 2010) reduction
in HIV incidence in serodiscordant heterosexual couples. More recently, investigators of
a prospective cohort study (He et al., 2013) reported a 66% fall in the rate of new HIV
infections among married serodiscordant couples receiving ART. These impressive results
have established treatment-as-prevention as an eﬀective strategy to reduce the spread of
HIV (Cohen et al., 2013; Montaner, 2011; Hayden, 2010; Cambiano et al., 2011). Attention
is now being drawn to whether ﬁndings based on the study of serodiscordant couples can
be generalized to the broader population (Cohen et al., 2013).
A small number of ecological studies have associated an increase in the uptake of ART
with a reduction in the number of new HIV diagnoses for a particular group, community or
administrative region over time (Das et al., 2010; Montaner et al., 2010; Wood et al., 2009).
However, such studies typically make use of aggregated outcomes and are therefore unable
to evaluate the preventive impact of ART at the individual level (Smith et al., 2012).
In a recent study, the investigators observed the time to seroconversion for 16,667 HIV-
uninfected individuals on the basis of ART coverage in the local surrounding community
(Tanser et al., 2013). They deﬁned ART coverage as the proportion of all HIV-infected
people on ART irrespective of CD4 count or disease stage. After controlling for multiple
determinants, they found that an individual living in a community with 30% ART coverage
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was 38% less likely to acquire HIV relative to an individual living in a community with low
ART coverage (<10% of all HIV-infected individuals on ART). This result provided powerful
evidence for the community-level eﬀectiveness of treatment as prevention. However, no
previous study has assessed the preventive eﬀect of ART at the household level.
Here, I aim to quantify the household-level preventive eﬀect of a public-sector HIV treat-
ment and care programme based in a rural South African community with poor knowledge
and disclosure of HIV status, frequent migration, late marriage, and multiple partnerships.
Speciﬁcally, I use information about the HIV serostatus and ART status of household resi-
dents to assess whether ART is associated with a reduction in HIV acquisition risk.
5.2 Methods
5.2.1 Study population
The Africa Centre's population-based surveillance, which was designed to mirror the de-
mographic reality of a highly ﬂuid and complex community, is located in the uMkanyakude
district of the northern KwaZulu-Natal province. The study area is approximately 440 km2
in size with a resident population of 75,000 and a total (resident and non-resident) popu-
lation of 87,000 at any given time-point. The area is generally poor and typical of a rural
South African population, with scattered, informal peri-urban settlements and a principal
urban township (Tanser et al., 2008). The level of unemployment is very high, with around
66% of working-age adults without work (Bor et al., 2012). Approximately 62% of the
population have access to electricity and 78% access to piped water (not necessarily within
their household) (Tanser et al., 2008).
The study area is characterized by high levels of individual mobility and a dynamic
household structure, two social conditions which have their origin in the Apartheid-era.
From the 1950s until the democratic transition in 1994, Apartheid authorities set about
redrawing the South African landscape along racial lines as a means to consolidate white
rule (Mamdani, 1996). This form of social engineering saw the development of white urban
centers and cities and the resettlement of black Africans into underdeveloped homelands
or rural areas. Racial segregation and resettlement was largely seen as the vehicle for
a more `rational' distribution of African labor between the urban areas and white farms
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(Posel, 1993). The study area, which now includes land under the Zulu tribal authority, was
formerly part of the homeland system of the Bantu Authorities Act of 1951 (Crankshaw,
2002).
The migrant labor system under Apartheid was further entrenched with the 1952 Pass
Laws Act (in eﬀect until 1986), which prohibited African adults from staying in white
urban areas without employment or accommodation. If working in urban centers, African
laborers were required to reside in segregated single-sex hostels and were prevented from
being joined by their partners or families. The extended absence of men from the rural
family home, the migration of both men and women, and separated living spheres led to
prolonged physical separation and marital instability during this period (Hosegood et al.,
2009; Preston-Whyte, 1993; Murray, 1981).
The control of settlement, together with the migrant labor system and the lack of local
employment opportunities, has resulted in high levels of mobility and migration within the
study area at present. Female-headed households are typical, and are largely the prod-
uct of male out-migration to urban areas in search of employment and income. Research
conducted here previously shows that 23% of all household members reside elsewhere; and
that approximately 35% of adult (18 years or older) female household members and 40%
of adult males reside outside the area but return periodically and maintain memberships
with households (Hosegood et al., 2004, 2007). Research has also shown a high level of
household mobility, with 11% of the households moving at least once during the 2.5 years
of the study (Hosegood et al., 2004).
Partnership stability in the study area has also been profoundly aﬀected by the impact
of frequent and long-term migration. More recently, marital rates (an important indicator
of partnership stability) have been on the decline for adults since 2000; in 2006, less than
20% of women and 10% of men aged 35 years or younger in our study area were ever married
(Hosegood et al., 2009). Polygamous marriages constituted 12% of all marriages in women
and 14% in men in 2006, higher than the national estimate of 7% at that time (Hosegood
et al., 2009). If it occurs, marriage is typically late for a male (median 34 years) (Statistics
South Africa, 2012) once he is able to aﬀord the Zulu bridewealth payment: during this time
he may have had several casual relationships, and increased his or his sexual partner's risk
of HIV infection (Ott et al., 2011; Hosegood et al., 2009). Among men who were sexually
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active, 28.9% (95% CI 27.030.8) reported having two or more concurrent partners, and
the median number of reported lifetime partners was ﬁve (Interquartile Range 38) (Tanser
et al., 2011). The mean number of reported lifetime sexual partners (6.3) varied between
3.4 and 12.9 in communities across the surveillance area between 2004 and 2009 (Tanser
et al., 2011; Todd et al., 2009).
The population-based HIV incidence between 2004 and 2010 was 2.63 new infections
per 100 person-years (95% CI 2.50 to 2.77) (Tanser et al., 2013). Incidence peaked at
6.6 per 100 person-years in women at age 24, and 5 years later in men at 4.1 per 100
person-years of observation (Tanser et al., 2013). There has been a steady increase in HIV
prevalence from 21.8% (95% CI 20.922.7) in 2004 to 29.0% (95% CI 27.930.1) in 2011
for the 15 to 49 age-group (Zaidi et al., 2013). ART was made available to patients with
CD4+ counts <200 cells/µl through government primary health-care clinics in September
2004. In April 2010, treatment eligibility was increased to <350 cells/µl for pregnant women
and tuberculosis patients and then for all adults in August 2011, using the standard South
African eligibility criteria and World Health Organisation (WHO) treatment guidelines
(Lessells et al., 2013). ART coverage estimates have risen sharply from 0.0% (95% CI 0.0
0.2) in 2004 to 30.7% (95% CI 29.332.1) in 2011; with 40% and 30% of all HIV-infected
women and men aged 25 to 49 years having successfully initiated ART (Zaidi et al., 2013).
The Africa Centre collects data on individuals who are members of one or more family
units or households. I deﬁne a household as a building or a group of buildings belonging to
a single owner and used by residents for the purposes of living (Africa Center, 2008). The
average size of a household is seven resident members (Bor et al., 2011). Approximately
21,500 households have been included in the Africa Centre household surveillance since
2000. Household response rates are typically >95%, and information is collected on both
resident and non-resident members. Individual HIV testing has taken place within the
household surveillance on an annual basis since 2003. Eligible participants aged ≥15 years
are interviewed in private by trained ﬁeld workers, who extract blood by ﬁnger prick for
HIV testing. About 80% of all individuals consent to provide a blood sample for anonymous
HIV testing (Tanser et al., 2008). ART is distributed through the HIV Treatment and Care
Programme by nurses and treatment counselors, and records of patient HIV serostatus and
ART status are updated and maintained in the ART Evaluation and Monitoring System
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(ARTemis) database (Houlihan et al., 2011). The Africa Centre surveillance and HIV
treatment programme are described in greater detail in Section 4.7.
5.2.2 Outcome and exposure measures
Seroconversion Event: The outcome measure of this study is the time to seroconversion
for a repeat-tester. I deﬁne a repeat-tester as an individual, aged 15 to 50 years, who
1) has had more than one HIV test, 2) was HIV-uninfected at ﬁrst test, and 3) was a
resident member of at least one household in the surveillance area between January 2004
and December 2012. These 18,802 repeat-testers, who are at risk of HIV infection, are a
subset of the total resident population under surveillance. I excluded 6270 households that
did not have a repeat-tester as a resident, as these households were unrelated to the study
outcome.
A seroconversion event is deﬁned as the point at which the repeat-tester tests posi-
tive for HIV antibodies in the blood. The precise time at which a seroconversion event
occurs is diﬃcult to establish in the absence of regular HIV testing. In this analysis, the
seroconversion event was determined by taking the mid-point of a repeat-tester's latest
HIV-negative (lower bound) and earliest HIV-positive (upper bound) test date. Figure 5.1
shows an example for a repeat-tester, whose latest HIV-negative and earliest HIV-positive
status was observed on 15 May 2008 and 22 November 2008 respectively. The mid-point of
this interval, 18 August 2008, is the inferred seroconversion date. I right-censored the data
for repeat-testers who were HIV-uninfected at their last clinic visit date, who were lost to
follow-up, or who migrated out of the surveillance area.
Figure 5.1: Computation of a repeat-tester's seroconversion date: an example
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Exposure Episodes: I used an exposure episode to measure the number of days spent
by a repeat-tester in a single, distinct household within a calendar year, and to enumerate
the co-resident characteristics of the household for the corresponding exposure episode.
Changes in household residencies within the surveillance area were captured with each new
exposure episode.
The household surveillance captures the complexity of a repeat-tester's living arrange-
ments through exposure episodes. The exposure episodes concept is built into the design
of the Africa Centre data so as to capture the complex life-cycle of the household and its
residents. The ﬁrst timeline in Figure 5.2 shows an example of a single exposure episode,
which can span no more than the length of calendar year. Typically, two episodes per year
are created for a repeat-tester: the length of the ﬁrst episode is from the 1st of January
until his or her birthday, and the length of the second episode is from his or her birthday to
the 31st of December. The second timeline in Figure 5.2 shows an example of repeat-tester
born on June 27th, 1981: here, the duration of the ﬁrst episode would be 178 days and the
second episode 187 days.
Figure 5.2: Example showing a single exposure episode (top timeline) for a calender year
(e.g., 2008) and the bifurcation of the calender into two exposure episodes by birthdate
(bottom timeline)
Importantly, additional and separate episodes are created for a calender year when a
change in a repeat-tester's residency status is observed. A new exposure episode begins with
the start of a new household residency; and ends with the migration of the repeat-tester to
a diﬀerent household within (or outside) the surveillance area. Figure 5.3 shows a simple
example of how new exposure episodes are created when the repeat-tester migrates out of
the household (or returns to it). The ﬁrst episode begins for a resident repeat-tester on the
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1st of January. On May 20th, the repeat-tester migrates out of the household and returns
December 1st. This change in residential residency creates a two episodes in addition to
the episodes created by the birthday bifurcation, giving four exposure episodes in total for
the 2008 calender year. The exposure episode in the ﬁrst household sums to 140 days; the
next two episodes outside of the ﬁrst household sum to 195 days; and the duration of the
fourth episode is 30 days.
Figure 5.3: Residential mobility and the computation of household exposure episodes (in
days) for the calender year (2008): an example
To continue the example, consider that the repeat-tester belongs to household number
1116 on 1 January 2008. The data indicates that there was at least one HIV-infected
resident member in this household until the outmigration of the repeat-tester on May 20th.
The repeat-tester migrates to household 214, where there is at least one resident observed
to be on ART. The repeat-tester returns to household 1116 on the 20th of December, where
records indicate that there is still one or more HIV-infected coresidents physically living in
this household. With this information, the exposure time for each household for the 2008
calender year can be calculated as follows: the repeat-tester spends two episodes and 170
(140 + 30) days in household number 1116 with ≥ 1 HIV-infected resident(s), and two
episodes and 195 (38 + 157) days in household number 214 with ≥ 1 resident(s) on ART. It
is with this method that a repeat-tester's exposure time to HIV and ART within diﬀerent
households is computed.
Co-resident characteristics: I am interested in a repeat-tester's time to HIV serocon-
version for varying levels of ART coverage and HIV prevalence in the household. To do this
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Figure 5.4: Calculation of exposure time to households with varying HIV prevalence and
ART coverage for a calender year: an example
I individually linked 7657 adults enrolled in the local HIV treatment and care programme
who successfully initiated ART and had an active follow-up statuswith the same individ-
uals in the surveillance database. I used the linked records to determine if a co-resident was
1) HIV-infected and not on ART, 2) HIV-infected and on ART, or 3) HIV-uninfected at
any given time-point. I then used the information of each co-resident's HIV serostatus and
ART treatment status to construct an HIV prevalence and an ART coverage measure for
the corresponding household. I deﬁne HIV prevalence as the total number of co-residents
(denominator) who are HIV-infected (numerator), and ART coverage as the total number
of HIV-infected co-residents (denominator) who are on ART (numerator). The household
ART coverage measure includes information on co-residents who are HIV-infected but not
on treatment.
Figure 5.5: Example for the computation of household HIV prevalence
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Figure 5.5 shows an example of how the HIV prevalence measure is computed for each
household. The circles in the household represent each coresident (n = 7), and the shaded
areas represent coresident members who are HIV-infected (n = 4). The HIV prevalence for
this household is 66%, with the repeat-tester being excluded from the denominator of this
calculation (the repeat-tester cannot be at-risk and an exposure unto him/herself). Figure
5.6 shows how the ART coverage measure is computed for the same household. One of
the four HIV-infected coresidents is on treatment, giving an ART coverage of 25% for this
household.
In our study, I use the household as a proxy for co-resident partners of the repeat-tester.
The household is a proxy because I do not speciﬁcally identify if the repeat-tester is in a
sexual relationship with one or more co-residents for a given exposure episode. In order to
construct reasonable ART coverage and HIV prevalence measures, I excluded co-resident
members younger than 15 years of age and within a 15 year age-gap of the repeat-tester
to prevent family membersgrandparents, parents or childrenof the repeat-tester from
being considered as possible sexual partners in the household. To ensure suﬃcient exposure
to HIV-infected co-residents (who are either on ART or not), I excluded 4297 repeat-testers
from our analysis with >50% non-residency exposure episodes. In addition, I excluded the
repeat-tester from the denominator of his or her HIV prevalence measure, and therefore
did not obtain a prevalence measure for single-person households in which the repeat-
tester was the only resident. Importantly, I used detailed surveillance information on co-
resident deaths, out-migrations, and loss to follow-up to dynamically update the respective
numerator or denominator of the household ART coverage and HIV prevalence measures
for each exposure episode accumulated by the repeat-tester.
It is likely that a reduction in HIV acquisition risk could be confounded with the un-
observed behaviors of the household residents. These behaviors, which may involve routine
HIV screening, regular health-care visits, the use of condoms, risk-adverse sexual practices,
abstinence, and ﬁdelity, for example, could account for a reduction in HIV transmission
risk independently of ART. Failure to consider these `health-seeking' behaviors as a source
of confounding could lead to an over-estimation of the biological impact of ART on the risk
of HIV acquisition. I undertook the following measures to address this problem.
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Figure 5.6: Example for the computation of household ART coverage
Figure 5.7: Example for the computation of sex-directional HIV prevalence in the household
Given the heterosexual transmission of HIV in our study area (Tanser et al., 2011), I
acknowledged that ART would have a preventive beneﬁt for partners of the opposite-sex.
I constructed two ART coverage measures for the household, each based on co-resident
sex; and repeated this exercise for the household HIV prevalence measure. I hypothesized
that a female repeat-tester's HIV acquisition risk would be a function of the opposite-sex
(male)but not the same-sex (female)ART coverage level in the household, and similarly
for a male repeat-tester. A signiﬁcant decline in HIV acquisition risk associated with an
increase in opposite-sex household ART usage would support the treatment-as-prevention
hypothesis at the biological (heterosexual) level. A decline in HIV acquisition risk would
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not be associated with both the opposite-sex ART and same-sex coverage measures: this
scenario would indicate confounding of the preventive eﬀect of ART with the unobserved
`health-seeking' behaviors of the household.
Figure 5.7 shows an example of how sex-directional HIV prevalence is computed for
each household. In this example, the repeat-tester is a male resident, and three of the
co-residents are female (the circles now contain a FEM indicator). Of these three females,
two are HIV-infected, which gives a 66% opposite-sex HIV prevalence for this household.
Figure 5.8 shows that one of the two HIV-infected female co-residents is on ART, which
gives an opposite-sex ART coverage of 50% for this household.
Figure 5.8: Example for the computation of sex-directional ART coverage in the household
5.2.3 Data analysis
I used a Cox proportional hazards model to obtain an estimate for a repeat-tester's hazard
of seroconverting conditional on household ART coverage, and adjusting for household
HIV prevalence, age and sex, awareness of HIV status and ART (yes, no, refused), area
of residence (rural, peri-urban, urban), household socio-economic status (in 20-quantiles),
number of opposite-sex household residents, and the number of household residency changes
by the repeat-tester (none, one, or two or more). All variables apart from the repeat-tester's
sex were time-varying. I report 95% CIs based on standard errors that have been adjusted
for clustering at the household level.
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The main results are reported for a regression model based on data for opposite-sex
coresidents only (opposite-sex model). Even after controlling for the independent variables
in the opposite-sex regression model, the relation between HIV seroconversion hazard and
household opposite-sex ART coverage could be confounded by a range of unobserved fac-
tors, such as conscientiousness of individual household members, attitudes towards risk, and
attitudes towards health. Although I cannot include these factors in the regression because
I do not have data for them, I can control for their confounding eﬀects by adding same-
sex ART coverage and same-sex HIV prevalence. A household's same-sex ART coverage
will depend on many of the same unobserved factors, such as household members' con-
scientiousness and attitudes, that are also likely to aﬀect a household's opposite-sex ART
coverage. Thus I also report the results after adding household same-sex ART coverage and
same-sex HIV prevalence to the regression (full model). I also did an alternative analysis in
which household ART coverage and HIV prevalence were treated as binary variables (none
vs one or more HIV-infected coresidents on ART, and none vs one or more HIV-infected
coresidents) rather than in units of ten percentage points.
5.2.4 Statistical model
Survival models diﬀer from standard regression models in their ability to account for the
censoring or the truncation of data (Gutierrez, 2002). The survival function, S(t), gives the
probability that a person survives longer than some speciﬁed time. The hazard function,
h(t), gives the instantaneous potential per unit time for the event to occur, given that the
individual has survived up to time t. The hazard function focuses on the person failing or
the event occurring. The hazard rate is expressed as:
h(t) = lim
∆t→0
P (t ≤ T ≤ t+ ∆t|T ≥ t)
∆t
(5.1)
This deﬁnition gives the probability that a person's survival time will lie between the interval
t and t + ∆t given that the survival time is greater or equal to t (Kleinbaum and Klein,
2005). The measure of eﬀect is a hazard ratio, which is the exponential of one or more
regression coeﬃcients in the model. The interpretation of a hazard ratio (HR) is much like
an odds ratio. Cox proportional hazard models are typically used to undertake survival
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analysis. The formula is written in terms of the hazard function, which is:
h(t) = h0(t) exp
(
p∑
i=1
βiXi
)
where X is a vector of predictor variables. The Cox formula states that the hazard at
time t is the product of the baseline hazard function h(t) and the exponent of the linear
expression βiXi over the explanatory variables X (Kleinbaum and Klein, 2005). This is
a time independent model since the second term does not involve t. The hazard ratio is
obtained by dividing the hazard for one individual or a group by the hazard for a diﬀerent
individual or group. The HR is obtained, using the maximum likelihood approach, with:
ĤR =
hˆ(t,X)
hˆ(t,X∗)
=
h0(t) exp
(
p∑
i=1
βˆiXi
)
h0(t) exp
(
p∑
i=1
βˆiX∗i
) = exp
(
p∑
i=1
βˆi(Xi −X∗i )
)
where X∗ denotes the set of predictors for a treatment individual or group, and X for a
control or placebo group. Extended Cox models include variables that are time-dependent.
A time-dependent variable is deﬁned as any variable whose value for a given subject may
vary over time (Kleinbaum and Klein, 2005). An extended Cox model can be written as:
h(t,X(t)) = h0(t) exp
[
p1∑
i=1
βˆiXi +
p2∑
i=1
δjXj(t)
]
where X1(t), X2(t), . . . Xp2(t) are deﬁned as the time-independent variables. The hazard
ratio is now deﬁned as:
ĤR =
hˆ(t,X(t))
hˆ(t,X∗(t))
= exp
[
p1∑
i=1
βˆi[Xi −X∗i ] +
p2∑
i=1
δj [Xj(t)−X∗j (t)]
]
X∗(t) and X(t) are two sets of predictors that identify two speciﬁcations at time t for
time-dependent and time-independent variables.
5.3 Results
14,505 repeat-testers met the inclusion and exclusion criteria of whom 8546 (59%) were
women. 2037 HIV seroconversions were recorded over 54,845 person-years of follow-up
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time during the 200412 period. The median follow-up time per repeat-tester was 3.2 years
(IQR 1.85.5), with a maximum of 10.2 years. The unadjusted HIV incidence over the
study period was 3.7 new infections per 100 person-years (95% CI 3.63.9). Incidence was
highest in the 2024 years age group for women and in the 2529 years age group for men
(Table 5.2). Unadjusted HIV incidence remained stable from 2004 to 2008 and then fell
from 3.9 per 100 person-years in 2008 to 2.8 per 100 person-years in 2012 (Table 5.2). An
average of 4102 (range 11315119) households per year were included in the analysis during
the study period. About 10% of the repeat-testers changed household residencies one or
more times during the study period. Repeat-testers were exposed to a mean of 1.2 (SD
0.5) diﬀerent ART coverage levels (coded in units of ten percentage points). Figures 5.9
and 5.10 show the change in mean HIV prevalence and ART coverage in the household over
time.
Adjusted HR 95% CI
10 percentage points 0.94 0.910.98
20 percentage points 0.89 0.820.96
30 percentage points 0.84 0.740.94
40 percentage points 0.79 0.670.92
50 percentage points 0.74 0.610.91
60 percentage points 0.70 0.550.89
70 percentage points 0.66 0.500.87
80 percentage points 0.62 0.450.85
90 percentage points 0.58 0.410.84
100 percentage points 0.55 0.370.82
Table 5.1: Eﬀect of percentage-point increases in opposite-sex household ART coverage on
HIV acquisition hazard
For every increase of ten percentage points in opposite-sex household ART coverage the
hazard of HIV acquisition was reduced by 6% (95% CI 29), after controlling for household
HIV prevalence and the other independent variables (Table 5.3).1 Table 5.1 shows the
adjusted HIV acquisition hazards for diﬀerent percentage point increases in household ART
1 In Table 5.3, 95% CIs are based on SEs that have been adjusted for clustering at the household level.
aAdjusted hazard ratio represents the change in HIV seroconversion hazard for any increase of ten percentage
points in household ART coverage, controlling for the other independent variables in the regression model.
bAdjusted hazard ratio represents the change in HIV seroconversion hazard for any increase of ten percentage
points in household HIV prevalence, controlling for the other independent variables in the regression model.
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coverage.2 For example, an increase of 50 percentage points in opposite-sex household ART
coverage (eg, an increase from 0% to 50%, from 10% to 60%, or from 20% to 70%), was
associated with a 26% (95% CI 939) reduction in the hazard of HIV acquisition.
The full model included measures of same-sex ART coverage and same-sex HIV preva-
lence. The point estimate for the change in hazard of HIV acquisition for an increase of ten
percentage points in household ART coverage was the same as the one in the opposite-sex
model (Table 5.3). The adjusted hazard ratio (HR) for household same-sex HIV prevalence
was not signiﬁcant (Table 5.3), implying that the opposite-sex ART coverage hazard ratios
are not being confounded with the unobserved `health-seeking' behaviors of the household.
2 Data in Table 5.1 are adjusted for opposite-sex household HIV prevalence and the other independent
variables included in the opposite-sex model; the eﬀect size for each percentage-point increase will be the
same irrespective of the baseline coverage.
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Person- No. Rate/100
Variable years Seroconversions person-years 95% CI
Calender year
2004 5,552 208 3.75 3.274.29
2005 7,060 269 3.81 3.384.29
2006 7,575 321 4.24 3.804.73
2007 7,347 268 3.65 3.244.11
2008 7,102 275 3.87 3.444.36
2009 6,389 237 3.71 3.274.21
2010 5,724 203 3.55 3.094.07
2011 4,858 164 3.38 2.903.93
2012 3,239 92 2.84 2.323.48
Age-Sex Strata
Female 1519 9,179 451 4.91 4.485.39
Female 2024 7,478 583 7.80 7.198.46
Female 2529 3,140 204 6.50 5.667.45
Female 3034 2,271 96 4.23 3.465.16
Female 3539 2,795 70 2.50 1.983.17
Female 4044 3,513 77 2.19 1.752.74
Female 4550 5,349 73 1.36 1.091.72
Male 1519 8,373 75 0.90 0.711.12
Male 2024 5,848 192 3.28 2.853.78
Male 2529 2,082 97 4.66 3.825.68
Male 3034 1,171 38 3.25 2.364.46
Male 3539 1,039 31 2.98 2.104.24
Male 4044 1,076 24 2.23 1.503.33
Male 4550 1,531 26 1.70 1.162.49
Knows HIV Status
No 36,596 1,372 3.75 3.563.95
Refused 4,331 131 3.02 2.553.59
Yes 13,918 534 3.84 3.524.18
Heard about ART
No 23,614 880 3.73 3.493.98
Refused 4,452 134 3.01 2.543.56
Yes 26,778 1,023 3.82 3.594.06
Area
Peri-urban 16,597 724 4.36 4.064.69
Rural 36,613 1,248 3.41 3.223.60
Urban 1,634 65 3.98 3.125.07
Household wealth quintile
Poorest 11,155 364 3.26 2.943.62
2nd poorest 12,254 439 3.58 3.263.93
3rd poorest 11,861 464 3.91 3.574.28
4th poorest 10,994 473 4.30 3.934.71
Wealthiest 8,582 297 3.46 3.093.88
No. of household changes
None 50,481 1,828 3.62 3.463.79
Once 3,642 169 4.64 3.995.39
More than once 722 40 5.54 4.067.55
Table 5.2: Incidence of HIV-1 seroconversion by sociodemographic variables, 200412
76
(1) Opposite-sex Model (2) Same-sex Model
HR (CI) p-value HR (CI) p-value
Household ART coveragea
Opposite-sex 0.9424 (0.90550.9808) 0.004 0.9421 (0.90520.9805) 0.003
Household HIV prevalenceb
Opposite-sex 1.0509 (1.03091.0713) <0.001 1.0508 (1.03091.0712) <0.001
No. of household residents:
Opposite-sex 0.9862 (0.95551.0178) 0.387 0.9834 (0.95221.0157) 0.311
Knows HIV status:
Yes 1 1
No 1.1136 (0.99121.2511) 0.070 1.1141 (0.99161.2516) 0.069
Refused 1.3032 (0.60522.8064) 0.499 1.2997 (0.60522.7915) 0.501
Heard about ART:
Yes 1 1
No 0.9817 (0.87821.0974) 0.745 0.9844 (0.88051.1006) 0.783
Refused 0.7019 (0.32981.4934) 0.358 0.7046 (0.33201.4953) 0.362
Age-Sex strata:
Male 1519 1 1
Male 2024 3.7643 (2.87204.9337) <0.001 3.7687 (2.87524.9397) <0.001
Male 2529 5.3562 (3.95087.2616) <0.001 5.3564 (3.94937.2649) <0.001
Male 3034 3.7199 (2.47455.5922) <0.001 3.7025 (2.46445.5626) <0.001
Male 3539 3.3880 (2.23325.1401) <0.001 3.3760 (2.22805.1156) <0.001
Male 4044 2.5681 (1.62004.0710) <0.001 2.5596 (1.61424.0587) <0.001
Male ≥ 45 2.0097 (1.28193.1507) 0.002 2.0059 (1.27963.1444) 0.002
Female 1519 5.7546 (4.52107.3248) <0.001 5.7475 (4.51197.3215) <0.001
Female 2024 9.5938 (7.521112.2375) <0.001 9.5838 (7.506712.2357) <0.001
Female 25-29 8.0424 (6.145910.5242) <0.001 8.0380 (6.138410.5255) <0.001
Female 3034 5.1052 (3.78016.8948) <0.001 5.0973 (3.77016.8918) <0.001
Female 3539 3.0302 (2.17654.2186) <0.001 3.0257 (2.17144.2161) <0.001
Female 4044 2.6354 (1.90253.6505) <0.001 2.6340 (1.90043.6507) <0.001
Female ≥ 45 1.6802 (1.21272.3280) 0.002 1.6802 (1.21212.3290) 0.002
Area of residence:
Rural 1 1
Peri-urban 1.2844 (1.15541.4278) <0.001 1.2836 (1.15481.4268) <0.001
Urban 1.2544 (0.95281.6513) 0.106 1.2538 (0.95251.6505) 0.107
Household wealth quintile:
Poorest 1 1
2nd poorest 1.0535 (0.91461.2136) 0.470 1.0536 (0.91461.2138) 0.469
3rd poorest 1.0822 (0.93511.2524) 0.289 1.0814 (0.93441.2515) 0.294
4th poorest 1.1571 (0.99651.3436) 0.056 1.1567 (0.99621.3431) 0.056
Wealthiest 0.9374 (0.78741.1161) 0.468 0.9369 (0.78701.1153) 0.464
No. of household changes:
None 1 1
Once 1.1469 (0.97161.3537) 0.105 1.1459 (0.97081.3527) 0.108
Twice or more 1.2650 (0.92391.7320) 0.143 1.2653 (0.92421.7324) 0.142
Household ART coveragea
Same-sex 1.0267 (0.97801.0779) 0.288
Household HIV prevalenceb
Same-sex 1.0048 (0.95881.0529) 0.843
Seroconversions N 2,037 2,037
At-risk Individuals N 14,505 14,505
Exposure Episodes N 118,032 118,032
Hazard ratio (HR), Conﬁdence interval (CI). Standard errors adjusted for household clusters.
Table 5.3: Results of multivariable analysis for the eﬀect of an increase in opposite-sex
household ART coverage on HIV seroconversion hazard
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Figure 5.9: Mean HIV prevalence by household: 20042012
Figure 5.10: Mean ART coverage by household: 20042012
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Alternative analysis: In this section I undertake an alternative analysis of the preventive
beneﬁts of ART. Rather than quantifying the ART coverage and HIV prevalence measures
for each household, I consider a repeat-tester to be a resident of one of four types of
households, which have:
1. one or more HIV-infected co-resident(s);
2. one or more opposite-sex co-resident(s) who are HIV-infected and on ART;
3. each opposite-sex co-resident is HIV-uninfected;
4. the HIV status of each opposite-sex co-resident is unknown (Figure 5.11).
The four types of households present an alternative method for quantifying the repeat-
tester's exposure to ART. Here, the comparison is between household types, rather than the
aﬀect of ART coverage and HIV prevalence levels within the household, on a repeat-tester's
risk of HIV acquisition. I undertake this analysis to ensure that the results produced in the
main analysis are not an artifact of the conceptual designthe decision to compute ART
coverage and HIV prevalence measures for each household.
Table 5.4 gives descriptive statistics of the household and HIV/ART-related charac-
teristics by calender year. Table 5.5 shows the results for the opposite-sex and same-sex
household types. In the alternative analysis, the hazard of HIV acquisition for an individual
living in a household with at least one HIV-infected coresident on ART was 23% less than
for an individual living in a household in which none of the HIV-infected coresidents were
on ART (adjusted HR 0.77, 95% CI 0.630.94, p=0.011).
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Figure 5.11: Schema for household HIV and ART measures in the alternative analysis
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2004 2005 2006 2007 2008 2009 2010 2011 2012
Household count 11,254 11,328 12,287 12,361 12,419 12,511 12,525 12,365 11,962
Inidvidual residents per household 9.53 9.41 9.19 9.18 9.18 9.2 9.17 9.16 9.08
Household count with a HIV+ coresident 2,415 2,986 3,410 3,829 4,176 4,544 5,037 5,202 5,227
Percentage of these households 21.46 26.36 27.75 30.98 33.63 36.32 40.22 42.07 43.7
Household count with a coresident on ART 4 107 304 567 928 1,244 1,608 1,965 2,075
Percentage of these household .04 .94 2.47 4.59 7.47 9.94 12.84 15.89 17.35
Table 5.4: Households with HIV+ residents and residents on ART in the study area
81
Alternative Model
HR (CI) p-value
Homestead Exposure:
≥1 HIV+ co-resident(s) 1
All co-residents known HIV− 0.5713 (0.39010.8366) 0.004
Co-resident HIV status unknown 0.8809 (0.78220.9921) 0.037
≥ 1 co-resident(s) on ART 0.7717 (0.63190.9425) 0.011
Heard about ART:
Yes 1
No 1.2879 (1.16211.4274) <0.001
Refused 0.9174 (0.36122.3302) 0.856
Knows HIV status:
Yes 1
No 0.7544 (0.67580.8422) <0.001
Refused 0.9213 (0.35932.3622) 0.864
Age-Sex strata:
Male 1519 1
Male 2024 2.8045 (2.19353.5858) <0.001
Male 2529 3.6241 (2.72344.8226) <0.001
Male 3034 3.5352 (2.48515.0292) <0.001
Male 3539 3.0689 (2.09064.5048) <0.001
Male 40-44 2.0991 (1.34773.2695) 0.001
Male ≥ 45 2.0741 (1.39053.0939) <0.001
Female 1519 4.8153 (3.87375.9857) <0.001
Female 2024 7.4132 (5.94239.2482) <0.001
Female 25-29 6.9468 (5.46068.8376) <0.001
Female 3034 4.5345 (3.43145.9923) <0.001
Female 35-39 2.9221 (2.14953.9723) <0.001
Female 40-44 2.4351 (1.79853.2972) <0.001
Female ≥ 45 1.6118 (1.18822.1866) 0.002
Area of residence:
Rural 1
Peri-urban 1.3389 (1.21261.4785) <0.001
Urban 1.1789 (0.91961.5113) 0.194
Household wealth quintile:
Poorest 1
2nd poorest 1.0144 (0.89031.1559) 0.830
3rd poorest 1.0219 (0.89431.1677) 0.750
4th poorest 1.0161 (0.88521.1663) 0.821
Wealthiest 0.9008 (0.76971.0541) 0.193
No. of household changes:
None 1
Once 0.8747 (0.74481.0273) 0.103
Twice or more 1.2513 (0.94881.6502) 0.112
Seroconversions N 2,309
At-risk Individuals N 15,304
Exposure Episodes N 163,322
Hazard ratio (HR), Conﬁdence interval (CI). SE adjusted for household clusters.
Table 5.5: Results of multivariable analysis for the eﬀect of household ART coverage (one
or more co-residents) on HIV seroconversion hazard
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5.4 Discussion
This study has shown that for each increase of ten percentage points in opposite-sex house-
hold antiretroviral therapy coverage, the HIV acquisition hazard was reduced by 6% (95%
CI 29), after controlling for other factors. This eﬀect size translates into large reductions
in HIV acquisition hazards when household antiretroviral therapy coverage is substantially
increasede.g., an increase of 50 percentage points in household antiretroviral therapy cov-
erage (eg, from 20% to 70%) reduced the hazard of HIV acquisition by 26% (95% CI 939).
Importantly, these results show that the preventive eﬀectiveness of antiretroviral therapy
can persist in social contexts in which stable sexual partnerships are diﬃcult to identify,
occur late in life, or are not the norm. This study provides the ﬁrst real-world evidence for
the preventive eﬀectiveness of antiretroviral therapy within the household setting (panel).
I did not do a systematic review of the scientiﬁc literature, but referred to three previ-
ously published systematic reviews (Loutfy et al., 2013; Baggaley et al., 2013; Anglemyer
et al., 2013) (synthesizing evidence from a total of one randomized controlled trial and nine
observational studies), which showed that antiretroviral therapy substantially reduced or
prevented HIV transmission among serodiscordant couples. The authors of two reviews
(Cohen et al., 2013; Smith et al., 2012) concluded that ecological studies have methodologi-
cal limitations, and that the population-level preventive beneﬁt of antiretroviral therapy has
yet to be proven. Results of one study (Tanser et al., 2013) showed that high antiretroviral
therapy coverage was associated with a reduction in individual risk of HIV acquisition at the
community level. I searched PubMed for reports published in English between January 1,
2004, and December 1, 2013, using the search terms `antiretroviral therapy', `prevention',
and `household'. I did not identify any studies that assessed the association between risk
of HIV acquisition at the individual level and household antiretroviral therapy coverage.
This study had several limitations. Although I used linked clinical and population-based
cohort data, I cannot completely rule out the eﬀect of unobserved confounding on these
results. A better approach to address confounding would be a randomized control trial, but
this strategy would not be possible at the household level for ethical and methodological rea-
sons. However, by controlling for same-sex antiretroviral therapy coverage in the household,
I do account for unobserved factors at the household level that aﬀect both opposite-sex and
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same-sex coverage and could confound the observed relation between opposite-sex coverage
and HIV acquisition. Such factors include the conscientiousness of household members, at-
titudes towards risk, and attitudes towards health, which are highly plausible confounders
in this study, but diﬃcult to measure directly.
This inability to individually link HIV-uninfected individuals to sexual partners outside
the household, along with the possible migration of sexual partners outside of the study
area, makes accurate measurement of the preventive eﬀectiveness of antiretroviral ther-
apy diﬃcult. Since a subset of HIV-infected individuals (who might or might not be on
antiretroviral therapy) in this cohort did not reside in the same household as their unin-
fected sexual partner and were therefore excluded from the analysis, this ﬁnding should be
regarded as a minimum estimate of the preventive eﬀectiveness of antiretroviral therapy.
In this study, I included a coresident member in the measure of household antiretroviral
therapy coverage if his or her date of antiretroviral therapy initiation was before a residency
in a household and if his or her clinic follow-up status was still active during the residency
period. I therefore could have further underestimated the preventive beneﬁt of antiretro-
viral therapy since I did not account for patients failing antiretroviral therapy. This study
provides further evidence that treatment with antiretroviral therapy signiﬁcantly reduces
the risk of onward transmission of HIV in a real-world setting in sub-Saharan Africa. Pub-
lic promotion of the preventive beneﬁts of antiretroviral therapy could help to motivate
individuals to learn their HIV status and seek treatment. Adherence to antiretroviral ther-
apy is more likely to be sustained if HIV-infected individuals are aware that the therapy
will protect their sexual partners from acquiring the infection. Similarly, the knowledge
that antiretroviral therapy can provide protection from HIV acquisition could motivate
HIV-uninfected individuals to persuade their infected coresident partners to initiate an-
tiretroviral therapy, improving the long-term use of life-saving drugs within the household.
Important strengths of this study include the use of one of the world's largest HIV
incidence cohorts and the ability of this data and study design to capture the changing
demographic conditions of an HIV-uninfected individual's living arrangements over time.
In this respect, this study is unique because it uses information about HIV serostatus and
antiretroviral therapy status among coresident household members to test the treatment-
as-prevention hypothesis in a real-world setting in sub-Saharan Africa. Awareness that
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antiretroviral therapy can prevent transmission to coresident sexual partners could motivate
individuals to disclose their HIV status and to seek and adhere to treatment, improving the
long-term use of live-saving antiretroviral therapy.
Chapter 6
Socio-demographic and Structural Predictors of Poor
ART Adherence
6.1 Introduction
In this chapter I turn to an examination of the survival beneﬁts of ART, focusing speciﬁcally
on the topic of treatment adherence. High adherence to ART can dramatically improve the
health and mortality outcomes of HIV-infected patients (Nachega et al., 2007; Paterson
et al., 2000; Bangsberg et al., 2000), and prevent the onward transmission of HIV (Cohen
et al., 2011; Baggaley et al., 2013; Tanser et al., 2013). As a result, eﬀorts to optimize the
eﬃcacy of ART in South Africa and elsewhere will be critically dependent on the ability
of the public health-care sector to start and then ensure that patients remain adherent to
their medications (Nachega et al., 2013). Unfortunately, a signiﬁcant proportion of patients
do not consistently adhere to their medications for reasons discussed in greater detail in
Section 6.2. In this chapter I examine the set of socio-demographic and structural variables
that are associated with ART adherence in a rural South African community. In addition,
I assess whether the predictive information of these variables can be used to augment the
clinical detection of imperfect adherence in resource-limited health-care settings.
The data for this analysis comes from the Hlabisa HIV Treatment and Care Programme,
which is a decentralized health-care program established by the South African Department
of Health (DOH) and the Africa Centre to provide ART free of charge to eligible HIV-
infected patients. The start of the HIV program coincides with the nation-wide launch of
the DOH's Comprehensive Management and Treatment Plan in 2004 (Houlihan et al., 2011).
The scale-up of ART to more than 6 million people through this treatment plan means that
a large number of people who are socially and economically marginalized will enter into the
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public health-care system. I argue that the ability of patients to maintain their treatment
schedules will be continually tested in social conditions characterized by a lack of resources
and poverty. In such contexts, patients are unlikely to have adequate ﬁnancial support to
travel to the clinic; or be able to access main routes or motorized transport to easily reach
the clinic; or they may have to migrate frequently in search of employment, and therefore
miss scheduled clinic visits to obtain their medications. Low levels of health literacy and a
lack social support are likely to further compromise adherence; and woman may be more
likely to experience the adverse consequences associated with the open use of treatment in
the household. These socio-demographic and structural factors are often recognized as the
major barriers to treatment adherence in the sub-Saharan African context.
My aim in this chapter is to investigate whether the types of broad, macro-social level
factors described above are statistically associated with ART adherence. Further, I suggest
that a patient's socio-demographic information, along with the structural factors that may
obstruct his or her interaction with the clinic setting, can be used by health-care workers to
improve and consolidate treatment-related services. In this regard, I aim to assess if such
socio-demographic and structural information can augment a laboratory methodCD4 cell
count monitoringto identify issues related to inconsistent ART usage. I discuss the CD4
count monitoring method in more detail below.
In this analysis, I use viral load count as a biomarker (or proxy) for ART adherence. A
viral load is a measure of the number of HIV copies in a cubic centimeter of blood. Viral
load count is used to assess the degree of virologic compromise in a patient. Brieﬂy, HIV has
a high rate of replication and produces millions of copies of itself every day. ART is designed
to keep the rate of HIV replication as low as possible for as long as possible (Stott et al.,
2012). High adherence to ART is the most important predictor of virologic suppression,
which indicates that the amount of virus within the patient is at a low level (typically <400
copies/ml) (Ford et al., 2010; Rosenblum et al., 2009; Arnsten et al., 2001; Paterson et al.,
2000; Bangsberg et al., 2000). Otherwise, persistent viral load counts >1000 copies/ml is
a strong indication that a patient has virologic failure and is therefore not adhering toor
even takingtheir ART medications (Roberts et al., 2012).1
1 For example, patients who have treatment interruptions within the ﬁrst three months of initiating
ART are more likely to have viral load counts >1000 copies/ml six months later (Meresse et al., 2014).
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My decision to use viral load as the outcome variable of this analysis is based on a
number of scientiﬁc studies that have identiﬁed high adherence to ART as a primary deter-
minant of virologic suppression (Ford et al., 2010; Wilson et al., 2009; Orrell et al., 2007;
Nachega et al., 2007). For this analysis, I deﬁne two consecutive viral load counts >1000
copies/ml as an indicator of virologic failure and therefore imperfect or non-adherence to
ART (see Section 6.3). This deﬁnition of virologic failure is consistent with WHO ART
treatment guidelines updated in June 2013 (WHO, 2013). This decision is further sup-
ported by the use of viral load measurements to validate self-reported ART adherence
(Usitalo et al., 2014; Simoni et al., 2006; Levine et al., 2006; Bangsberg, 2008). Various
methods or techniques to measure adherence, most notably self-reporting, electronic pill
counting, or pharmacy reﬁll records, tend to be inaccurate or involve complicated logistics.
Furthermore, these measures cannot completely determine whether the medications have
been physically ingested by the patient (Kagee and Nel, 2012). For these reasons, viral load
monitoring is often promoted as the recommended method or gold-standard for assessing
treatment adherence (Hamers et al., 2012b; Gupta et al., 2009; Keiser et al., 2011).
There is a close relationship between a patient's viral load and CD4 cell count. A CD4
cell count is a measure of the number of T-lymphocyte cells in a cubic milliliter of blood
(cells/µl). HIV destroys CD4 cells, which play an important role in the functioning of the
immune system. A CD4 count is therefore used to indicate the degree of immunological
compromise in a patient. For example, patients with CD4 counts <50 cells/µl have a 50%
annual mortality rate, while individuals with counts <200 cells/µl have mortality rates of
10% to 15% per year (Zijenah and Katzenstein, 2002; Volberding et al., 2012; Gilks et al.,
2006; Lawn et al., 2005). CD4 count is further used to determine the risk of opportunistic
infections, to assess prognosis, and to decide when the patient is eligible for ART initiation.
Importantly, high adherence to ART is closely associated with the health of a patient's
immune system, with continuous recovery for up to 7 years after initiation (Sempa et al.,
2013). Research has also shown that patients who have a higher a CD4 count at the date of
initiation are likely to have a better treatment response at 12 months (Anude et al., 2013;
Ramadhani et al., 2007; Djomand et al., 2003; Elul et al., 2013).
Because persistently high viral load results in a decline in CD4 cells, WHO guidelines
recommend that CD4 monitoring can be used to identify patients who have virologic failure
88
(WHO, 2013).2 However, there is a large debate as to whether CD4 count monitoring should
be used for this purpose. A number of studies have shown that CD4 monitoring lacks the
sensitivity to accurately detect patients who have virologic failure (Reynolds et al., 2012,
2009; Castelnuovo et al., 2009; Mee et al., 2008; Moore et al., 2008).3 For this chapter,
I include the contested CD4 count predictor in the analysishoping to avoid the current
debate surrounding this laboratory measure for nowfor two reasons. First, I wish to
examine the magnitude of the socio-demogaphic and structural variables in comparison
to this biological level measure. Second, the socio-demographic and structural variables
evaluated in this analysis are not considered to be exclusive or suﬃcient predictors of
virologic failure. My aim in this analysis, rather, is to assess whether information on a
patient's socio-demographic characteristics, including his or her interaction with the clinic
setting, can be used to augment existing laboratory methods to assess patient response to
ART.
I undertake this analysis in two parts. I ﬁrst use a Cox proportional hazards model to
examine the time to virologic failure conditional on the 1) socio-demographic, 2) structural,
and 3) CD4 count variables. I speciﬁcally use this statistical approach to address potential
bias in longitudinal cohort studies that may result from patient loss to follow-up or mortal-
ity. Further, I use the complexity and depth of the Africa Centre data to allow for some of
the socio-demographic and structural factorsparticularly, migration outside of the study
areato vary over time. I speciﬁcally undertake the Cox proportional hazards model to
assess the inferential association between these predictors and the time to virologic failure.
I then turn to an evaluation of the diagnostic performance of the socio-demographic,
structural, and CD4 count variables. I recode all time-varying predictors as constants,
which reﬂect, for example, the number of times migrated outside of the study area, the
duration of ART therapy, or the overall number of clinic visits from the date of ART
initiation to the date of censorship, etc. CD4 count was estimated as a monthly change for
each patient using a ﬁxed eﬀects model. I argue that these recoded variables are likely to
2 For example, the WHO's Consolidated guidelines on the use of antiretroviral drugs for treating and
Preventing HIV infection (WHO, 2013) states that there is still insuﬃcient evidence for the survival beneﬁt
of viral load monitoring over CD4 or clinical monitoring.
3 The authors of the cited studies propose that viral load monitoring alone be used to monitor patient
response to ART. The debate surrounding these two monitoring strategies is explored in greater detail in
Chapter 7 of this dissertation.
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be more reﬂective of the information presented by the patient or database records to the
health-care worker during routine clinic visits. I use a logistic regression model to examine
the association between the virologic failure outcome and the socio-demographic, structural,
and CD4 count variables. I then use a receiver operating characteristics (ROC) analysis to
assess the predictive power of the logistic regression submodels, and to classify patients who
are at low, medium, or high risk of virologic failure. The ROC method is frequently used in
medical and epidemiological research, but may be unfamiliar to the sociological audience.
My justiﬁcation for the use of the logistic regression and ROC analyses is to evaluate if
the socio-demographic and structural information of the patient can be used in conjunction
with existing laboratory methods (i.e., CD4 count monitoring) to facilitate the detection
of virologic failure. Ideally, my approach is one that combines the use of both social and
clinical data to facilitate current health-care eﬀorts to achieve this purpose.
6.2 The socio-demographic and structural barriers to ART
adherence
There are a number of behavioral, socio-demographic, and structural barriers that are
associated with imperfect adherence to ART. Barriers related to the behavioral level may
include a patient's fear of disclosure, substance abuse, forgetfulness, suspicion of treatment,
treatment complexity, the number of pills required to take daily, food insecurity, and work
and family responsibilities (Kagee et al., 2011; Musumari et al., 2014, 2013; Kekwaletswe
and Morojele, 2014; Morojele et al., 2013; Lyimo et al., 2014; Nyamhanga et al., 2013; Mills
et al., 2006). Researchers have identiﬁed a number of socio-demographic or structural level
barriers that make adherence to treatment diﬃcult in the sub-Saharan African context. In
a systematic review, (Peltzer and Pengpid, 2013) report that having a low income, a lower
level of education, and being unemployed are negatively associated with ART adherence.
However, there is a lack of deﬁnitive or conclusive support for a clear association between
socioeconomic status and treatment adherence in low- and middle-income countries where
ART is freely available. Braitstein et al. (2006) ﬁnd that ART is most eﬀective when it
is administered for free to patients, although these gains are potentially lost the longer
patients are on treatment due to a number of the factors listed above. In South Africa,
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treatment retention has decreased over time: as few as 64% of patients initiating ART
between 2002 and 2007 were retained in care at 36 months and that this number was lower
(50%) for individuals living in rural areas (Cornell et al., 2010).
Socioeconomic status may aﬀect treatment adherence through other factors not specif-
ically related to income, education, or employment status. For example, patients typically
have to spend time and money to travel to the health-care clinic to collect their medications,
a lifelong process given the nature of HIV and its progression to AIDS. For this reason,
indicators related to travel and transport are often considered to be important predictors of
ART adherence, along with patient mobility and migration. Research has shown voluntary
or forced migration to be an important predictor of adherence in sub-Saharan Africa. One
South African study reports that patients often had to travel to family events, and were
reluctant to take their medications around distant family members (Coetzee et al., 2011).
In a Kenyan study, 68% of patients identiﬁed being away from home as the most important
factor that aﬀected the timing of ART doses; and 59% of the patients who lived outside of
the municipality (where treatment was easily accessible) had poor adherence. In a study
from Botswana, 13% of the patients reported having to travel or migrate as a barrier to
adherence, and the frequency of required visits to the clinic was also cited as a signiﬁcant
reason for inconsistent treatment use. Approximately 54% of the study participants re-
ported having traveled or lived in more than one place since the start of their treatment,
which was identiﬁed as disruptive to their treatment schedule (Weiser et al., 2003). In a
Ugandan study, 11% of patients reported traveling away from home to signiﬁcantly impact
treatment adherence (Byakika-Tusiime et al., 2005).
Marital status and issues related to gender inequality within the household have been
identiﬁed with poor ART adherence. In sub-Saharan Africa, the sexual division of power
the product of a patriarchal social systemgenerally limits the ability of female partners to
engage in positive treatment behaviors. This power diﬀerential has important implications
for the eﬃcacy of ART, particularly because women are unlikely to ensure that their HIV-
infected male partners adhere to treatment. For example, fear of partner reprisal may
lead women to discontinue or undermine their treatment ﬁdelity. In a qualitative study
of 78 participants in Zimbabwe, Skovdal et al. (2011) report that social constructions of
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masculinity resulted in husbands interfering with their wives' treatment schedule. HIV-
infected women were also unable to fully inform their husbands of their status and to
openly comply with their treatment requirements. One Ugandan study found that patients
who were single and never married were more likely to adhere to ART (Byakika-Tusiime
et al., 2005). In general, research has shown that women who had disclosed their status
to their husbands were more likely to accept treatment initiation and return for treatment
counseling (Msuya et al., 2008; Farquhar et al., 2004; Msuya et al., 2006; Semrau et al.,
2005).
An unlikely source of poor treatment adherence in the study area may come from
the provision of disability grants by the South African government at public health-care
facilities. Disability grants can be collected by patients who have CD4 count <200 cells/µl
for a period of six months. The grants are motivated by the idea that ART will increase CD4
counts and enable the patient to return to work after an improvement in health (Natrass,
2004). Prior research has reported that patients may sometimes deliberately stop taking
ART in order to maintain a low CD4 count and therefore re-qualify for the disability grant
(Coetzee et al., 2011).
Alongside the socio-demographic predictors are the structural barriers that reﬂect the
diﬃculties a patient experiences in his or her interaction with the health-care environment.
These structural barriers describe either the institutional characteristics of the treatment
clinic or the patient's living space that facilitate or disrupt eﬀorts to access and collect
medications on a frequent basis. For example, a patient may have to overcome physical
obstacles (such as distance and multiple transport routes) to reach the treatment clinic,
which may be overly expensive, time consuming, or require the scheduling of time oﬀ from
the workplace. For this reason, travel to the clinic is often recognized as an important
barrier to adherence. Coetzee et al. (2011) report that treatment adherence is inﬂuenced
by transport diﬃculties in South Africa that include disruptions to schedules and taxi
routes that do not take patients all the way to the clinic. Research by Siedner et al. (2013)
found that GPS-measured distances, rather than self-reported distance, to clinic was highly
correlated with poor adherence to ART. The frequency of clinic visits, duration between
clinic visits, and change of clinic are measures that are likely to reﬂect a patient's interaction
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with the treatment setting, and may be strongly associated with the ability to adhere to
ART.
6.3 Methods
6.3.1 Setting and participants
Data was collected from patients presenting at one of 17 primary health-care clinics and
the local hospital (Hlabisa) in the study area (Houlihan et al., 2011) between 2004 and
2013. ART was made available free of charge through the HIV Treatment and Care Pro-
gramme to patients who met treatment eligibility criteria previously outlined in Section 5.2
of this dissertation. Patient demographic and clinical information was collected through a
standardized form at routine clinic visits. CD4 count measures were taken every 6 months
(Houlihan et al., 2011). Prior to 2010, viral load was measured every six months and re-
peated after three months if patient viral load was >5000 copies/ml. After 2010, viral load
was measured at month 6 and month 12, and then every 12 months if viral load remained
<400 copies/ml. Viral load >1000 copies/ml resulted in a repeat measurement every three
months (Manasa et al., 2013). Patient data was entered and stored into the Africa Centre's
ART Evaluation and Monitoring System (ARTemis).
6.4 Statistical analysis
Imperfect adherence was determined using WHO criteria (WHO, 2013) for virologic failure,
deﬁned as a patient's ﬁrst two successive viral load counts >1000 copies/ml after initiating
ART (thus indicating persistent viremia). I use the virologic failure outcome as a biomarker
(or proxy) for adherence to ART, and justify this decision in Section 6.1. Patients had to
be on ART for a minimum of 6 months,4 and all viral load measures were selected 30 days
after the ART initiation date (to allow for viral load response to treatment) until the date
of virologic failure or last clinic visit.
4 This time frame is recommended by WHO criteria (WHO, 2013).
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6.4.1 Cox proportional hazards analysis
I use a Cox proportional hazards model to evaluate the time to virologic failure and to
address potential biases related to patient drop-out or mortality while under observation.
Importantly, I use this model to quantify the inferential association between the time to
virologic failure and the independent variables of the socio-demographic, structural and
CD4 count submodels. The socio-demographic submodel includes age, sex, employment,
highest education level, and history of migration out of the study area. The structural
submodel includes the distance to clinic or main road, previous use of ART, frequency of
clinic visits, duration between clinic visits, and change of clinic since the date of initiation. I
speciﬁed age, migration, distance to clinic and main road, and duration between clinic visits
as time-varying predictors. Distance to clinic or main road was considered time-varying to
account for changes in household residency. As discussed in Chapter 5, a strength of Cox
proportional hazards model is its ability to account for changes in patient mobility and
migration within and outside of the study area. For the third submodel, I assess the
association between CD4 cell count, a time-varying predictor, and time to virologic failure
(and justify this inclusion in Section 6.1 of this chapter).
6.4.2 Logistic regression analysis
I move from the inferential analyses of the Cox proportional hazards analyses to evaluate the
predictive performance of the socio-demographic, structural, and CD4 count submodels. To
do this I recoded the time-varying predictors used in the socio-demographic and structural
submodels as constants for the logistic regression analyses. For example, I coded migration
as the number of times a patient migrated out of the study area, and employment was
calculated as the proportion of time employed while under observation. I used an individual
ﬁxed eﬀects model to capture the change in CD4 cell count as a single estimate for each
patient using methods discussed in the Appendix (page 181). This estimate reﬂects the
monthly change in a patient's CD4 count, expressed as a slope or coeﬃcient.
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The logistic regression model is brieﬂy outlined below. Let Yj be a single, unobserved
response for the jth patient (j = 1, . . . , n), where
Yj =
1 the patient has virologic failure0 the patient does not have virologic failure.
Let pi(x) = Pr(Y = 1|X = x) be the conditional probability that a patient has virologic
failure, given the covariate value X = x. We consider the response Y to be a single random
variable with a Bernoulli distribution. Let y1, . . . , yn be the realizations of the Y1, . . . , Yn
independent Bernoulli random variables. Then
(Yj |X = xj) ∼ Bin(1, pi(xj)) (6.1)
has a binomial distribution, and pi(xj) is the probability that the jth patient will have
virologic failure for a ﬁxed value xj (Weisberg, 2005). An important assumption of this
binomial distribution is that i) each patient has the same marginal probability pi of having
virologic failure and ii) the outcomes for all patients are independent. We can express the
logit of pi(xj) for the univariate model as:
loge
pi(xj)
1− pi(xj) = β0 + β1Xj . (6.2)
which produces β coeﬃcients in the log-odds form and where β1 = 0 indicates that the
response variable Y is independent of the predictor variableX. It is easier to interpret the β
coeﬃcients as the odds that a patient will have virologic failure. To do this we exponentiate
both sides of (6.2) and get:
pi(xj)
1− pi(xj) = exp(β0 + β1Xj). (6.3)
Equation (6.3) is a multiplicative model where the odds is in the range [0,∞), and where
eβ1 = 1 indicates that the response variable Y is independent of the predictor variable X.
Thus, a one unit change in CD4 count slope changes the odds of a patient having virologic
failure by a factor of eβ1 . The predicted probability (pp) that a patient will have virologic
failure for a ﬁxed value xkj is:
pi(xj) =
exp(β0 + β1X1j+, . . . ,+βkXkj)
1 + exp(β0 + β1X1j+, . . . ,+βkXkj)
, (6.4)
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which maps the linear predictor Y = β0+β1X1j+, . . . ,+βkXkj onto the [0,1] interval for the
multivariate model (for k number of independent variables) (Fox, 2008). As discussed, the
predicted probabilities give the probability of virologic failure for each patient conditional
on the independent variables of the submodel. We can assess the predictive performance
of the submodel by performing an AUC analysis, which I describe in greater detail in the
next section.
6.4.3 ROC analysis
I use a receiver operating characteristics (ROC) analysis to assess the predictive performance
of the socio-demographic, structural, and CD4 count logistic regression submodels. An
ROC analysis goes beyond the interpretation of odds and hazard ratios, and their p-values,
to determine the error rate of a given classiﬁcation schema. The application of the ROC
analysis in this chapter can be demonstrated with the following example. Having performed
a logistic regression using the independent variables for the socio-demographic submodel,
I decide to classify all patients with a predicted probability of virologic failure less than a
0.40 cut-point as belonging to a low risk group and all patients with a predicted probability
greater or equal than a 0.40 cut-point as belonging to a high risk group. To what extent
does this classiﬁcation schema correctly identify the proportion of patients in the sample
that truly have virologic failure? Since no predictive model is perfect, it is likely that this
classiﬁcation schema will have some degree of error: not all patients in the high risk group
will have virologic failure; and some patients in the low risk group will have virologic failure.
ROC analyses are often used by the medical decision-making community to evaluate
the performance of diagnostic systems (Swets et al., 2000). It is a method for selecting
classiﬁers based on their performance (Fawcett, 2006; Brown and Davis, 2006). Figure 6.1
shows an example of a classiﬁcation model, called a contingency table or confusion matrix,
using only two classes. In this example, the two classes produce four possible outcomes
by mapping observed or known instances (the true class) to the predicted (hypothesized)
class. If an instance is positive (+) and has been classiﬁed under the hypothesized class as
positive (+), then it is a true positive. If an instance is positive (+) but has been classiﬁed
under the hypothesized class as negative (−) then it is a false negative, etc.
96
Figure 6.1: Example of a confusion matrix showing four possible outcomes
Consider the confusion matrix in Table 6.1, which shows toy data for the example
presented at the beginning of this section. The true class consists of the patients who
have or do not have virologic failure using the deﬁnition for ﬁrst two consecutive viral load
measures >1000 copies/ml. These patient outcomes have been observed in the data. The
hypothesized class are the patients that are classiﬁed under a high or low risk group based
on their predicted probabilities (obtained from the logistic regression analysis).
Group
Failure Low Risk High Risk Total
No 4,104 209 4,313
Yes 944 317 1,261
Total 5,048 526 5,574
Table 6.1: Example of a confusion matrix showing the outcomes classiﬁed by virologic
failure and risk group status
Using this classiﬁcation schema, each patient is mapped to one of four possible and
distinct outcomes, which correspond with Figure 6.1. These are:
• True negatives: all patients in the low risk group are correctly classiﬁed as not having
virologic failure (n = 4104).
• True positives: all patients in the high risk group are correctly classiﬁed as having
virologic failure (n = 317).
• False negatives: patients in the low risk group have been incorrectly classiﬁed as not
having virologic failure (n = 944).
• False positives: patients in the high risk group have been incorrectly classiﬁed as
having virologic failure (n = 209).
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The cells in Table 6.1 can be used to determine the error rate of the low/high risk group
classiﬁcation schema. The sensitivity is a measure of how well the classiﬁcation schema
(using the low/high risk group categories) identiﬁes true positives, that is, the patients that
were observed in the sample to have virologic failure. Sensitivity, is deﬁned as the number
of true positives in a group over the total number of positives. Looking at Table 6.1, the
sensitivity for the high risk group is:
positives correctly identiﬁed
total positives
=
317
1261
× 100 = 25.14%. (6.5)
If we used membership of the high risk group to `diagnose' virologic failure, then we would
only correctly identify 25% of the sample as truly having virologic failure, which is a poor
sensitivity. From this example, the selection of the 0.40 cut-point to deﬁne a low or high
risk group does not appear to adequately identify patients who truly have virologic failure.
The speciﬁcity is a measure of how well the classiﬁcation schema identiﬁes true nega-
tives, that is, the patients in the sample that were observed to not have virologic failure.
The speciﬁcity for the classiﬁcation schema using membership of the high risk group is
determined ﬁrst by the false positive (fp) rate, which is the number of negatives incorrectly
classiﬁed in the high risk group over the total number of negatives:
negatives incorrectly classiﬁed
total negatives
=
209
4313
= 0.048 (6.6)
From this the speciﬁcity is computed as 1−(fp rate) = (1−0.048)×100 = 95.2%. Thus, the
high risk group threshold can detect 95.2% of the patients that truly do not have virologic
failure. The classiﬁcation rate measures all the cases correctly classiﬁed, which is:
true positives + true negatives
total cases
=
4104 + 317
5574
× 100 = 79.31%.
Table 6.2 shows the sensitivity, speciﬁcity, and classiﬁcation rates for the low and high
risk groups. Technically, each group is called a threshold candidate because the sensitivity
and speciﬁcity measures are computer for all instances ≥ or > than a selected cut-point.
Table 6.2 is important because it can be used to graph each of the threshold cut-points,
as shown in Figure 6.2. The point in the top right corner represents a sensitivity=100%
and a speciﬁcity=0%, which is the ≥ Low risk group threshold (as labeled). Thus, all low
and high risk groups would be diagnosed as having virologic failure, thereby identifying
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all true positives, but failing to identify any true negatives. The point in the bottom left
corner represents a sensitivity=0% and a speciﬁcity=100%, indicating the > High risk
group threshold. The remaining point represents the threshold for the ≥ High risk group
threshold, which was computed in (6.5) and (6.6) above. The area under the points, called
the AUC, is computed using the trapezoidal rule, and gives an objective measure of the
predictive performance of the classiﬁcation schema. This area can be maximized by selecting
the appropriate thresholds that give the highest AUC. A strong predictive performance is
set at 0.80 or greater (thus an AUC of 0.60 conﬁrms the weak predictive power of the
current risk group classiﬁcation used in the example).
Candidate Correctly
Threshold Sensitivity Speciﬁcity Classiﬁed
≥ Low 100.00% 0.00% 22.62%
≥ High 25.14% 95.20% 79.31%
> High 0.00% 100.00% 77.38%
Table 6.2: Speciﬁcity, sensitivity, and classiﬁcation rate for threshold candidates
6.4.4 Determining the risk group classiﬁcation schema
In the cited example, I arbitrarily selected a cut-point threshold of 0.40, but how can the
criteria for classifying patients under a particular risk group status (or any other classiﬁ-
cation schema) be more systematically determined? We can use the power of statistical
and predictive modeling to deﬁne or construct such cut-points. In this chapter, the criteria
for determining membership of a risk group (the hypothesized class) are obtained in three
steps: 1) Using a logistic regression analysis, regress the virologic outcome on the relevant
submodel variables, 2) undertake a post-estimation analysis and obtain a predicted proba-
bility of virologic failure (conditional on the submodel variables) for each patient, 3) classify
the predicted probability (pp) for each patient under the relevant low, medium, or high risk
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Figure 6.2: Area under the curve (AUC) showing the performance of the classiﬁcation
schema presented in Table 6.2
group. Patients in step 3) are assigned to a risk group using the following algorithm:
risk group =

low if 0 ≥ pp < x
medium if x ≥ pp < y
high if y ≥ pp ≤ 1,
(6.7)
where 0 < x < y < 1. The cut-points x and y are selected that give the maximum AUC of
an ROC graph.5 The error rate of the classiﬁcation schema, which uses the (x, y) pair to
determine the low, medium, and high risk groups, is then evaluated using the ROC analysis.
5 Using the statistical software package Stata (version 12.1), I iterate over incremental values between 0
and 1 for both x and y, and select the pair (x, y) which gives the maximum AUC. An example of the Stata
code is given on page 188 of the Appendix.
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6.5 Results
There were 6, 137 patients in the ARTemis database that initiated ART. Patients on ART
for less than 6 months were dropped from the analysis (n = 2, 190). A further 196 and 226
patients were dropped because they had less than two viral load or CD4 measurements.
There were 3, 525 patients in the ﬁnal analytic dataset, of which 2, 614 (74.2%) patients
were female. The median age was 35 years. There were 510 patients that met the criteria
for virological failure, and thus identiﬁed as having poor or imperfect ART adherence.
On average, patients were exposed to ART for a duration of 35.1 months (i.e., from 30
days after treatment initiation to the virologic failure event or the last clinic visit). The
summary statistics for the socio-demographic, structural variables, and CD4 count variables
are shown in Table 6.3.
6.5.1 Univariate hazards model
Table 6.4 shows the univariate associations for the Cox proportional hazards model. The
hazard ratios for age, education (high school and tertiary education), migration out of the
study area, duration on ART, change of clinic and number of clinic visits since initiation,
and change in CD4 count were signiﬁcant at the 0.05 level. Younger patients and patients
that migrated outside of the study area were more likely to have an increased hazard of
virologic failure. Straight line distance to nearest clinic or main road was not signiﬁcant
at the 0.05 level, although it is unclear if this measure accurately captures the real-time
distance (and cost) needed to travel to this destination. For the structural predictors,
results show that patients attending more clinic visits after treatment initiation were less
likely to have virological failure. A patient was more likely to have virological failure if he
or she changed clinics one or more times since initiating treatment. Sample sizes diﬀered
for each univariate analysis. I explore these variables in greater detail in the submodel
analyses below.
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Female No. %
No 911 26
Yes 2,614 74
Age category No. %
16- 53 2
20- 273 8
25- 665 19
30- 719 20
35- 625 18
40- 1,190 34
Married No. %
No 152 80
Yes 38 20
Living with Partner No. %
No 157 85
Yes 27 15
Highest Education No. %
No School 233 7
Primary School 723 21
High School 1,754 50
Tertiary 815 23
Employed >50% of time No. %
No 2,421 69
Yes 1,104 31
Km (line) to level 1 road No. %
0- 1,114 32
1- 530 15
2- 207 6
3- 272 8
5- 528 15
10- 874 25
Km (line) to nearest clinic No. %
0- 540 15
1- 977 28
2- 729 21
3- 869 25
5- 410 12
Residential migration once or more No. %
No 2,255 64
Yes 1,270 36
Out migration once or more No. %
No 2,925 83
Yes 600 17
Disability grant No. %
No 3,514 100
Yes 11 0
Previous ART No. %
Don't know 403 11
No 2,905 82
Yes 217 6
Clinic visit count No. %
0- 502 14
2- 795 23
3- 1,098 31
5- 765 22
8- 365 10
Changed clinic No. %
No 2,889 82
Yes 636 18
Table 6.3: Summary statistics of socio-demographic, structural and CD4 count variables
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Univariate Model
HR (CI) p-value
Male 1.170 (0.9621.424) 0.116
Age 0.966 (0.9560.976) 0.000
Highest education: No school (Ref.)
Primary school 1.173 (0.7201.910) 0.522
High school 1.844 (1.1712.902) 0.008
Tertiary education 1.654 (1.0302.656) 0.038
Employed 0.862 (0.7131.042) 0.125
Married 1.514 (0.6033.800) 0.377
Km to nearest main road 0.987 (0.9731.001) 0.071
Km to nearest clinic 0.991 (0.9431.041) 0.713
Migrated out of surveillance area 4.885 (3.1967.469) 0.000
Migrated out of current residence 2.575 (1.8393.604) 0.000
Disability grant 1.470 (0.3675.897) 0.586
Previous ART: No (Ref.)
Don't know 0.701 (0.5320.923) 0.012
Yes 0.880 (0.6321.225) 0.448
Duration between clinic visits (mths) 1.002 (0.9811.024) 0.827
Duration of ART (mths) 0.803 (0.7910.816) 0.000
Changed clinic 1.343 (1.1061.631) 0.003
Clinic visit count 0.234 (0.2120.259) 0.000
CD4 Counta 0.972 (0.9650.980) 0.000
a For a 20 cell count increase in CD4
Table 6.4: Univariate results for the socio-demographic, structural, and CD4 count predic-
tors of virological failure
6.5.2 Submodel 1: Socio-demographic predictors
For submodel 1 I examine the association between the time to virologic failure and the socio-
demographic predictors sex, age, highest level of education, employment, and disability
grant received. The Cox proportional hazard results are shown in Table 6.5. Results show
that older patients are less likely to have virologic failure when compared with patients
aged 1619 years, holding all else constant. Migration out of the study area is associated
with a 4.03 (95% CI: 2.666.10) increase in the hazard of virologic failure, holding all else
constant. Patients with a history of employment were less likely to have virologic failure.
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Submodel 1
HR (CI) p-value
Male 1.383 (1.1311.689) 0.002
Age:
1619 (Ref.)
2024 0.351 (0.2000.616) 0.000
2529 0.387 (0.2350.638) 0.000
3034 0.338 (0.2050.557) 0.000
3539 0.312 (0.1870.521) 0.000
≥ 40 0.171 (0.1020.286) 0.000
Highest education:
No school (Ref.)
Primary school 1.038 (0.6361.695) 0.882
High school 1.216 (0.7571.954) 0.419
Tertiary education 1.163 (0.7101.907) 0.548
Employed 0.820 (0.6750.996) 0.045
External migration 4.025 (2.6586.096) 0.000
Disability grant received 1.905 (0.4747.667) 0.364
Virologic Failure 510
Total 3,525
Exposure Episodes 25,459
Table 6.5: Submodel 1: Cox proportional hazards model output for the socio-demographic
variables
Table 8.2 of the Appendix shows the results for the logistic regression model. The AUC
(0.57) for the ROC graph was maximized using the cut-points x = 0.10 and y = 0.15,
from which the low, medium, and high risk group categories were constructed. I present
the confusion matrix for submodel in Table 6.6, which shows the number and percentage
of patients that were classiﬁed under each risk group. Table 6.7 shows the sensitivity and
speciﬁcity for this classiﬁcation schema. We would identify 90.98% of the patients who
truly have virologic failure using the ≥ medium risk group threshold (i.e., all medium and
high risk patients). This is a strong sensitivity for the ≥ medium risk group threshold;
however, the very low speciﬁcity of 17.51% indicates that only a small number of patients
would have been correctly identiﬁed as not having virologic failure at this threshold.6
6 As a result, a substantial number of patients would be classiﬁed as false positives, and would likely be
referred to additional health-care services or monitoring, that would place an unnecessary cost on already
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Risk group
Failure Low Risk Med Risk High Risk Total
No. % No. % No. % No. %
No 528 92 1,162 86 1,325 83 3,015 86
Yes 46 8 184 14 280 17 510 14
Total 574 100 1,346 100 1,605 100 3,525 100
Table 6.6: Confusion matrix for submodel 1
Threshold Sensitivity % Speciﬁcity % Correctly
Classiﬁed %
≥ Low Risk 100.00 0.00 14.47
≥ Medium 90.98 17.51 28.14
≥ High 54.90 56.05 55.89
> High 0.00 100.00 85.53
AUC = 0.57
Table 6.7: Speciﬁcity and sensitivity for submodel 1
We would only identify 54.90% of the patients that truly have virologic failure under the
≥ high risk group threshold (i.e., only patients in the high risk group). Further, the high
risk threshold gives a low speciﬁcity of 56.05%. The AUC for this submodel is low at 0.57
(see Figure 8.1 in the Appendix), which indicates that the socio-demographic predictors
perform poorly in correctly classifying the virologic failure outcomes of patients using the
data. This result already conﬁrms the weak eﬀects for the odds ratios shown in Table 8.2.
Figure 8.1 in the Appendix plots the sensitivity and speciﬁcity for each threshold and shows
the area under the curve for the ROC analysis. Figure 6.3 shows the Kaplan-Meier survival
curves for each risk group proﬁle.
6.5.3 Submodel 2: Structural predictors
For this submodel I examine the structural predictors associated with virologic failure. I
include the distance from the patient's home to the nearest clinic or main road, along with
limited logistic, ﬁnancial, and human resources in the study area. This issue is explored in greater detail
in Chapter 7.
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Figure 6.3: Submodel 1: Kaplan-Meier survival estimates for each risk group
other measures related to the patient's interaction with the health-care environment, which
include the previous use of ART, duration of time between clinic visits, number of clinic
visits, and change in clinic since treatment initiation. Table 6.8 shows the Cox proportional
hazard results. Straight line distance to the clinic (or main road, result not shown), previous
use of ART, and changed clinic since treatment initiation are not signiﬁcantly associated
with the hazard of virologic failure at the 0.05 level. However, more frequent clinic visits,
and shorter time between clinic visits are associated with a reduced hazard of virologic
failure. These two variables may indicate a patient's level of interaction with the clinic
setting.
I use the predicted probability thresholds of x = 0.10 and y = 0.25 to determine the risk
group categories, as obtained from the maximized AUC of the ROC graph. Table 6.9 shows
the confusion matrix, and Table 6.10 shows the sensitivity and speciﬁcity of the structural
predictors by risk group. We would correctly identify 83.33% of patients that have virologic
failure using the≥medium threshold, with a speciﬁcity of 52.54%. The structural predictors
perform better than the socio-demographic predictors in correctly classifying patients who
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Submodel 2
HR (CI) p-value
Km (line) to nearest clinic 1.030 (0.9801.082) 0.250
Previous ART:
No (Ref.)
Don't know 0.752 (0.5680.996) 0.047
Yes 0.886 (0.6351.237) 0.478
Ave. months between clinic visit 0.891 (0.8730.908) 0.000
Clinic visit count 0.380 (0.3530.409) 0.000
Changed clinic 1.169 (0.9591.424) 0.122
Virologic Failure 510
Total 3,525
Exposure Episodes 25,459
Table 6.8: Submodel 2: Cox proportional hazards model output for the structural factors
Risk group
Failure Low Risk Med Risk High Risk Total
No. % No. % No. % No. %
No 1,584 95 1,247 88 184 42 3,015 86
Yes 85 5 170 12 255 58 510 14
Total 1,669 100 1,417 100 439 100 3,525 100
Table 6.9: Confusion matrix for submodel 2
have virologic failure as reﬂected by the AUC of 0.77 for submodel 2 (higher than the AUC
of 0.57 for submodel 1). Figure 8.2 in the Appendix plots the sensitivity and speciﬁcity for
each threshold and shows the area under the curve for the ROC analysis. Figure 6.4 shows
the Kaplan-Meier survival curves for each risk group proﬁle.
6.5.4 Submodel 3: CD4 count predictor
To more clearly assess the predictive performance of the socio-demographic and structural
variables, I examine the association between virologic failure and change in patient CD4
count since treatment initiation. I use an individual ﬁxed eﬀects model to obtain the
patient-speciﬁc slopes, which represent the monthly change in CD4 cell count and show
this distribution in Figure 8.3 of the Appendix: the mean is 8.35 (sd = 16.13) cells/µl per
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Threshold Sensitivity % Speciﬁcity % Correctly
Classiﬁed %
≥ Low Risk 100.00 0.00 14.47
≥ Medium 83.33 52.54 56.99
≥ High 50.00 93.90 87.55
> High 0.00 100.00 85.53
AUC = 0.77
Table 6.10: Speciﬁcity and sensitivity for submodel 2
month. Table 6.11 shows the results: a 20 cell count increase in CD4 count decreases the
hazard of virologic failure by a factor of 0.05 (95% CI: 0.940.96), holding all else constant.
The hazard of virologic failure is negatively associated with age.
Submodel 3
HR (CI) p-value
CD4 Counta 0.951 (0.9400.962) 0.000
Age:
1619 (Ref.)
2024 0.445 (0.2540.781) 0.005
2529 0.498 (0.3030.817) 0.006
3034 0.463 (0.2820.758) 0.002
3539 0.400 (0.2420.662) 0.000
≥ 40 0.205 (0.1240.340) 0.000
Male 1.102 (0.9021.345) 0.342
Virologic Failure 510
Total 3,525
Exposure Episodes 12,230
aFor a 20 cell count increase in CD4
Table 6.11: Submodel 3: Cox proportional hazard model output for the CD4 count, age,
and sex predictors
I then ran a logistic regression analysis using the patient-speciﬁc changes in CD4 count
slope. To make the association between virological failure and the CD4 count slopes more
interpretable, I grouped the slopes into categories of <−10; 10 to −1; 0 to 5; and > 5.
The CD4 slope categories are shown in Table 8.3 in the Appendix. I then regressed the
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Figure 6.4: Submodel 2: Kaplan-Meier survival estimates for each risk group
virological failure variable on the categorical variable and show the regression output in
Table 8.4 of the Appendix. Results show a strong inverse association between CD4 count
slope and the odds of virological failure.
I used the predicted probability cut-points x = 0.10 and y = 0.23 to determine the risk
group categories, as obtained from the maximized AUC of the ROC graph for this submodel.
Table 6.12 shows the confusion matrix and Table 6.13 shows the sensitivity and speciﬁcity
for each risk group. We would correctly identify 72.35% of the patients that have virologic
failure using the ≥ medium risk group threshold, with a speciﬁcity of 71.55%. Figure 8.4
in the Appendix plots the sensitivity and speciﬁcity for each threshold and shows the area
under the curve for the ROC analysis. Figure 6.7 shows the Kaplan-Meier survival curves
for each risk group proﬁle.
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Risk group
Failure Low Risk Med Risk High Risk Total
No. % No. % No. % No. %
No 2,157 94 613 87 245 47 3,015 86
Yes 141 6 93 13 276 53 510 14
Total 2,298 100 706 100 521 100 3,525 100
Table 6.12: Confusion matrix for submodel 3
Threshold Sensitivity % Speciﬁcity % Correctly
Classiﬁed %
≥ Low Risk 100.00 0.00 14.47
≥ Medium 72.35 71.54 71.66
≥ High 54.12 91.87 86.41
> High 0.00 100.00 85.53
AUC = 0.77
Table 6.13: Speciﬁcity and sensitivity for submodel 3
Figure 6.5: Submodel 3: Kaplan-Meier survival estimates for each risk group
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Submodel 4: Model selection
I continue to use the maximum AUC of an ROC analysis to select the ﬁnal submodel for
this analysis. To do this I compared the AUC for various submodels. For example, for the
ﬁrst submodel I include only CD4 slope (which gives an AUC of 0.759), in the second model
I include CD4 slope and age (which gives an AUC of 0.776), in the third model I select CD4
slope, age, and sex (which gives an AUC of 0.774), and so on. The highest AUC obtained
is 0.856 for the following variables: CD4 slope, age, male, proportion of time employed,
migrated outside of study area, changed clinic since treatment initiation, number of clinic
visits, duration on treatment, and the average time between clinic visits.
Risk group
Failure Low Risk Med Risk High Risk Total
No. % No. % No. % No. %
No 2,197 97 648 84 170 35 3,015 86
Yes 70 3 122 16 318 65 510 14
Total 2,267 100 770 100 488 100 3,525 100
Table 6.14: Confusion matrix for submodel 4
Threshold Sensitivity % Speciﬁcity % Correctly
Classiﬁed %
≥ Low Risk 100.00 0.00 14.47
≥ Medium 86.27 72.87 74.81
≥ High 62.35 94.36 89.73
> High 0.00 100.00 85.53
AUC = 0.86
Table 6.15: Speciﬁcity and sensitivity for submodel 4
The logistic regression results are shown in Table 8.5 in the Appendix. The low, medium,
and risk groups were determined using the x = 0.10 and y = 0.30 cut-points that maximized
the AUC for the model selection procedure. Table 6.14 and Table 6.15 show the confusion
matrix and sensitivity/sensitivity analysis respectively for submodel 4. Figure 6.6 shows
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the area under the curve for the ROC analysis and Figure 6.7 shows the Kaplan-Meier
survival curves for each risk group proﬁle.
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Figure 6.6: ROC graph for submodel 4 (selected predictors)
Figure 6.7: Submodel 4: Kaplan-Meier survival estimates for each risk group
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6.6 Discussion
In this chapter I have presented an analysis of the socio-demographic, structural, and clinical
predictors of virologic failure, which I use as a proxy for ART adherence. Adherence to
ART is the single most important determinant of reduced mortality and improved health
outcomes in HIV-infected patients, and is critical to preventing the onward transmission of
HIV. Imperfect adherence to ART is a signiﬁcant problem in sub-Saharan Africa because
patients typically have to overcome a range of social and structural obstacles in order to take
their medications consistently and on a daily basis. I have argued that eﬀorts to optimize
the eﬃcacy of ART in South Africa and elsewhere will be critically dependent on the ability
of the public health sector to initiate and then ensure that patients remain adherent to their
HIV medications. The work presented in this chapter is therefore strongly motivated by
the need to understand the socio-demographic and structural predictors that are likely to
disrupt or attenuate high adherence to ART. It is hoped that this work can be used to
contribute to health-care eﬀorts designed to detect imperfect adherence in resource-limited
settings.
I argued in the introduction of this chapter that viral load monitoring oﬀers an accurate
method for determining imperfect adherence to ART. We would expect to see viral loads
below 400 copies/ml for patients that take their medications on a consistent basis. The
use of viral load counts as a biomarker for ART adherence avoids the problems associated
with the measure of adherence more generally, which cannot establish for certain whether
patients have actually ingested their medications. Viral loads consistently >1000 copies/ml
indicate that a patient is not adhering to his or her treatment requirements. For this
reason, virologic failurethe presence of two or more viral loads >1000 copies/ml after
treatment initiationwas selected as the outcome of this analysis, and as a proxy for
imperfect adherence to ART.
I began the analysis by using a Cox proportional hazards model to estimate the hazard
of virologic failure conditional on the structural and socio-demographic predictors. The
structural predictors measured the degree of interaction between the patient and the treat-
ment and care setting. Multivariate results show that migration out of the study area was
most signiﬁcantly associated with a higher hazard of virologic failure, which conﬁrms the
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ﬁndings of previous research. Generally, travel or migration away from home results in
disruptions to the patient's treatment schedule and the timing of doses (Coetzee et al.,
2011; Weiser et al., 2003). The results also show that employed individuals were less likely
to have virologic failure, but the remaining socio-demographic variables (except for age)
were not statistically signiﬁcant at the 0.05 level. Previous research has shown that ART
adherence in low- and middle-income countries is associated with a higher income, a higher
level of education, and being employed. But these predictors are less likely to be salient in
contexts where ART is freely available (as is the case in the study area), and the results
from the multivariate Cox proportional model appear to conﬁrm this ﬁnding.
Results further show statistically signiﬁcant associations between virologic failure and
a patient's interaction with the treatment and care setting. More frequent clinic visits was
associated with a reduced hazard of virologic failure. And shorter average time between
clinic visits was associated with a decreased hazard of virologic failure. These two results
suggest that frequent interaction with the clinic setting is likely to be associated with
a reduced hazard of virologic failure. Thus public health-care eﬀorts to ensure routine
visits with the health-care setting may help to improve patient response to ART. The
logistic regression results also show that increased duration on ART was associated with
a greater hazard of virologic failure. This ﬁnding conﬁrms what is currently established
in the literaturethat patients more likely to have poor adherence the longer they are on
treatment (Elul et al., 2013; Cornell et al., 2010).
I turned to a logistic regression analysis of the socio-demographic and structural predic-
tors. I ran submodels separately on the socio-demographic and structural predictors, and
added an additional model that included age, sex, and change in CD4 count since treat-
ment initiation. My intention was to compare the eﬀect sizes of the socio-demographic and
structural variables with a more proximate predictor (i.e., CD4 count), and then ultimately
develop a submodel which included the strongest predictors of virologic failure. Results
for the socio-demographic submodel show that age was the only signiﬁcant predictor at
the 0.05 level. Migration out of the study area, which had a relatively large eﬀect size in
the Cox proportional hazards model, was attenuated but still signiﬁcant at the 0.05 level.
This result should be interpreted with caution, since the logistic regression model did not
consider the longitudinal impact of migration on virologic failure. In the case of the Cox
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proportional hazards model, I was able to incorporate the duration of migration directly into
the estimate of virologic failure through the use of the exposure episodes concept discussed
in greater detail in Chapter 5.
Results for the structural predictors submodel show that distance from clinic was not
signiﬁcantly associated with virologic failure. Previous research has shown distance to clinic
to be an important predictor of poor adherence (Siedner et al., 2013). In this analysis,
distance to the clinic was measured as a straight line from the patient's residence to the
clinic. This measure may not accurately capture the cost and time to reach this destination:
actual distance by road to the clinic may be longer than a straight line, the patient's
residence may not be close to a transport hub, and multiple taxi rides may be required to
reach the clinic. The direction of the eﬀects for duration on ART, frequency of clinic visits,
and average time between clinic visits was consistent with the multivariate Cox proportional
hazard results. I then ran a CD4 count submodel to assess the eﬀect size of this biological
predictor. Results show that the eﬀect size for CD4 count was the highest of the socio-
demographic and structural predictors. The odds of virologic resistance were increased by
a factor of 43.06 (95% CI: 26.3470.40) for patients with CD4 count slope <−10 compared
with >5 CD4 count slope (holding all else constant).
I used an ROC analysis to assess the predictive power of the socio-demographic, struc-
tural, and CD4 count submodels. The socio-demographic submodel had the lowest pre-
dictive power (AUC=0.57), followed by the structural (AUC=0.77) and the CD4 count
submodels (AUC=0.77). The AUC results for each of the submodels suggest that the struc-
tural and CD4 count submodels share the same predictive power, even though the change
in CD4 count (per month) has a substantially larger odds ratio.7 In this respect, the ROC
analysis should be seen as validating the submodel estimates by comparing the ratio of the
observed virologic failure outcomes with the classiﬁcation of the predicted probabilities for
each submodule into the low, medium, or high risk groups, as explained in greater detail
in Section 6.4.3 of this chapter.
I the AUC of an ROC graph to make the ﬁnal model selection. The ﬁnal model included
the following predictors: CD4 slope, age, male, proportion of time employed, migrated
outside of study area, changed clinic since treatment initiation, number of clinic visits,
7 The size of this odds ratio is also largely dependent on how the categories for the patient-speciﬁc CD4
count slopes have been determined, speciﬁcally the reference category.
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duration on treatment, and the average time between clinic visits. The ﬁnal model had an
AUC of 0.856, which shows that the inclusion of certain socio-demographic and structural
variables can improve the predictive performance of this model when compared with a
model that includes only CD4 count, age, and sex. In this respect, the analyses presented
in this chapter shows that societal level factors, such as the socio-demographic or structural
variables, along with CD4 count monitoring, can be used to facilitate the detection of
imperfect ART adherence. However, there is debate as to which method can best detect
treatment response and adherence in resource-poor settings. Some researchers have argued
that CD4 count monitoring, along with other clinical monitoring strategies (e.g., assessing
patient symptoms) lacks the sensitivity to adequately detect virologic failure, and hence
may not be an appropriate measure to determine if a patient is not adhering to his or
her treatment schedule (Reynolds et al., 2009; Soria et al., 2009; Hoﬀmann et al., 2009).
These researchers have argued that viral load monitoring alone should be the standard to
determine poor adherence. However, this method of monitoring is expensive and may not
be feasible in resource-limited settings, such as the Hlabisa study area, where a single viral
load test is ﬁve times the price of a CD4 count test (NHLS, 2013).
I continue to explore the issue of treatment adherence in the following chapter. Speciﬁ-
cally, I extend the analysis undertaken in this chapter in two important ways. First, I draw
from the results of submodel 2, which suggest that patient interaction with the health-care
setting is an important component in ensuring ART adherence. This interaction implies a
range of health-seeking behaviors that increase exposure to treatment monitoring, adher-
ence counseling, and a constant supply of ART medications. The results of this chapter,
supported by the ﬁndings of similar studies, make a strong case for the improvement of, and
investment in, interventions that increase patient interaction with the treatment and care
setting. Second, if the treatment clinic is a critical site for the improvement or mainenance
of treatment adherence, then attention must be drawn to the cost-eﬀective strategies that
are available to monitor patient response to ART. In this chapter I have pointed to the po-
tential use of patient information relating to socio-demographics and clinic interaction that
can be used for this purpose. Overall, strategies to ensure reliable treatment monitoring
at reasonable costing structures will ensure that poor adherence can be detected earlier,
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thereby improving the long term response to ART and avoiding the costs of switching to
second-line ART regimens. I turn to this topic in greater detail in the following chapter.
Chapter 7
The Diagnostic Performance and Cost-Eﬀectiveness
of Two Monitoring Strategies to Identify Poor ART
Adherence
7.1 Introduction
In this chapter I continue to examine the topic of poor adherence to ART. This work
follows from the analyses undertaken in Chapter 6, where I identiﬁed CD4 cell count and
patient interaction with the clinic setting to be signiﬁcantly associated with virologic failure.
The central aim of this chapter is motivated by these ﬁndings in two important respects.
First, the results from the previous chapter suggest that patient response to ART could
be improved or maintained through increased exposure to adherence services, counseling
support, and regular access to treatment supplies.1 Second, frequent clinic visits could
enable health-care providers to better monitor patient response to ART, thereby leading
to the earlier detection of adherence issues and the subsequent modiﬁcation of existing
treatment options. I consider treatment monitoring to be an important public health-care
strategy to keep patients on ART, and devote the remainder of the chapter to this topic as
a result.
In the previous chapter, I showed that a decline in CD4 cell count was strongly associated
with virologic failure, and suggested that diagnostic eﬀorts to detect imperfect adherence
should include at least one of the three WHO recommended monitoring strategies. Brieﬂy,
1 For example, health-care staﬀ could help a patient to partner with a `treatment buddy' in order to
facilitate short-term adherence to ART (Thomson et al., 2014; Ramin and Pottie, 2013; Unge et al., 2010;
Wouters et al., 2009).
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the three monitoring strategies are: 1) the evaluation of clinical signs and symptoms ac-
cording to WHO clinical stage (15) condition, 2) routine immunological monitoring (612
months) which requires CD4 cell count testing, and 3) routine monitoring (612 months) of
patient viral load (VL). The WHO's Consolidated Guidelines on the Use of Antiretroviral
Drugs recommend VL monitoring as the preferred method to diagnose and conﬁrm treat-
ment failure, although the authors of the document acknowledge that this recommendation
is based on `low-quality' evidence (WHO, 2013: 133). In the absence of routine VL mon-
itoring, the Guidelines recommend the use of both clinical and immunological monitoring
to diagnose treatment failurea position based on `moderate-quality' evidence.
In this chapter I assess two strategiesCD4 and VL monitoringto detect poor or
imperfect adherence to ART. More speciﬁcally, I assess the diagnostic performance and cost-
eﬀectiveness of both monitoring strategies in a decentralized primary health-care setting in
the Hlabisa subdistrict of the KwaZulu-Natal province, South Africa. In resource limited
settings, CD4 monitoring is often implemented because of its aﬀordability. However, CD4
monitoring may not be as accurate as VL monitoring in detecting treatment failure. I
discuss the advantages and disadvantages of both monitoring strategies in greater detail in
7.2. Importantly, I am interested in whether the poorer sensitivity/speciﬁcity of CD4 count
monitoring will oﬀset its advantage in aﬀordability when compared with VL monitoring.
In Section 7.4.4, I review recent studies that have evaluated the cost-eﬀectiveness of the
clinical, immunological, and virological monitoring strategies. In general, cost eﬀectiveness
analyses are used to `identify the optimal allocation of available resources to maximize
health' (Eichler et al., 2004). Generally, budgetary constraints will not allow health-care
systems to make resources available to everyone. For this reason, a systematic (rather than
intuitive) approach is required to inform decisions that are made about the distribution
or allocation of health-care resources. The concept of a `threshold' therefore plays an
important role in cost-eﬀectiveness evaluations. Often, policy makers will make a technology
or treatment available belowor ration access abovesome `acceptable threshold'. In this
context, consideration is given to both the monetary cost and health gain achieved at a
speciﬁc threshold. In this analysis, I rely heavily on the threshold concept to deﬁne and
identify patients at risk (very-low, low, medium, high) of treatment failure, and compare the
cost-eﬀectiveness of the CD4 and VL monitoring strategies at diﬀerent risk group thresholds.
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In this analysis, I use genotypic resistance as a measure of treatment failure, and as a
proxy for imperfect adherence to ART.2 Genotypic resistance is a more accurate and robust
method to detect treatment failure. Brieﬂy, HIV has a high rate of replication and produces
millions of copies of itself every day (Stott et al., 2012). Many of these copies go unchecked
in the replication process, resulting in structural changes to the make-up of the virus over a
short period of time. As a result, these mutations make HIV resistant to one or more ARV
drugs in the patient's current regimen.3 Importantly, ARVs must be present in the patient's
system for resistance to occur, and therefore indicates that a patient is not taking his or
her medications consistently.4 Resistance issues are addressed by switching the patient to
a second-line regimen, which consists of ARV drugs that are eﬀective or active against the
virus. However, switching to second-line regimens is expensive, limits future treatment
options, and increases the probability that a patient will have a poor response to future
regimens. Adherence to standardized and aﬀordable ﬁrst-line ART regimens is therefore of
critical importance to the success of HIV treatment and care strategies in resource-limited
settings.
In the Section 7.3, I develop and explain the predictive model to assess the diagnostic
performance of the CD4 and VL monitoring strategies. The ﬁrst component of this predic-
tive approach is to use a ﬁxed eﬀects model to compute the change in a patient's CD4 and
VL count over the last 6 months (since their resistance test or last clinic visit). Patients
are then classiﬁed as being at very-low, low, medium, or high risk of genotypic resistance
given their change in CD4/VL count over the last 6 months. The cut-points used to deﬁne
the risk groups are determined by the AUC of an ROC graph, as demonstrated in the
previous chapter. I then use two established measures in medical statisticsthe positive
predictive value (PPV) and the number needed to test (NNT)in order to complete the
predictive/diagnostic component of this analysis.
2 In other words, I do not use the criteria for ﬁrst two consecutive VL>1000 copies/ml to measure
virologic failure, as I did in Chapter 6. A genotypic resistance test is expensive and undertaken in a
laboratory, the details of which are outlined in Section 7.3.2.
3 In fact, the patient may become resistant to a class of ARV drugs. For example, Non-Nucleoside
Reverse Transciptease Inhibitors (NNRTIs) and Protease Inhibitors (PIs) target HIV at diﬀerent stages in
the replication cycle. For example, a patient who develops resistance to efavirenz (EFV) is also likely to be
resistant to nevirapine (NVP), both of which are NNRTIs.
4 Patients who have no history of ingesting their medications typically have elevated VL measurements
>1000 copies/ml and test negative for genotypic resistance.
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I then evaluate the cost-eﬀectiveness of the CD4 and VL strategies under three diﬀerent
scenariostesting high risk patients only, testing high and medium risk patients, and testing
high, medium, and low risk patients. To achieve this task, I present an equation to determine
the total dollar cost for each monitoring strategy by risk group scenario. The total cost
is a function of 1) the amount required to test every patient twice in order to detect 1000
genotypic resistance cases, and 2) the amount associated with incorrectly switching patients
to a second-line ART regimen for the minimum period of one year. The costing model relies
mainly on the speciﬁcity, PPV, and NNT measures as discussed in greater detail in Sections
6.4.3 and 7.4.3.
As explained in Section 7.4.4, my work diﬀers from recent analyses that have assessed
the cost-eﬀectiveness of the three WHO recommended monitoring strategies. These studies
often use sophisticated mathematical modeling techniques that make large assumptions
about the dynamic transition of the population under investigationtypically over a 520
year costing period. Further, these studies typically rely on external and population level
data to inform model parameters, and have to account for long-term price inﬂation, as
well as the age-adjusted mortality and disability of the local population, amongst many
other variables. The calculations required to estimate the cost-eﬀectiveness of monitoring
strategies under this approach are often quite complex and elaborate (Sassi, 2006), and
often are not evaluated for their sensitivity (Fox-Rushby and Hanson, 2001).
In this study I present an analysis that uses simpler statistical methods and relies
on observed, clinical data. This analysis is based on the idea that the cost-eﬀectiveness
of a speciﬁc monitoring strategy is a function of its predictive performance. For a given
threshold, the health gain of a monitoring strategy is reﬂected by the proportion of patients
correctly identiﬁed to have treatment failure. Having identiﬁed these patients, they would
then be switched to second-line regimens in order re-suppress viral load and improve their
health and survival outcomes. Further, the cost of given monitoring strategy is likely to
increase if its diagnostic or predictive performance is poor. This means that more patients
will have to be tested to detect treatment failure, with an increased proportion of false
positives resulting in the switching of patients to more expensive second-line regimens. My
aim in this chapter is to present a statistical analysis that will be informative in terms of
the cost and health-gains achieved at speciﬁc thresholds and by monitoring strategy.
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7.2 Background
A substantial body of research has shown that combination antiretroviral therapy (ART)
can prevent the onward transmission of HIV (Cohen et al., 2011; Tanser et al., 2013; Bagga-
ley et al., 2013), and dramatically improve the health and survival outcomes of HIV-infected
patients (Ford et al., 2010; Nachega et al., 2013). In recent years, the development of stan-
dardized and aﬀordable ﬁrst-line drug regimens has resulted in the scale up of ART to
more than six million people in sub-Saharan Africa (UNAIDS, 2012a). The monitoring
of patient response to ART will now be crucial to the eﬀectiveness of HIV treatment and
care programs in this context (Hamers et al., 2012a). Monitoring strategies can be used
to determine if treatment is successful and to identify or improve patient adherence. Re-
search has shown that imperfect adherence to ﬁrst-line ART is a primary determinant of
treatment failure and acquired drug resistance (Ford et al., 2010; Wilson et al., 2009; Orrell
et al., 2007; Nachega et al., 2007; Paterson et al., 2000; Bangsberg et al., 2000; Manasa
et al., 2013). Switching patients to second-line ART regimens is expensive, increases the
probability of treatment failure, and therefore limits future treatment options (Barth et al.,
2012; Hosseinipour et al., 2009; Bartlett and Shao, 2009).
Three monitoring strategies are recommended by theWHO's Consolidated Guidelines on
the Use of Antiretroviral Drugs. These are: 1) the evaluation of clinical signs and symptoms
according to clinical stage (15) condition, 2) the routine monitoring of CD4 count (612
months), and 3) the routine monitoring of HIV-1 RNA viral load (VL) (612 months). The
Guidelines recommend VL monitoring as the preferred method to diagnose and conﬁrm
treatment failure, although this recommendation is based on `low-quality' evidence (WHO,
2013: 133). Clinical and CD4 monitoring are recommended in the absence of routine VL
monitoring, although research has shown that these two strategies have a poorer sensitivity
and speciﬁcity in detecting treatment failure (Hamers et al., 2012b; Gupta et al., 2009;
Keiser et al., 2011; Reynolds et al., 2012; Rawizza et al., 2011; Reynolds et al., 2009;
Castelnuovo et al., 2009; Soria et al., 2009; Mee et al., 2008; Moore et al., 2008). Decreased
speciﬁcity is likely to result in the unnecessary switching of patients who have virologic
suppression to more expensive second-line ART regimens (Sigaloﬀ et al., 2011). However,
it may not be economically feasible to implement VL monitoring because of the higher cost
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of the assay, the technical complexity of the test, and the logistics required to transport the
samples to centralized laboratory facilities (Estill et al., 2013; Roberts et al., 2012; Kahn
et al., 2011). Decision-makers in public health-care facilities will therefore need to consider
the diagnostic vs. cost trade-oﬀ as treatment monitoring strategies are implemented across
resource-limited settings.
In this chapter I evaluate the predictive performance and cost-eﬀectiveness of two
strategiesCD4 and VL monitoringto poor patient response to ART. The study is based
in a decentralized public health-care setting in KwaZulu-Natal, South Africa, where HIV
treatment and care services are provided at no cost to enrolled patients. I speciﬁcally deter-
mine the dollar cost to detect 1000 genotypic resistance cases for each monitoring strategy,
which is the sum of 1) the amount needed to undertake baseline CD4 or VL testing, and 2)
the amount associated with incorrectly switching patients to a more expensive second-line
ART regimen for the duration of a year. This analysis is based on the idea that the cost-
eﬀectiveness of a speciﬁc monitoring strategy is a function of its predictive performance.
Ultimately, the cost-eﬀectiveness model presented here will enable me to assess whether the
aﬀordability of CD4 baseline testing is oﬀset by its poorer speciﬁcity when compared with
VL monitoring.
7.3 Methods
7.3.1 Study setting
The Hlabisa HIV Treatment and Care Programme is located in the Umkhanyakude district
of the northern KwaZulu-Natal province. Established in 2004 by the South African De-
partment of Health and the Africa Centre for Health and Population Studies, the program
provides ART free of charge to HIV-infected patients using standard South African and
WHO treatment guidelines (Lessells et al., 2013). HIV services are provided primarily by
nurses and counselors across 17 primary health-care clinics and one district hospital within
the study area. Between 2004 and early 2010, ﬁrst-line ART regimens consisted of stavu-
dine (d4T), lamivudine (3TC), and either efavirenz (EFV) or nevirapine (NVP). In 2010,
tenofovir (TDF) replaced d4T in ﬁrst-line regimens and was available for substitution in the
presence of AZT toxicity. The demographic characteristics of the study setting and HIV
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program are described in greater detail elsewhere (Vandormael et al., 2014; Tanser et al.,
2008; Houlihan et al., 2011).
7.3.2 Study design
The study is a longitudinal cohort design enrolling patients from HIV Treatment and Care
Programme between January 2006 and early January 2014. Patient information was col-
lected using a standardized clinical form and entered into the Africa Centre's ART Evalua-
tion and Monitoring System (ARTemis). I used the ARTemis database to identify all adults
(≥18 years) on a ﬁrst-line ART regimen for more than 6 months. All patients underwent
routine CD4 and VL testing. CD4 tests were scheduled on a 6 month basis (Houlihan et al.,
2011). Prior to 2010, VL tests were scheduled every six months and repeated after three
months if VL was >5000 copies/ml. From 2010 onwards, VL tests were scheduled at month
6 and month 12, and then every 12 months if VL remained <400 copies/ml. A VL >1000
copies/ml resulted in a repeat measurement at three months (Manasa et al., 2013).
Treatment failure was identiﬁed through genotypic resistance testing. Resistance testing
was undertaken using the following criteria: Patients with latest VL >1000 copies/ml were
identiﬁed by clinic staﬀ during routine visits and referred to a physician for review, or were
proactively identiﬁed, contacted by program staﬀ, and booked for a physician review. Only
patients with indications of virologic failure were therefore sent and tested for genotypic
resistance. A 5 ml blood sample was collected during the clinical evaluation, and an in-house
HIV-1 drug resistance genotyping method was used to evaluate the samples, as previously
described (Manasa et al., 2013). A genosusceptibility score (GSS) for each antiretroviral
(ARV) agent in the ﬁrst-line regimen was determined using a Rega 8.0.0.2 algorithm. The
scores for each agent were totaled, with a GSS <2 indicating genotypic resistance. Patients
not sent for a resistance test, who had no VL>400 copies/ml 30 days after ART initiation, or
had a GSS ≥2 were deﬁned as not having treatment failure. Clinical information for patients
undergoing genotype testing was entered into the SATuRN REGA database (de Oliveira
et al., 2010).
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7.3.3 Ethics statement
The study was approved by the Biomedical Research Ethics Committee of the University
of KwaZulu-Natal and the Health Research Committee of the KwaZulu-Natal Department
of Health. Written informed consent was obtained from all the study participants
7.4 Statistical analysis
I selected all CD4 and VL test measurements 30 days after the date of ART initiation until
the genotype test date or the last clinic visit date. The baseline was deﬁned as the most
recent CD4 and VL measurement prior to the exposure start date, which I also included in
the analysis. I carried forward any CD4 measurements for 180 days and VL measurements
for 90 days, and then interpolated the remaining missing values between tests dates no
greater than 12 months. I transformed all VL measures onto the log10 scale. Only patients
with a baseline count followed by at least one CD4 or VL measurement were included in
the analysis.
7.4.1 Predictive/diagnostic model
The following statistical procedures were undertaken to develop the predictive/diagnostic
model.
Step 1: Fixed eﬀects model. First, I obtained patient-speciﬁc estimates for the mean
change in CD4 and VL count using a ﬁxed eﬀects model. The model is:
yij = β0j + β1jxij + ij , i = 1, . . . , nj ; j = 1, . . . ,m (7.1)
where for the jth patient: β0j is the CD4/VL count at baseline (i = 1), β1j is the monthly
rate of change in CD4/VL count, xij represents the number of months between the test
date (time point = i) and baseline date, and ij is the ith statistical error.
I then computed a relative percentage change in patient CD4 count using the predicted
values obtained from the individual ﬁxed eﬀects model (equation 7.1) at the date of the
genotype test or last clinic visit (i = 2) and six months prior to this date (i = 1). The
predicted values were obtained with:
y˜ij = βˆ0j + βˆ1jxij , i = 1, 2; j = 1, . . . ,m (7.2)
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where for patient j: y˜ij is the point prediction (at time-point i = 1, 2), βˆ0j and βˆ1j is the
estimated intercept and slope respectively, x2j is the duration of exposure to ART, and x1j
is the duration of exposure less 6 months. The relative percentage change in a patient's
predicted CD4 count over the last 6 months, abbreviated to pCD4 (6mo), was computed
as follows:
pCD4 (6mo)j =
y˜2j − y˜1j
y˜1j
× 100. (7.3)
I computed each patient's absolute change in predicted log10VL over the last 6 months,
abbreviated to aLVL (6mo):
aLVL (6mo)j = y˜2j − y˜1j . (7.4)
The percentage change in CD4 and absolute log change in VL could also be computed
using the two most recent observed measurements across a six month period, as was done
in Hoﬀmann et al. (2013). I justify the use of a ﬁxed eﬀects model because a) all patient
CD4 and VL measurements since exposure to ART are used, and b) to produce estimates
that are less sensitive to large variations between two successive CD4 or VL measurements
over the six month period.
Step 2: Deﬁne the risk groups. I then classiﬁed patients as having a very-low, low,
medium, or high risk of genotypic resistance based on their pCD4 (6mo) or aLVL (6mo)
estimates. The classiﬁcation model for the pCD4 (6mo) estimates was determined by the
step function:
Risk group =

very-low if pCD4 (6mo) > z
low if y > pCD4 (6mo) ≤ z
medium if x ≥ pCD4 (6mo) ≤ y
high if pCD4 (6mo) < x,
(7.5)
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where x < y < z, and (x, y, z) are variables taking on real values called cut-points. The
classiﬁcation model for the aLVL (6mo) estimates was similarly determined:
Risk group =

very-low if aLVL (6mo) < x
low if x ≥ aLVL (6mo) < y
medium if y ≥ aLVL (6mo) < z
high if aLVL (6mo) ≥ z,
(7.6)
where x < y < z. The cut-points, which deﬁne the risk group categories, are derived
from the maximum area under the curve (AUC) of a receiver operating characteristics
(ROC) graph, as explained in greater detail in Section 6.4.3. For example, the cut-points
(x = 0%, y = 5%, z = 20%) would classify patient pCD4 (6mo) <0% as high risk, patient
pCD4 (6mo) between 05% as medium risk, patient pCD4 (6mo) between 5.120% as low
risk, and patient pCD4 (6mo) >20% as a very-low risk of genotypic resistance. To validate
the predictive model, I perform a logistic regression model to assess the association between
the genotypic resistance outcome and the CD4 and VL risk groups separately (adjusting for
age, sex, and duration of virologic failure). I then plotted the time to genotypic resistance
for the low, medium, and high risk groups using Kaplan-Meier survival curves.
7.4.2 Performance of the predictive model
I ﬁrst demonstrate how the predictive performance of the CD4 and VL monitoring strategies
are evaluated using example cut-points with toy data. Table 7.1 shows a confusion matrix
for the four risk groups, where all patients with a pCD4 (6mo) <0% are classiﬁed as high
risk, etc. (see the above section).
Very-low Low Medium High
Resistance Risk Risk Risk Risk Total
No 315 2,137 749 165 3,366
Yes 6 76 178 137 397
Total 321 2,213 927 302 3,763
Table 7.1: Confusion matrix showing toy data for pCD4 (6mo) risk groups
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I use the confusion matrix to obtain the sensitivity, speciﬁcity, positive predictive value
(PPV), and the number needed to test (NNT) for each risk group. I demonstrated the
calculation of the sensitivity and speciﬁcity measures in greater detail in Section 6.4.3 of
the dissertation; I brieﬂy demonstrate the calculation of the PPV and NNT measures in
this section. The PPV is deﬁned as the number of true positives detected of the total (true
and false) positives classiﬁed. Or more speciﬁcally, it is the number of patients that test
positive for genotypic resistance divided by the total number of patients classiﬁed as having
genotypic resistance for a given risk group. Using the example data presented in Table 7.1,
the PPV for the high risk group is:
PPV =
number of true positives
number of true positives + number of false positives
=
137
302
× 100 = 45%.
For the high risk group, the sensitivity and PPV measures share the same numerator (137),
but diﬀer in the denominatorthe PPV denominator is 302 and the sensitivity denominator
is 397 (i.e., the total number of patients that tested positive for genotypic resistance). The
PPV is the inverse of the NNT, which represents the number of patients that must be tested
in order to detect one true positive case of genotypic resistance. The ideal NNT is 1, with
a higher NNT indicating a less eﬀective diagnostic strategy (Laupacis et al., 1988). For our
example, the NNT is computed as 1/PPV = (137/302)−1 = 2.2, which gives the number
of high risk patients that need to be tested to detect one treatment failure case. The NNT
can be multiplied by the dollar amount for a single CD4 or VL test.
7.4.3 Cost-eﬀectiveness model
In this section I present a model with which to evaluate the cost-eﬀectiveness of the CD4 and
VL monitoring strategies. My aim is to estimate a single dollar amount for both strategies
under three scenarios (or thresholds). The three scenarios are:
Scenario A: Test high risk patients only,
Scenario B: Test high and medium risk patients,
Scenario C: Test high, medium, and low risk patients.
For each combination of strategy and scenario (n = 6), the dollar amount reﬂects the
sum of two diﬀerent costs. The ﬁrst is the baseline cost needed to test patients twice using
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a CD4 or VL test; and the second is the cost associated with incorrectly switching patients
to a more expensive second-line regimen for the duration of a year.
Let Λ be the total cost for the CD4 and VL monitoring strategies separately under
Scenario A, B, and C. Let α be the number of patients that need to be tested to detect
the ﬁrst 1000 genotypic resistance cases. Let η be the false positive rate, and let δ be the
diﬀerence in annual cost between a ﬁrst-and second-line ART regimen. Then, the total cost
for each monitoring strategy under Scenario A, B, or C is:
Λij = αij + (βij × δ)
= 2(κijti) + (κijηij × δ), (7.7)
where i indexes the CD4 or VL monitoring strategy and j indexes the three scenarios.
• For each scenario (and ignoring subscripts), I deﬁne α as the baseline cost to test
each patient twice. I expand α to 2(κt), where κ is the total number of patients
that need to be tested to determine the ﬁrst 1000 genotypic resistance cases (thus
κ = NNT × 1000). κ is then multiplied by t, which represents the cost of a single
CD4 count test ($9.18) or a VL test ($45.88) at a primary health care clinic in South
Africa (NHLS, 2013).
• I deﬁne β as the number of patients that would have been incorrectly switched to a
second-line ART regimen under each scenario. β is derived from the false positive rate
η which is calculated as 1 − s, where s is the speciﬁcity expressed as a proportion.
η is therefore multiplied by κ, the total number of patients tested to detect 1000
genotypic resistance cases, in order to arrive at the number of patients incorrectly
identiﬁed to have genotypic resistance (and who would therefore be switched to a
second-line regimen).
• I deﬁne δ as $319, the diﬀerence between the annual cost of a ﬁrst-line regimen
($146.50) and a second-line regimen ($465.50) at public health-care clinics in South
Africa (Estill et al., 2013).
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To demonstrate the costing model, I compute the total cost for the CD4 monitoring strategy
in Scenario A (test high risk patients only) and the information from Table 7.6:
α = 2(κt) = 2(2200× $9.18) = $40, 392
β = κη = 2200× 0.049 = 107.8
δ = ($465.50− $146.50) = $319, and
Λ = α+ (β × δ) = $74, 780
Some notes that can be made about this cost-eﬀectiveness model:
1. Patients are tested twice to simplify the comparisons between the monitoring strate-
gies, and because a minimum of two measurements are required to compute a change
in CD4 or VL count over a given time period.
2. The cost to switch patients to second-line regimens who have been correctly identiﬁed
to have genotypic resistance is a constant for both monitoring strategies by scenario,
and is therefore not factored into the costing equation. Since I represent the dollar
amount to detect 1000 genotypic resistance cases, the constant represents a cost of
1000× δ for all monitoring strategyscenario combinations.
3. The total dollar amount does not include the cost of a patient's current ﬁrst-line
regimen, which is a constant under all monitoring-scenario combinations.
4. The cost of incorrectly switching a patient to a second-line regimen is computed for
the duration of a year, represented by β×δ . It is possible to compute the cumulative
cost over a 5-year period or longer adjusting for price inﬂation.
5. The model does not factor the logistical costs associated with implementing VL lab-
oratory equipment and facilities, staﬀ training, and other associated costs. The cost-
eﬀectiveness analysis presented here is concerned speciﬁcally with the diagnostic or
predictive component of CD4 and VL monitoring in resource-limited settings. The
additional cost of introducing laboratory facilities may inﬂuence the decision to im-
plement VL monitoring, a factor that is not considered in the costing model.
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7.4.4 Review of alternative cost-eﬀectiveness analyses
As mentioned in Section 7.1 of this chapter, a cost-eﬀectiveness studies often rely on a
threshold estimate, which is a rate expressing the monetary cost and the health gain for a
given monitoring program. Quality Adjusted Life Years and Life Years Saved (LYS) are two
popular measures that reﬂect the health gain component (the denominator) of a threshold
estimate, whereas DALYs reﬂect a health loss (Eichler et al., 2004). More speciﬁcally,
DALYs are the sum of the present value of future years of lifetime lost through premature
mortality (YYL), and the present value of years of future life-time adjusted for the average
severity of a particular disability (YLD) (Fox-Rushby and Hanson, 2001). For example, the
YLL is the time from death to the expected age at which that person was expected to live;
and the YDL is the time experiencing severe morbidity. One DALY is equal to one year
of healthy life lost. In terms of the cost-eﬀectiveness of WHO recommended monitoring
strategies, the number of DALYs averted reﬂects the diﬀerence between DALY computed
for a person undergoing a more eﬀective monitoring strategy and the standard monitoring
strategy.
A review of the literature shows that a large proportion of studies use QALYs (Estill
et al., 2013; Kahn and Marseille, 2013; Phillips et al., 2008), DALYs (Braithwaite et al.,
2014; Kahn et al., 2011; Keebler et al., 2014; Lara et al., 2012; Sempa et al., 2013; Marseille
et al., 2012) or LYS (Boyer et al., 2013; Bendavid et al., 2008) measures over a speciﬁed
time period to undertake the cost-eﬀectiveness of the three ART monitoring strategies. The
majority of these studies cited use the incremental cost eﬀectiveness ratio (ICER), which
is the diﬀerence in the cost between two monitoring options divided by the diﬀerence in
QALYs/DALYs/LYS. For mutually exclusive programs (i.e., a control or treatment arm),
an incremental cost eﬀectiveness ratio (ICER) is used to compare the cost-eﬀectiveness of
a each intervention with the next most eﬀective option. In their analysis, for example,
Kahn et al. (2011) assess the cost and health value for each incremental use of resources to
monitor patient response to ART. Their method reﬂects the diﬀerences in costs per person-
year for the monitoring tests themselves; a diﬀerence in costs of antiretroviral regimens;
and out/in-patient care. They also projected costs of future HIV care for 15 years.
The equations to compute QALYs are presented in Sassi (2006) and DALYs are presented
in Murray (1994) and Murray and Lopez (1996). The computation of DALYs require many
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assumptions relating to the weights for life expectancy, age, future time, and disability
(Fox-Rushby and Hanson, 2001). For this reason, data on cohort life expectancy, age
speciﬁc mortality rates, and country or region speciﬁc life tables are required (Sassi, 2006).
Disability weights necessary for the computation of the YDL measure and are sometimes
derived from the Global Burden of Disease project (Mathers et al., 2008). Further, in an
ideal scenario, the total DALYs would be computed as the sum of person-speciﬁc DALYs.
In reality, the calculations are made from the population level and require a number of
assumptions relating to the proportion of the population monitored, and so on. For this
reason, mathematical models are often invoked to compute QALYs/DALYs using observed
data from existing projects to inform the parameter settings (Estill et al., 2013; Keebler
et al., 2014; Phillips et al., 2008; Braithwaite et al., 2011).
My work diﬀers from these studies, which often use sophisticated mathematical model-
ing techniques that are dependent on large assumptions about the dynamic transition of the
population under investigationtypically over a 520 year costing period. Further, these
studies typically have to account for long-term price inﬂation amongst many other vari-
ables. The calculations required to estimate the cost-eﬀectiveness of monitoring strategies
under this approach are often quite complex and elaborate (Sassi, 2006), and often are not
evaluated for their sensitivity (Fox-Rushby and Hanson, 2001). I present a straightforward
cost-eﬀectiveness model that relies on observed/clinical data, and that use techniques that
are common in the ﬁeld of medical statistics. Here, I obtain the health gain component for
a given threshold as a function of the PPV, and the cost component as a function of the
speciﬁcity, of the predictive model.
7.5 Results
A total of 5596 patients ≥18 years of age and on ART for at least 6 months were eligible
for this study. Of these eligible patients, 493 were referred for a genotypic resistance test:
397 patients tested positive for genotypic resistance with a GSS <2, and thus identiﬁed as
having treatment failure. Patients with a GSS ≥2 (n = 83) remained in the study and were
identiﬁed as not having treatment failure. There were 5103 patients that were not consid-
ered as candidates for a genotypic resistance test. Of these, 3283 had virologic suppression
<400 copies/ml. I dropped 1112 patients that had one or more VL ≥400 copies/ml and 708
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Figure 7.1: Data ﬂow diagram of eligible patients (≥18 years) on ART for 6 or more months
that were included in the study
patients that had either less than two CD4 or VL counts in total (including the baseline
measure). The ﬁnal analytic sample consisted of 3763 patients. The data ﬂow diagram is
shown in Figure 7.1.
The mean age of the cohort was 40.8 (sd = 10.5) years and there were 965 (25.6%)
men. The mean duration of ART exposure (30 days after the date of cART initiation to
the genotypic resistance test or last clinic visit date) was 49.6 (sd = 23.2) months, and the
average time between test dates was 8.01 (sd = 3.03) months. At baseline, the median CD4
count was 150 (IQR = 82206) cells/µl and the median VL count was 40 (IQR = 2511000)
copies/ml. The ﬁxed eﬀect CD4 slopes had a median of 7.4 (IQR = 3.912.3) cells/µl change
per month, and the ﬁxed eﬀect VL slopes had a median of log −0.03 (IQR = −0.060.00)
copies/ml change per month. The distributions for the CD4 and VL ﬁxed eﬀects (slopes)
are shown in Figures 8.5 and 8.6 of the Appendix.
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7.5.1 Risk group cut-points
I used the AUC of an ROC graph to determine the risk group cut-points. The cut-points
(x = 0%, y = 5%, z = 20%) for the pCD4 (6mo) estimates were derived with an AUC
of 0.79; Figure 7.3 displays the AUC and ROC graph used to construct the risk groups.
Patients were classiﬁed as having a very-low (pCD4 (6mo) >20%), low (pCD4 (6mo) be-
tween 5.120%), medium (pCD4 (6mo) between 05%), or high risk (pCD4 (6mo) <0%)
of genotypic resistance. Table 7.2 shows the number of patients with genotypic resistance
classiﬁed under the four risk groups. The cut-points for the aLVL (6mo) estimates were
(x = −0.3, y = 0, z = 0.3) for the aLVL (6mo) estimates, with an AUC of 0.87; Figure 7.3
displays the AUC and ROC graph used to construct the risk groups. Patients were classiﬁed
as having a very-low (aLVL (6mo) <−0.3), low (aLVL (6mo) between −0.30), medium
(aLVL (6mo) between 0.010.3), and high risk (aLVL (6mo) >0.3) of genotypic resistance.
Table 7.3 shows the number of patients with genotypic resistance classiﬁed under the four
risk groups.
Very-low Low Medium High
Risk Risk Risk Risk Total
Resistance No. % No. % No. % No. % No. %
No 315 98.1 2,137 96.6 749 80.8 165 54.6 3,366 89.4
Yes 6 1.9 76 3.4 178 19.2 137 45.4 397 10.6
Total 321 100.0 2,213 100.0 927 100.0 302 100.0 3,763 100.0
Table 7.2: Confusion matrix showing the classiﬁcation schema for pCD4 (6mo) risk groups
Very-low Low Medium High
Risk Risk Risk Risk Total
Resistance No. % No. % No. % No. % No. %
No 1,418 98.5 1,757 95.7 125 42.5 66 34.2 3,366 89.4
Yes 22 1.5 79 4.3 169 57.5 127 65.8 397 10.6
Total 1,440 100.0 1,836 100.0 294 100.0 193 100.0 3,763 100.0
Table 7.3: Confusion matrix showing the classiﬁcation schema for aLVL (6mo) risk groups
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Figure 7.2: ROC graph showing risk groups to classify pCD4 (6mo) estimates
Figure 7.3: ROC graph showing risk groups to classify aLVL (6mo) estimates
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7.5.2 Models of association
Logistic regression: I used a logistic regression model to assess the association between
the risk group categories and the odds of genotypic resistance. Table 7.4 shows that the
univariate associations are large and statistically signiﬁcant: the odds of genotypic resis-
tance for high risk patients (i.e., a pCD4 (6mo) estimate <0%) is increased by a factor
of 43.01 (95% CI: 18.5999.53), compared with very-low risk patients (i.e., a pCD4 (6mo)
estimate >20%). The multivariate model (Table 7.4) shows the odds for the added sex,
and age covariates for the CD4 risk groups. There is no signiﬁcant diﬀerence between the
very-low and low risk groups once adjusting for the covariates. Holding all else constant,
the odds of genotypic resistance for high risk patients is increased by a factor of 55.52
(95% CI: 23.80129.51), compared with very-low risk patients.
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
CD4 Count:a
Very-low risk Ref. Ref.
Low risk 1.87 (0.814.32) 0.145 2.33 (1.005.40) 0.050
Medium risk 12.48 (5.4728.44) 0.000 16.99 (7.4039.02) 0.000
High risk 43.01 (18.5999.53) 0.000 55.52 (23.80129.51) 0.000
Ageb 0.59 (0.520.67) 0.000
Male 1.15 (0.881.49) 0.306
Constant 0.02 (0.010.04) 0.000 0.11 (0.050.28) 0.000
Log VL:d
Very-low risk Ref. Ref.
Low risk 2.90 (1.804.67) 0.000 2.85 (1.774.60) 0.000
Medium risk 87.14 (53.90140.88) 0.000 88.19 (54.32143.16) 0.000
High risk 121.21 (72.43202.85) 0.000 118.12 (70.19198.77) 0.000
Ageb 0.66 (0.570.76) 0.000
Male 1.47 (1.082.00) 0.015
Constant 0.02 (0.010.02) 0.000 0.07 (0.040.14) 0.000
N 3763 3763
aRelative percentage change in CD4 count over 6 months b10 year increase
dAbsolute change in log10VL over 6 months
Table 7.4: Logistic regression output for the CD4 and VL risk group categories
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Table 7.4 shows large associations between the VL risk groups and the odds of genotypic
resistance. The odds are increased by a factor of 121.21 (95% CI: 72.43202.85) for high
risk patients (i.e., an aLVL (6mo) estimate >0.3), compared with a very-low risk group
(i.e, an aLVL (6mo) estimate <−0.3). Younger patients and men are more likely to have
genotypic resistance, holding all else constant.
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
CD4 Counta 1.13 (1.111.14) 0.000 1.12 (1.111.14) 0.000
Ageb 0.57 (0.510.64) 0.000
Male 0.99 (0.791.24) 0.954
Log VL 3.17 (2.973.39) 0.000 3.10 (2.903.31) 0.000
Age 0.96 (0.950.97) 0.000
Male 1.15 (0.931.44) 0.200
N 3763 3763
aFor a 20 cell count decrease in CD4 b10 year increase
Table 7.5: Cox proportional hazard results for CD4/VL measures and covariates
Survival analysis: I undertook a Cox proportional hazards model to validate the asso-
ciation between the CD4/VL measures and genotypic resistance. I included the raw CD4
and log10VL measures as time-varying predictors in the model, with the outcome variable
deﬁned as the time to genotypic resistance. Table 7.5 shows the univariate and multivariate
results for CD4 count, age, and sex. For the univariate model, a 20 unit decrease in CD4
cell count is associated with a 1.12 (95% CI: 1.111.14) increase in the hazard of genotypic
resistance. Multivariate results shows that the hazard of genotypic resistance is associated
with younger patients, holding all else constant. Table 7.5 shows that a one unit increase in
log10VL is associated with a 3.10 (95% CI: 2.903.31) increase in the hazard of genotypic
resistance, holding all else constant. Figures 7.4 and 7.5 show the Kaplan-Meier survival
curves by CD4 and VL risk groups respectively.
7.5.3 Predictive model
I assess the predictive performance for the CD4 and VL monitoring strategies under three
scenarios: Scenario A (test high risk patients only), Scenario B (test high and medium
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Figure 7.4: Kaplan-Meier survival curves by CD4 risk group
Figure 7.5: Kaplan-Meier survival curves by VL risk group
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risk patients), and Scenario C (test high, medium, and low risk patients). For the CD4
monitoring strategy, the three scenarios equate to testing all patients with a pCD4 (6mo)
<0% (Scenario A), <5% (Scenario B), and <20% (Scenario C). For the VL monitoring
strategy, the three scenarios equate to testing all patients with a aLVL (6mo) >0.3 (Scenario
A), >0 (Scenario B), and >−0.3 (Scenario C).
The results are shown in Table 7.6. For the CD4 monitoring strategy: of the 397 patients
that tested positive for genotypic resistance (GSS<2), 137 were correctly classiﬁed as having
genotypic resistance under Scenario A, giving a sensitivity of 34.5% and a speciﬁcity of
95.1%. Scenario B shows a higher sensitivity (79.3%) but lower speciﬁcity (72.8%) with the
testing of medium and high risk patients, when compared with Scenario A. Testing low,
medium, and high risk patients under Scenario C gives the highest sensitivity of the three
scenarios (98.5%), but with the lowest speciﬁcity (9.4%).
There were 302 patients classiﬁed to have genotypic resistance under Scenario A. Of
these patients, 137 tested positive for genotypic resistance, giving a PPV of 45.4% (Table
7.6). For Scenario A, 2.2 patients would have to be tested to detect one genotypic resistance
case; and the cost to detect one positive case would be 2.2 × $9.18 = $20.2. Of the three
scenarios, Scenario A would be the most cost-eﬀective to detect one genotypic resistance
case, however, it would miss 65.5% of the patients that truly have genotypic resistance.
Scenario B misses less positive cases (20.7%), but has a lower PPV (25.6%) compared with
Scenario A, and therefore a higher cost ($35.8) to detect one positive case. Scenario C
misses the least number of genotypic resistance cases (1.5%) but is the most costly at $80.8
to detect one genotypic resistance case.
Table 7.7 shows the results for the VL monitoring strategy. Of the three scenarios,
testing high risk patients only under Scenario A gives the poorest sensitivity (32%), but the
highest speciﬁcity (98%) and PPV (65.8%), and the lowest NNT (1.50) and cost to detect
one genotypic resistance case ($68.8). The sensitivity is increased to 74.6% under Scenario
B, with a slight decrease in speciﬁcity (94.3%). The NNT is 1.60 and the cost to detect
one genotypic resistance case is $73.4. Scenario C is the least cost-eﬀective in detecting
one genotypic resistance case ($285) given an NNT of 6.2. However, only 5.5% genotypic
resistance cases are missed under Scenario C. The cost to detect one genotypic resistance
case is substantially higher under the three scenarios compared to CD4 monitoring.
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Scenario A B C
pCD4 (6mo) Threshold <0% <5% <20%
N 302 1,229 3,442
Genotypic resistance (GR) N 137 315 391
No genotypic resistance N 165 914 3,051
Sensitivity (%) 34.5 79.3 98.5
Speciﬁcity (%) 95.1 72.8 9.4
Missed genotypic resistance (%) 65.5 20.7 1.5
PPV (%) 45.4 25.6 11.4
Number needed to test (NNT) 2.2 3.9 8.8
Cost to detect one GR case ($) 20.2 35.8 80.8
AUC for this ROC analysis is 0.79
Table 7.6: Sensitivity, speciﬁcity, and NNT for CD4 risk groups
Scenario A B C
aLVL (6mo) Threshold >0.3 >0 >−0.3
N 193 487 2,323
Genotypic resistance (GR) N 127 296 375
No genotypic resistance N 66 191 1,948
Sensitivity (%) 32 74.6 94.5
Speciﬁcity (%) 98 94.3 42.1
Missed genotypic resistance (%) 68 25.4 5.5
PPV (%) 65.8 60.8 16.1
Number needed to test (NNT) 1.5 1.6 6.2
Cost to detect one GR case ($) 68.8 73.4 285
The AUC for this ROC analysis is 0.87
Table 7.7: Sensitivity, speciﬁcity, and NNT for VL risk groups
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7.5.4 Cost-eﬀectiveness model
In this section I report the total cost to detect 1000 genotypic resistance cases for the CD4
and VL monitoring strategies by risk group scenario. The results are shown in Figure 7.6.
The cost to test high risk patients only under Scenario A using CD4 monitoring is $74, 780,
compared with a cost of $147, 210 for VL monitoring. Under Scenario A, the diﬀerence
in sensitivity between the two monitoring strategies is not substantially large (i.e., 34.5%
vs. 42.1%). Indeed, the CD4 count monitoring strategy for Scenario A is substantially
more cost eﬀective and is comparable in sensitivity to the VL monitoring strategy. CD4
count monitoring is substantially more expensive than VL monitoring for Scenario B, when
medium and high risk patients are tested. The cost for CD4 monitoring increases in Scenario
B because of a higher NNT = 3.9 (vs. a Scenario A NNT = 2.2) and, more importantly,
because of the higher percentage (27.2%) of the κ = 3900 patients incorrectly switched to a
second-line regimen. The total cost for CD4 monitoring is therefore $409, 999 vs. the total
cost of VL monitoring, which is $175, 909. Of the three scenarios, Scenario C is the least
cost-eﬀective because of the higher NNT for both the CD4 and VL monitoring strategies.
The high NNT and poor speciﬁcity for CD4 monitoring in Scenario C results in a less
cost-eﬀective strategy when compared with VL monitoring.
7.6 Discussion
The virologic suppression of HIV is the most important indicator that a patient is re-
sponding well to ART (Nachega et al., 2007; Paterson et al., 2000; Bangsberg et al., 2000),
and patients who have treatment interruptions are at greatest risk of HIV drug resistance
(Meresse et al., 2014; Gupta et al., 2009). At the start of this chapter I argued that the mon-
itoring of patient response to ART will be crucial to public health-care eﬀorts to manage
and treat HIV. Unfortunately, the successful implementation of eﬀective treatment monitor-
ing strategies is often constrained by the economic realities of resource-limited settings. In
the case of VL monitoring, the requirement for expensive laboratory facilities and the cost
of the test mean that this strategy is not easily implemented in decentralized health-care
settings in rural South Africa.
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Because of these economic constraints, CD4 monitoring is generally promoted as an
aﬀordable alternative to VL monitoring. However, concerns have been raised about the
diagnostic performance of this monitoring strategy, as was discussed in Section 7.2. In this
analysis, I speciﬁcally evaluate if the aﬀordability of CD4 testing is oﬀset by its poorer
diagnostic performance (when compared with VL monitoring). For the cost-eﬀectiveness
model, I wanted to represent the predictive performance of CD4 count monitoring as a
cost-beneﬁt ratio in dollar terms. This dollar amount included a baseline cost to test
patients twice based on the predictive positive value (PPV) and the cost associated with
incorrectly switching patients to a second-line regimen (as measured by the speciﬁcity). My
aim therefore was to evaluate both the CD4 and VL monitoring strategies on the bases of
both their predictive and cost performance in identifying treatment failure.
Patients for this study were recruited from the HIV Treatment and Care Programme
in the Hlabisa district of the KwaZulu-Natal province of South Africa. All patients in this
study had at least 2 CD4 and VL measures, and were on ﬁrst-line ART for six or more
months. Patients with poor treatment response were identiﬁed and sent for a genotypic
resistance test; patients with a GSS < were deﬁned as having drug resistance and hence
treatment failure. Patients undergoing routine monitoring who had all VL <400 copies/ml
were deﬁned as not having treatment failure. I used a ﬁxed eﬀects analysis to obtain the
relative percentage change in predicted CD4 count over six months, abbreviated to pCD4
(6mo), and the absolute change in predicted log10VL over six months, abbreviated to aLVL
(6mo). These changes were then used to classify patients as being in a high, medium, low, or
very-low risk group for genotypic resistance. Under three testing scenarios, I then obtained
the sensitivity, speciﬁcity, positive predictive power (PPV), and the number needed to test
(NNT) for each scenario by CD4 or VL monitoring strategy. Finally, I computed the dollar
cost to detect 1000 genotypic resistance cases, a measure which is the sum of the amount
needed to test patients twice and the amount associated with incorrectly switching patients
to a second-line ART regimen for the duration of a year.
For both the CD4 and VL monitoring strategies, testing only high risk patients under
Scenario A was the most cost-eﬀective of the three scenarios. Under this scenario, how-
ever, a high percentage (>65%) of patients who have genotypic resistance would be missed
regardless of the monitoring strategy. Compared with Scenario A, testing medium and
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high risk patients (Scenario B) was more expensive for both the CD4 and VL monitoring
strategies, with a lower percentage of missed genotypic resistance cases (20.7% missed for
CD4 monitoring, and 25.4% missed for VL monitoring). Of the three scenarios, testing low,
medium, and high risk patients (Scenario C) gave the highest sensitivity (98.5% and 94.5%
for CD4 and VL monitoring respectively) and lowest speciﬁcity (9.4% and 42.1% for CD4
and VL monitoring respectively). Scenario C was also the most expensive of the threshold
scenarios for both monitoring strategies.
I extended this analysis by evaluating the dollar cost of each monitoring strategy as a
function of the baseline cost to detect 1000 genotypic resistance cases and the cost associated
with incorrectly switching patients to a second-line regimen. Under Scenario A, the cost to
detect 1000 genotypic resistance cases using CD4 monitoring was halved when compared
with VL monitoring. Importantly, the sensitivity for the CD4 monitoring strategy in this
scenario was not substantially poorer than its VL counterpart (i.e., 34.5% vs. 42.1%).
The cost-eﬀectiveness and diagnostic performance of CD4 monitoring to detect genotypic
resistance in high risk patients only could be an attractive option for health-care clinics in
resource-limited settings.
Unlike Scenario A (testing of high risk patients only), CD4 monitoring was substantially
more expensive than VL monitoring in Scenario B (testing high and medium risk patients).
While the baseline cost to detect 1000 genotypic resistance cases using CD4 testing was
more aﬀordable (than baseline VL testing), this advantage was oﬀset by the higher NNT
and number of patients that would be incorrectly switched to second-line regimens. In
Scenario B, the percentage of patients incorrectly switched under the CD4 monitoring
strategy (27.2%) was substantially higher than that of the VL strategy (5.70%). These
results show that CD4 monitoring is not a more cost-eﬀective strategy than VL monitoring
when high and medium risk patients are monitored.
Testing of high, medium, and low risk patients (Scenario C) is the most expensive of the
three monitoring strategies. The highest number of patients per 1000 genotypic resistance
cases would be incorrectly switched to a second-line regimen under Scenario C. The cost
of CD4 monitoring is also higher than VL monitoring, for the same reasons outlined in
the discussion of Scenario B. Results show that 90.6% would be incorrectly switched to
a second-line regimen under Scenario C, thereby substantially increasing treatment costs.
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In addition, the VL monitoring strategy had a better sensitivity and speciﬁcity. Further
evaluation and consultation will need to undertaken to determine if the inclusion of low risk
patients in a monitoring strategy can be balanced with the available ﬁnancial and logistical
resources of a given public health-care facility.
A limitation of this study is that all eligible patients with VL >1000 copies/ml not sent
for genotypic resistance testing were excluded from the analysis. The results of this analysis
show that CD4 monitoring is not always a more cost-eﬀective strategy when compared
with VL monitoring. The cost advantage of CD4 testing is oﬀset by its inferior diagnostic
performance when used to classify patients that are at a medium and/or low risk of HIV
drug resistance.
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Figure 7.6: Joint cost to detect 1000 genotypic resistance cases and incorrectly switching
patients to second-line cART
Chapter 8
Conclusion
I undertook three empirical analyses in this dissertation using data from the Africa Cen-
tre for Health and Population Studies. For the ﬁrst empirical analysis, presented in Chapter
5, I quantiﬁed the preventive impact of ART on HIV acquisition risk at the household level.
Next, I examined the socio-demographic and structural variables associated with poor ad-
herence to ART in Chapter 6. I continued with the topic of ART adherence in the third
empirical analysis, presented in Chapter 7, where I evaluated the diagnostic performance
and cost eﬀectiveness of two ART monitoring strategies. I consider each of these analyses
to address a real-world topic or problem in the HIV treatment and care domain, and frame
these three empirical analyses as the substantive contribution of this dissertation.
Underlying each of these empirical analyses is a conceptual or explanatory framework
of health, which I presented in Chapters 2 and 3. In Chapter 2, I addressed the challenging
sociological question of how social facts come to be embodied as individual pathology. I
suggested that a reasonable starting point would be to consider the complex interaction of
various causal factors positioned at diﬀerent levels in a hierarchical model of health. Such
a model would conceptualize a given social fact to operate on lower level factors in the
hierarchy in order to aﬀect a particular health outcome. Here, I identiﬁed and delineated
three such levels, the proximate determinants (Level 1), socioeconomic position (Level 2),
and the societal context (Level 3). My aim in this chapter was to motivate a sociological
approach to the study of health outcomes based on this proposed model.
I developed the proposed conceptual model in Chapter 3 by discussing the macro-social,
micro-social, and individual level factors that are associated with HIV-related outcomes in
the sub-Saharan African context. I brieﬂy provided a cursory outline of the viral etiology
of HIV, its progression to a global pandemic, and the social determinants that make the
epidemic particular to the African continent. I argue in this chapter that the complex
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epidemiology of HIV/AIDS in this context warrants the use of a conceptual framework
that addresses the broad range of social, behavioral, and biological factors known to be
associated with the spread and treatment of HIV.
In Chapter 3 I reviewed the proximate determinants of HIV: these are the behavioral and
biological mechanisms through which macro- and micro-social factors are conceptualized to
aﬀect HIV-related outcomes. Much of the work in this chapter was devoted to the household
contextthe micro-social level of the proposed model. The household was conceptualized
to be the site where community level eﬀects were mediated, and where social relationships
deﬁned, constrained, and reproduced a range of HIV-related behaviors. In Section 3.1.3 I
brieﬂy discussed four macro-social factors of the proposed conceptual model, which were the
1) social attitudes and beliefs, 2) institutions and structures, 3) epidemiological conditions,
and 4) demographic characteristics of an individual's community.
The proposed multilevel model of health was used for each of the three empirical chapters
to explain how the various HIV-related outcomes are aﬀected by the proximate, behavioral,
or social variables. Take for example the ﬁrst empirical analysis where I investigated if ART
usage in the household was associated with a reduction in HIV acquisition risk. Under the
assumption of heterosexual HIV acquisition risk, I considered the household to be a proxy
for the potential sexual partners of the repeat-tester. Here, the hazard of HIV acquisition
would be a function of the three biological determinants: the rate of sexual contact with co-
residents in the household, the probability of acquiring HIV in one sexual contact with an
infected co-resident, and the duration of susceptible time in the household. Each biological
determinant would in turn be aﬀected by one or more of the HIV proximate determinants
(shown in Figures 3.2 and 3.3). To illustrate, the duration of susceptible time would be
reduced if a repeat-tester migrated to a household with no infected co-residents. ART usage
among co-infected residents would reduce the probability of acquisition in one sexual act
since the transmission of HIV between serodiscordant sexual partners is strongly correlated
with the concentration of the virus in the bloodwhich treatment is designed to reduce. A
repeat-tester's rate of contact with infected co-residents would be substantially reduced in
he or she was in a monogamous relationship and practicing safe sex. The decision to practice
safe sex would ultimately be shaped or reinforced by the prevailing social and patriarchal
norms toward abstinence, condom use, monogamy, concurrency, and gender equality.
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The proposed multilevel conceptual framework can be applied to the second empirical
analysis where I selected virologic failure as a proxy for imperfect adherence to ART. As
cited in Section 6.1, high adherence to ART is the strongest predictor of virologic sup-
pression. Therefore, any socio-demographic or structural factor must operate through this
(behavioral) proximate determinantART usagein order to vary the amount of HIV in
a patient's blood. Under the multilevel conceptual model, societal level factors associated
with migration, residential mobility, distance to the clinic, and transport costs are concep-
tualized to facilitate, interrupt, or modify a patient's adherence to treatment. For example,
frequent migration would break a patient's regular contact with his or her treatment clinic.
Additional resources, time, and cost would then be required to locate a new treatment clinic
at the point of destination. Under this illustrative scenario, these macro- and micro-social
challenges would result in treatment interruptions that reduce the level of ART in the pa-
tient's system, allowing HIV to replicate more eﬃciently and leading to mutant strains that
are resistant to the current treatment regimen.
It is for this reason that adherence monitoring is the central aim of Chapter 7. Here,
public health eﬀorts to monitor treatment response to ART would help to detect adherence
issues early, resulting in the introduction of additional treatment support services or al-
ternative treatment options. These public health initiatives would ensure that the patient
maintains an adequate level of ART in the system to suﬃciently suppress the amount of
HIV. Under conditions of high patient interaction with the treatment clinic, monitoring
strategies would facilitate eﬀorts to assess patient response to ART. However, as discussed
in Chapter 7, the economic realities of resource-limited settings often limit the implementa-
tion and distribution of standard or recommended treatment monitoring strategies. In this
respect, economic and institutional constraints, which are societal level factors that aﬀect
the eﬃcacy and implementation of monitoring strategies, are conceived to operate through
a speciﬁc proximate determinantART usage and adherenceto aﬀect the development
of HIV drug resistance.
Given this brief discussion, I therefore argue that the proposed multilevel model is
continually operating in the background of the empirical analyses even though it is not
explicitly discussed or referenced in these chapters. The multilevel model provides a general
causal framework by which the societal, socio-economic, and behavioral factors of interest
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come to aﬀect the speciﬁed HIV-related outcome, whether this be acquisition, virologic
failure, or genotypic resistance. It is to this degree that the theoretical and empirical work
of this dissertation is synthesized. As mentioned, the acknowledged primacy of the empirical
chapters can be justiﬁed by the grave and pressing issues that confront HIV prevention and
management eﬀorts in sub-Saharan Africa. It is my hope that the work presented in this
dissertation can contribute to a branch of sociology that is concerned with the evaluation
of program interventions; that is invested in the production of solutions to the material,
technical, and immediate problems of the real-world domain; and that is interdisciplinary
in its scope and application.
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Appendix
Material for Chapter 6
Individual Fixed Eﬀects Model: Let Yij be a random variable denoting the CD4 count
response at time-point i for patient j. Let xij be the diﬀerence in months between the CD4
test date at time-point i and the baseline CD4 count test date (time-point i = 1) for patient
j. Let m indicate the total number of patients, and n the total number of time-points in the
sample. An individual ﬁxed eﬀects model acknowledges the grouping structure of the data
for which the jth patient has i = 1, . . . , nj time-points, where nj > 1 and the total number
of time-points for the sample is
∑m
j=1 nj = n. The observations (xij , yij), . . . , (xnjm, ynjm)
are realizations of the paired sequence (xij , Yij), . . . , (xnjm, Ynjm) for the j = 1, . . . ,m
patients and i = 1, . . . , nj time-points.
The individual ﬁxed eﬀects model in matrix notation is given by:
Y = Xβ +  (8.1)
where Y is a n x 1 response vector, X is a n x 2 matrix with the ﬁrst column set to ones
and the second column set to the values of the predictor variable x, β is a 2 x 1 vector of
coeﬃcients, and  is a n x 1 vector of statistical errors.
Three important assumptions are made about the error terms: 1) They are normally dis-
tributed random variables, with 2) expectation equal to zero and common variance σ2; and
3) are independent (that is, the value of one error does not provide information about the
value of another error).
The individual ﬁxed eﬀects model is:
yij = β0j + β1jxij + ij , i = 1, . . . , nj ; j = 1, . . . ,m (8.2)
where β0j and β1j are the patient-speciﬁc intercepts and slope respectively, xij are the
number of months between the CD4 test date (time-point i) and the baseline CD4 count
test date (time-point i = 1) for patient j, and ij is the ith statistical error for patient j.
An individual ﬁxed eﬀects model used the ordinary-least squares (OLS) method to obtain
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the βˆ estimators of β, which consists of minimizing the residual sum of squares (rss) for
the jth patient:
rssj =
nj∑
i=1
(yij − yˆij)2 (8.3)
where yij is the observed response and yˆij = βˆ0j + βˆ1jxij is the ﬁtted value for patient j at
time-point i. The residual sum of squares for the full sample is minimized by minimizing
the residual sum of squares for each patient in the sample (Fox, 2008).1
1 My decision not to use a random eﬀects model to obtain the patient-speciﬁc CD4 count slopes is
explained in greater detail in Vandormael (2014).
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Submodel 1
OR (CI) p-value
Male 1.269 (1.0191.581) 0.034
Age 0.970 (0.9590.982) 0.000
Highest education:
No school (Ref.)
Primary school 1.237 (0.7382.074) 0.419
High school 1.310 (0.7902.173) 0.295
Tertiary education 1.257 (0.7442.124) 0.393
Employed >50% time 0.961 (0.7771.188) 0.711
External migration (more than once) 1.312 (1.0381.659) 0.023
Disability grant received 1.798 (0.3848.425) 0.457
Constant 0.347 (0.1710.705) 0.003
N 3525
Table 8.1: Submodel 1: Logistic regression output for the socio-demographic factors
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Figure 8.1: ROC graph for submodel 1 (socio-demographic predictors)
Submodel 2
OR (CI) p-value
Km (line) to nearest clinic 1.003 (0.9431.065) 0.935
1.PreviousARTYes 1.299 (0.9171.839) 0.140
Yes 1.565 (1.0082.430) 0.046
Duration of ART (months) 1.125 (1.1101.141) 0.000
Ave. months between clinic visit 0.801 (0.7710.831) 0.000
Clinic visit count 0.239 (0.2050.278) 0.000
Changed clinic 2.279 (1.7542.961) 0.000
Constant 2.492 (1.6043.872) 0.000
N 3525
Exponentiated coeﬃcients
Table 8.2: Submodel 1: Logistic regression output for the socio-demographic factors
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Figure 8.2: ROC graph for submodel 2 (structural predictors)
Figure 8.3: Distribution of CD4 count slopes obtained from the individual ﬁxed eﬀects
model.
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CD4
count slopes Freq. Perc.
< -10 99 2.8%
-10 to -1 411 11.7%
0 to 5 1,114 31.6%
> 5 1,901 53.9%
Total 3,525 100.0%
Table 8.3: CD4 count slopes by category
Submodel 3
OR (CI) p-value
CD4 Count Slope:
>5 (Ref.)
<−10 43.060 (26.33870.399) 0.000
−10 to <0 14.536 (11.04519.130) 0.000
0 to 5 2.008 (1.5362.626) 0.000
Age:
1619 (Ref.)
2024 0.360 (0.1630.792) 0.011
2529 0.505 (0.2451.041) 0.064
3034 0.460 (0.2230.946) 0.035
3539 0.333 (0.1600.693) 0.003
≥ 40 0.188 (0.0910.388) 0.000
Male 1.257 (0.9831.607) 0.068
Constant 0.175 (0.0870.352) 0.000
N 3525
Table 8.4: Submodel 3: Regression output for the CD4 count, age, and sex predictors
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Figure 8.4: ROC graph for submodel 3 (CD4 count predictor)
Submodel 4
OR (CI) p-value
CD4 Count Slope 0.892 (0.8790.905) 0.000
Age 0.961 (0.9490.974) 0.000
Male 1.124 (0.8591.471) 0.393
Prop. time employed 0.886 (0.6591.190) 0.421
External migration 1.305 (0.5822.923) 0.518
Changed clinic 1.797 (1.3492.394) 0.000
Clinic visit count 0.249 (0.2110.295) 0.000
Duration on treatment (mths) 1.106 (1.0891.122) 0.000
Duration between clinic visits (mths) 0.802 (0.7710.835) 0.000
N 3525
Table 8.5: Submodel 4: Regression output for the CD4 count, age, and sex predictors
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** Code to maximize the AUC
** First compute predicted probabilities for the submodel
predict phat1 if e(sample)
** Set the variables to be populated for each iteration
gen Lower = .
gen Upper = .
gen AUC= .
local irow = 0
** Now iterate using incremental values of 0.05
forvalue ub = 0(0.05)1 {
forvalue lb = 0(0.05)0.5 {
local ++irow
capture drop profile
gen profile = 2 if phat1 >`ub'
replace profile = 1 if phat1 >=`lb' & phat1 <=`ub'
replace profile = 0 if phat1 < `lb'
replace Lower = `lb' if _n==`irow'
replace Upper = `ub' if _n==`irow'
qui roctab Failure profile
replace AUC = `r(area)' if _n==`irow'
}
}
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Material for Chapter 7
Figure 8.5: Change in patient CD4 cell count per month
Figure 8.6: Change in patient VL count per month
